What is Pharmacovigilance and How Has it Developed?
Concepts Types and Sources of Data The Process of Pharmacovigilance
Regulatory Aspects of Pharmacovigilance
International Collaboration
Clinical Aspects of Adverse Drug Reactions
Ethical and Societal Considerations
Future Directions
Learning More About Pharmacovigilance Glossary Index
Foreword
No effective medicine is without risk, and full understanding of a medicine’s safety profile is only achieved after wide clinical use. The advent of new therapies which hold the promise of transforming disease outlook means that patients and healthcare professionals are unwilling to wait to access them. It also means that the uncertainties around the balance of benefits and risks at the time of first availability of a new medicine may be greater than ever. With every therapeutic advance, the boundaries between categories of healthcare products – medicines, advanced therapies, diagnostic agents – become ever more blurred and the practice of medicine more personalised to the individual patient. The continuing need for the study of medicines safety in wider populations could perhaps be called into question. In fact, the study of drug safety in clinical use has moved to centre stage in public health, precisely because of the recognition that although by and large adverse effects are rare, it is only by undertaking systematic large‐scale surveillance that we can detect serious problems early and take prompt action to minimise harms – as it were, to ‘fix it while you fly’. Pharmaceuticals are used internationally and the need for effective drug safety monitoring is recognised worldwide. A signal of a safety issue associated with a new medicine introduced in a public health programme in a resource‐limited setting is just as relevant to a patient who may receive the same medicine in a high‐tech healthcare environment. The political landscape may shift, but pharmacovigilance knows no borders.
xForeword

The detection and evaluation of adverse effects associated with medicines involves specialists from a range of scientific disciplines who are attracted by the challenges of adding new knowledge that supports safe use of medicines. But pharmacovigilance can only be effective if it is relevant to the daily lives and embedded in the professional practice of all those who use medicines – the prescriber, the patient and their carer. There is clear evidence that reports from patients provide invaluable information on the impact of an adverse effect on life and work, and are of an equivalent level of seriousness to those from healthcare professionals. This all adds up to the value of a broad appreciation and an up‐to‐ date understanding of the principles and practice of pharmacovigilance. This new edition of a clear and succinct yet comprehensive guide to the field provides exactly the right introduction for those new to the challenges and the excitement of pharmacovigilance. It conveys the importance to public health protection of an effective safety net to pick up new information, and the need for well‐planned strategies to generate new evidence as an enabler of innovation. Everyone who uses a medicine has a part to play in helping to fill the knowledge gaps on safety in as near to real‐time as possible. While pharmacovigilance has now moved on to more robust forms of evidence than reliance on individual case reports of adverse effects, the alert prescriber or patient who observes a possible link between a medicine they are using and an adverse effect is still the cornerstone of pharmacovigilance. The appreciation that each one of us has a role in drug safety means that this updated book is not only a welcome but an essential guide.
Preface to the Second Edition

The general aim of this book – to provide a brief and broad introduction
for newcomers to the field which can be read through in a few
hours – has not changed since publication of the first edition in early
1.In this second edition, we have updated every chapter to reflect
pharmacovigilance practice in mid‐2016 and have also broadened its
international scope. Pharmacovigilance today is a global activity and
our aim is to provide a short introduction relevant to readers world-
wide. In response to feedback received on the first edition, we have
added a new chapter on clinical aspects of pharmacovigilance
(Chapter 7), which we hope will help readers without a medical back-
ground understand the importance of drug safety in ‘real life’. For refer-
ence, we have added a list of all the abbreviations used in the book and
we have also considerably expanded the glossary.
All scientific books are at risk of rapidly becoming out of date. When
this one was first published, major changes in the landscape of regula-
tory pharmacovigilance were already in progress, particularly in the
European Union (EU). During the intervening years, these changes have
come into force and bedded down (see Chapter 5). In June 2016, the UK
electorate voted to leave the EU and the full implications of ‘Brexit’ are
not yet clear. However, the need for international collaboration in phar-
macovigilance will not diminish and we expect that the worldwide net-
works discussed in Chapter 6 will be more important than ever before.
We hope that the new edition of this book will prove useful to those
entering this interesting and important field. Life may have moved on, but
the challenges involved in monitoring the safety of medicines – and taking
effective action to protect patients from harm – remain as great as ever.

Patrick Waller, UK
Mira Harrison‐Woolrych, New Zealand
September 2016
xiii
­Preface to the First Edition

Everyone knows that safety is important but, apart from a few people
whose job it is to oversee safety, this is probably something that most
people have at the back of their minds for most of the time. There are
likely to be two reasons for this – first, safety is about something
adverse not happening (and we tend to be more concerned about
things which are happening) and, secondly, it seems to be human
nature to think that ‘it will not happen to me’, perhaps as a mechanism
for coping with potential threat of something devastating.
The past decade has seen a marked rise in the numbers of people
working in the field of clinical drug safety or pharmacovigilance,
mostly in the pharmaceutical industry. The trend seems likely to con-
tinue, hopefully reflecting a greater focus on the safety of medicines.
This book is specifically targeted at newcomers to the field who, of
necessity, are often narrowly focused, and it aims to provide them
with a brief and broad introduction to the field. My purpose here is to
aid rapid understanding of the environment and key principles of
pharmacovigilance at the industry–regulatory interface.
My background is in regulation and my experience is of the UK and
EU systems and I readily acknowledge these inherent biases in my
narrative. This book probably will not help the newcomers with
detailed day‐to‐day aspects of their job but I hope it will enable them
to see where they fit into a bigger picture. I have assumed that readers
will at least have a science degree but not necessarily much specific
knowledge about drugs.
The new entrant needs to know how we got where we are today.
The most important historical drug safety issues have shaped the
development of pharmacovigilance and I have therefore used these as
xivPreface to the First Edition

a starting point. I hope that the book will also help the newcomers to
appreciate that they are now working in an interesting and important
field that is likely to develop much in the near future.
I have deliberately not included any reference citations within the
text since, initially, I hope the reader will want to read on rather than
go elsewhere. Ample references can be found in the larger texts on to
which the reader should next move. In the last chapter, I have selec-
tively cited some important sources that might usefully be consulted
for further reading. A glossary defining key terms is provided at the
end for reference.

Patrick Waller
xv
Acknowledgements

We are most grateful to Ian Boyd and Nourieh Hoveyda who provided
valuable comments on the whole redrafted manuscript for this e­ dition.
We are also grateful to the following people for review of specific
chapters and useful suggestions: Priya Bahri, Keith Beard, Stephen
Evans, Valerie Joynson, Marie Lindquist, Julie Williams and Jonathan
Woolrych. We would also like to thank the Medicines and Healthcare
products Regulatory Agency for providing data from the Yellow Card
scheme.
xvii
List of Abbreviations

ACE angiotensin converting enzyme
ADR adverse drug reaction
AE adverse event
ATC Anatomical Therapeutic Chemical (classification
system)
CIOMS Council for International Organizations of
Medical Sciences
COX cyclo‐oxygenase
CSM Committee on Safety of Medicines
CTD Common Technical Document
CYP450cytochrome P450
DIA Drug Information Association
DoTS dose‐relatedness, time course and susceptibility
DSRU Drug Safety Research Unit
DSUR Development Safety Update Report
EBGM empirical Bayes geometric mean
ECG electrocardiogram
EMA European Medicines Agency
ENCePPEuropean Network of Centres for
Pharmacoepidemiology and Pharmacovigilance
ESoP European Society of Pharmacovigilance (now ISoP)
ESTRIElectronic Standards for the Transfer of Regulatory
Information
EU2P European Programme in Pharmacovigilance and
Pharmacoepidemiology
FDA Food and Drug Administration
2Gsecond generation (oral contraceptive)
3Gthird generation (oral contraceptive)
xviiiList of Abbreviations

GPgeneral practitioner
GVPgood pharmacovigilance practice
HRThormone replacement therapy
IBDinternational birth date
ICinformation component
ICHInternational Council (formerly Conference) on
Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use
ICMRA International Coalition of Medicines Regulatory
Authorities
IMMP Intensive Medicines Monitoring Programme
ISoP International Society of Pharmacovigilance
ISPE International Society for Pharmacoepidemiology
MAmarketing authorisation
MedDRAMedical Dictionary for Regulatory Activities
MGPS Multi‐Item Gamma Poisson Shrinker
MHRA Medicines and Healthcare products Regulatory
Agency
MHTmenopausal hormone therapy
MMRmeasles, mumps and rubella (vaccine)
NOAC novel oral anticoagulant
NSAID non‐steroidal anti‐inflammatory drug
OCoral contraceptive
OTCover‐the‐counter (medicine)
PASS post‐authorisation safety study
PBRER Periodic Benefit–Risk Evaluation Report
PEMprescription‐event monitoring
PIDM Programme for International Drug Monitoring
PILPatient Information Leaflet
PPAR peroxisome proliferator‐activated receptor
PRAC Pharmacovigilance Risk Assessment Committee
PRRproportional reporting ratio
PSUR Periodic Safety Update Report
QPPV qualified person for pharmacovigilance
RMPrisk management plan
RORreporting odds ratio
SAMM Safety Assessment of Marketed Medicines
SIGspecial interest group
SJSStevens–Johnson syndrome
SPC (or SmPC) Summary of Product Characteristics
List of Abbreviationsxix

SSRIselective serotonin re‐uptake inhibitor
SUSARserious and unexpected suspected adverse reaction
TENtoxic epidermal necrolysis
TGATherapeutic Goods Administration
UMCUppsala Monitoring Centre
UNESCOUnited Nations Educational, Scientific and Cultural
Organization
VTEvenous thromboembolism
WHOWorld Health Organization
WHO‐ARTWorld Health Organization Adverse Reaction
Terminology
WHO‐PIDMWorld Health Organization Programme for
International Drug Monitoring
WMAWorld Medical Association
1
1

What is Pharmacovigilance and How Has it Developed?

­Origins and Definition of Pharmacovigilance

In the beginning, there was thalidomide.The history of drug safety goes back further but, for practical purposes, the story of modern pharmacovigilance begins there.In the late 1950s there was little, if any, regulation of medicines outside the USA (where thalidomide was not allowed on to the market),and their testing and development was almost entirely in the hands of pharmaceutical companies. In the case of thalidomide, unjustified claims of safety in pregnancy were made, and its use as a sedative and treatment for nausea and vomiting was targeted at pregnant women.The drug turned out to be a teratogen, producing a variety of birth defects but particularly limb defects known as phocomelia (Figure 1.1).Worldwide, about 10 000 babies were affected, particularly in Germany where the drug was first marketed. As phocomelia was otherwise avery rare congenital abnormality, a major increase in its incidence did not go unnoticed in Germany, but the cause was initially thought to been environmental. In 1961, a series of just three cases of congenital anomalies associated with thalidomide use in Australia was reported in The Lancet, the problem was finally recognised and the drug withdrawn from sale.
At the beginning of the 1960s, publication of possible adverse effects of drugs in the medical literature was effectively the only mechanism for drawing attention to them. Thalidomide produced a non‐lethal but visible and shocking adverse effect, leading people to ask why so many damaged babies had been born before anything had been done? This question is central to subsequent developments. It is unlikely that we will ever be able to predict and prevent all the harms that may be caused by medicines, but limiting the damage to much smaller numbers is now achievable. Today we would expect to be able to ­identify an association between drug and outcome analogous to thalidomide and phocomelia after the occurrence of less than 10 cases, so at least three orders of magnitude more effectively than six decades ago. The overriding lesson learnt from thalidomide was that we cannot just wait until a drug safety problem hits us. The thalidomide tragedy of the 1960s led directly to the initial development of the systems we have in place today, although it is only since the early 1990s that the term pharmacovigilance has become widely accepted. Pharmacovigilance is defined by the World Health Organization as ‘The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug‐ related problems.’ There are other definitions but this very broad one seems to be the most appropriate because there is a clear implication that the process is one of risk management. This is a concept that is applicable to many aspects of modern life but, surprisingly, its explicit use in relation to pharmaceuticals is a fairly recent development.
Thalidomide is not merely of historical interest, as in recent years it has made a comeback on to the market in some countries but with very narrow indications and extensive safeguards. The reasons for this exemplify the point about risk management, as the risk of fetal malformation can be successfully managed by avoidance of the drug during pregnancy. It also demonstrates another concept that is central to the practice of pharmacovigilance – the balance of benefit and risk. Thalidomide has benefits in some diseases that are otherwise difficult to treat (e.g. refractory multiple myeloma) and these appear to out weigh the risk of fetal malformation if there is an effective pregnancy prevention scheme in place. A further point that thalidomide illustrates well – and which is relevant to many other drug safety issues – is that not everyone is at the same risk of a particular adverse effect. In this case, a substantial part of the population (including men and also women who are not of childbearing capacity) are not at risk of phocomelia.

Main Lessons Learned from Thalidomide

The thalidomide tragedy taught us many lessons:
●●The need for adequate testing of medicines prior to marketing.
●●The need for government regulation of medicines.
●●The need for reporting systems to identify the adverse effects of
medicines.
●●The potential safety implications of unproven marketing claims.
●●Most medicines cross the placenta and this results in fetal
exposure.
●●Avoidance of unnecessary use of medicines in pregnancy.
●●That some risks can be successfully minimised.
The ramifications of the thalidomide tragedy were manyfold, but
the key lesson for the development of pharmacovigilance was that
active systems for detecting hazards are needed. Within a few years
this had been taken forward with the introduction of voluntary
(or ‘spontaneous’) schemes for reporting of suspected adverse drug
reactions (ADRs). These have stood the test of time as an alerting
mechanism or early warning system, and are covered in more detail in
Chapter 3.

­Scope and Purposes of Pharmacovigilance
In the past, the process of pharmacovigilance has often been considered to start when a drug is first authorised for use in ordinary ­practice. Nowadays, it is more commonly considered to include all safety‐related activity beyond the point at which humans are first exposed to a new medicinal product. The ultimate purpose of pharmacovigilance is to minimise, in practice, the potential for harm that is associated with all active medicines. Although data about all types of ADRs are collected, a key focus is on identifying and preventing those that are defined to be serious. This is generally defined as an ADR that meets at least one of the following criteria:

- Fatal
- Life‐threatening
- Causes or prolongs hospitalisation
- Results in long‐term disability
- All congenital anomalies.

The definition of serious also allows the application of medical judgement, such that a reaction can be considered serious even if there is not clear evidence that one of the above criteria is met.
Non‐serious reactions are important to individual patients and health ­professionals involved in their treatment, but they can usually be managed clinically and impact less on the balance of benefit and risk for individual products and on public health in general.
Thus, pharmacovigilance can be seen as a public health function in which reductions in the occurrence of serious harms are achievable through measures that promote the safest possible use of medicinal products and/or provide specific safeguards against known hazards.
Pregnancy prevention in users of thalidomide is an example of such a safeguard; monitoring white blood cell counts to detect agranulocytosis (absent white blood cells) in users of the antipsychotic drug clozapine is another (see Chapter 7).
In order to minimise harms, there is first a need to identify and assess the impact of unexpected potential hazards.
For most medicines, ­serious ADRs are rare, otherwise their detection would result in the drug not reaching (or being withdrawn from) the market.
For products that do reach the market, serious hazards are seldom identified during pre‐marketing clinical trials because sample sizes are ­invariably too small to detect them.
In addition, the prevailing conditions of clinical trials selected patients, short durations of treatment, close monitoring and specialist supervision usually mean that the frequency of ADRs will be underestimated relative to what will really occur in ordinary practice.
During pre‐marketing clinical development and research on new medicines, the aims of pharmacovigilance are rather different from the broad public health functions described here.
In volunteer stud ies and clinical trials, there is a need to protect individuals exposed to experimental products (from which they may derive no benefit) from potential harm.
There is also a need to gather information on risks (including the frequencies at which they happen) in order to make a provisional assessment of safety and to plan for post‐­marketing safety development (see Risk Management Planning in Chapter 5).

­Development of Pharmacovigilance
We next consider some of the most important examples of drug
safety issues and discuss how they have affected the development of
pharmacovigilance practice from the 1960s to the present day.

Practolol

In the early 1970s another drug safety disaster occurred; this was the oculo‐mucocutaneous syndrome, a multi‐system disorder, caused by practolol (Eraldin), a cardioselective beta‐blocker used to treat angina and hypertension. As in the case of thalidomide, several thousand individuals were permanently damaged before the association was recognised. The fundamental problem in this instance was a failure of timely identification, as despite having an early warning system in place, the system was dependent on doctors suspecting an association between drug and disease. Probably because of the unusual nature of the syndrome – dry eyes, skin rash and bowel obstruction – and a long latency period (averaging almost 2 years in respect of the onset of the most serious bowel manifestations), relevant cases were not reported until the association was identified in the medical literature. Around 3000 cases were then retrospectively reported to the UK Yellow Card spontaneous ADR reporting scheme (see Chapter 3), an example of the potential effect of publicity on ADR reporting. Interestingly, subsequent attempts to develop an animal model of practolol toxicity failed, indicating that the problem could not have been predicted from pre‐clinical studies.

Main Lessons learned from Practolol

- Some adverse effects are not predictable from pre‐clinical studies.
- Spontaneous reporting schemes are not always effective at identify-
  ing new ADRs.
- Health professionals may not be able to identify long latency effects
  and clinical manifestations not known to be related to other drugs
  as ADRs.
- Additional, proactive and more systematic methods of studying
  post‐marketing safety are needed.

The overriding message from practolol was that spontaneous ADR reporting alone is insufficient as a means of studying post‐marketing safety. Thus, in the late 1970s various schemes designed to closely monitor the introduction of new drugs were suggested, but few ­implemented. The basic idea was that initial users of new drugs would be identified through prescriptions and monitored systematically rather than waiting for someone to recognise a possible adverse effect. The concept did come to fruition in New Zealand and in England in the late 1970s with the development of nationwide prescription‐event monitoring (PEM) programmes (see Chapter 3).

## Benoxaprofen

The first drug studied by PEM in England was benoxaprofen (Opren), a non‐steroidal anti‐inflammatory drug (NSAID) which frequently produced photosensitivity reactions (i.e. rashes in light‐exposed areas). A published case series from Northern Ireland of five deaths related to hepatic and renal failure led to withdrawal of the drug in 1982, although the PEM study did not reveal any indication of these effects. Many of the patients who experienced serious ADRs with benoxaprofen were elderly; this was a result of reduced excretion of the drug as a consequence of renal impairment. Even though it is well‐recognised that many patients who use NSAIDs are elderly (e.g. for arthritis or chronic pain), benoxaprofen had not been adequately studied in this population prior to marketing. A reduction in the ­dosage recommendations for the elderly was implemented briefly, but benoxaprofen was withdrawn soon afterwards.

Because the usage of benoxaprofen took off rapidly after launch and an important adverse effect photosensitivity reactions was common, a large number of spontaneous reports were received in a short period of time, swamping the primitive computer systems then used and pointing to the need for purpose‐designed databases. The issue also illustrated the need for patients to be properly informed about possible ADRs and how to minimise the risk in this case by avoiding exposure to the sun. It was therefore influential in moving towards the introduction of patient information leaflets, which became compulsory in the European Union (EU) during the 1990s.

Main Lessons learned from Benoxaprofen

- Uncertainty about cause and effect from individual case
  reports – further impetus to the need for formal post‐marketing
  studies in patient cohorts of sufficient size.
- The need to study a drug in populations most likely to use it (e.g. the
  elderly).
- The need for purpose‐designed computer systems to handle ADR
  reports more promptly and effectively.
- The concept of intensive surveillance of new drugs, later achieved in
  the UK by the introduction of the Black Triangle scheme (see Glossary).
- The need for patients to be informed about possible ADRs.

Benoxaprofen was just the first of a series of NSAIDs withdrawn for various safety reasons in the 1980s. During this decade, pharmaceutical companies started to conduct their own post‐marketing surveillance studies and UK guidelines related to their conduct were drawn up in 1987. However, initially, the value of such studies turned out to be limited because they usually lacked comparator groups and often failed to meet the planned sample size. The UK guidelines were revised in 1993 with the aim of improving the quality of studies. The principles of the revised Safety Assessment of Marketed Medicines (SAMM) guidelines also became a blueprint for the first EU level guidance on the topic.

## ­Development of Pharmacoepidemiology

Epidemiology is the study of the distribution and determinants of health and disease in populations. During the mid 1980s, the term pharmacoepidemiology was first used to mean the scientific discipline of the study of drug use and safety at a population level. The discipline developed strongly during the 1990s with the increasing use of computerised databases containing records of prescriptions and clinical outcomes for rapid and efficient study of potential safety hazards. In some instances, prescription records are held in a separate database to clinical events, and linkage between the two databases needs to be achieved (through common identifiers in the two sets of data) in order to study adverse events at an individual patient level.

Towards the end of the 1980s, pharmacovigilance and pharmacoepidemiology started to investigate the problem of dependence on benzodiazepines so called minor tranquillisers such as chlordiazepoxide (Librium) and diazepam (Valium) which had been introduced in the 1960s. Advice was issued to limit the dosage and duration of such treatments and this issue brought into focus the problems faced in dealing with the misuse and abuse of prescription drugs. This is another example of a situation where spontaneous ADR reporting failed to highlight an important concern, the issue eventually coming into focus as a result of pressure from advocates for groups of affected patients.

As well as the problem of delayed identification of real hazards, pharmacovigilance has suffered from the reverse, the apparent identification of hazards that turn out not to be real. To some extent this is inherent in a system that relies much on clinical suspicions ­sometimes these will be wrong. The consequences are that sometimes a drug is unnecessarily withdrawn, or people become "too" scared to use it. For example, Debendox (or Bendectin), a combination product containing the antihistamine doxylamine, was widely used for the treatment of nausea and vomiting in pregnancy in the 1970s. It was withdrawn in the early 1980s on the basis of concerns that it might cause fetal malformations, a concerted campaign against the drug and impending litigation. At the time, the evidence of a hazard was very weak, but it was not possible to exclude a significant risk to the fetus. Subsequently, many studies of this potential association were performed and, collectively, they provided no evidence of an increased risk of fetal malformations. This example illustrates the intrinsic difficulty of disproving the existence of a hazard once concern has been raised.

A more recent, very high profile example illustrating the same point was the suggestion made in late 1990s that the combined measles, mumps and rubella (MMR) vaccine might be a cause of autism in ­children. Despite there being little evidence for this suggestion, it was impossible to completely disprove and hard to convince worried parents. Some years later the paper that provoked this concern was discredited and retracted but in the meantime vaccine campaigns were damaged and a significant number of cases of measles occurred in the UK for the first time in many years.

## Oral contraceptives and "Pill Scares"

This major pharmacovigilance story began in the late 1960s when it was discovered through spontaneous ADR reporting – and later con- firmed in formal studies – that combined oral contraceptives (OCs) (containing an estrogen and a progestogen) increased the risk of venous thromboembolism (VTE). This led to a reduction in the dose of estrogen to 20–30 µg ethinylestradiol, which lessened (but did not abolish) the risk without compromising efficacy. Nevertheless, when the risk of thrombosis became public knowledge (highlighted by media ‘pill scare’ stories in some countries), many women became very worried and stopped taking OCs. When OCs are stopped abruptly by sexually active women, without immediate use of an effec- tive alternative, unintended pregnancies occur and rates of induced abortion increase.

There have been several ‘pill scares’ over the years related to VTE
and also to other safety issues such as a possible association with myo-
cardial infarction and a small increase in the risk of breast cancer. In
each of these scares, many women stopped using OCs and the public
health impact, in terms of unintended pregnancies, was considerable.
This has been particularly unfortunate because pregnancy itself is
riskier (with higher rates of VTE for example) than using any OC.
In 1995, a World Health Organization (WHO) study of OCs found
a twofold increase in the risk of VTE when use of third‐generation
(3G) OCs was compared with second‐generation (2G) OCs. The
difference between these pills was the progestagen component;
­
­desogestrel or gestodene for 3G OCs and levonorgestrel for 2G OCs.
This was surprising, as it had always been considered that VTE risk
was simply related to the dose of estrogen in the pill. Within about
3 months of the WHO study, the results of two other studies reached
similar conclusions. Arguments were put forward that the associa-
tions seen in these studies were not necessarily causal and that 3G

OCs might have benefits that would compensate for the increase in
VTE risk. However, there was general agreement that although the
relative risk of VTE was doubled with 3G pills, the absolute level of
risk (see Chapter 2) was very low, as VTE is rare in healthy young
women, even if they take the pill. Thus, there was general agreement
that 3G OCs should not be withdrawn from the market.
The UK’s Committee on Safety of Medicines (CSM) decided that
the emerging information on VTE risk should be shared with doctors
and patients, but faced several challenges around communicating
the risks of the OC pill. Scare stories had already been published in
the British press and despite CSM messages that no one should stop
taking OCs, many women did, and hundreds of unintended pregnan-
cies subsequently occurred. It seemed that women had acted on
­information provided by the mainstream media, rather than on advice
provided by a national medicines advisory committee. Interestingly,
the pill scare that occurred in the UK in 1995 was not seen in other
countries, even those where use of OCs is high. There could be
many reasons for this, including the role of the British press in risk
communication.
Following the 1995 pill scare, more studies were carried out and the
effects of the various progestagens on blood clotting investigated.
Ultimately, it was shown that there were plausible differential effects
of these agents on clotting and further pharmacoepidemiological
studies have now convinced most scientists that the observed associa-
tion was causal and that 2G pills have the lowest risk of VTE. It has
also been acknowledged that the risk communication tools used in
1995 were inadequate and, in many respects, pharmacovigilance risk
communication at that time failed to prevent serious public health
outcomes. In 1997, the WHO convened a meeting of experts to con-
sider how communication in pharmacovigilance could be improved
(see Chapter 4). Since then, there have been other significant develop-
ments in risk communication for all medicinal products and many of
these have been informed by lessons learned from OC pill scares.

Main Lessons Learned from the OC Safety Issues

●●Drugs are sometimes marketed at a higher dose than is required
for efficacy.
●●There may be differences in safety between drugs of the same class.
●●Harm can result from poor communication of safety warnings.
11

●●When communicating risks of medicines, it is important to distin-
guish between relative and absolute risks (see Chapter 2) and to
explain the difference in plain language.
●●Uncertainty and debate about risks can fuel public concern.
●●The power of the media to influence users may be greater than the
authorities.
●●The need for greater international cooperation in pharmacovigilance.
●●The need to develop more effective communication tools.
●●Risk communication is a specific skill in pharmacovigilance.
An important point about the OC issues discussed is that the data
on which they were based did not, after the initial signal in the 1960s,
come from spontaneous ADR reporting. Despite that, causation was
debatable because the studies were not randomised trials but observa-
tional pharmacoepidemiology studies. VTE is a sufficiently rare out-
come in young women that it would be extremely difficult to conduct
a large enough randomized clinical trial to detect a doubling of risk.­ ormone Replacement Therapy (Menopausal
H
Hormone Therapy)
Later in life, women have also been prescribed sex hormones as
replacement therapy (HRT, now renamed menopausal hormone
­therapy; MHT). In this age group, the baseline risks of VTE, arterial
cardiovascular disease and various cancers are much greater and
therefore it has been more feasible to study them in clinical trials,
although studies have needed to be large and long‐term. Therefore,
observational studies of these outcomes were performed first and, in
general, they appeared to show that HRT reduced the risk of arterial
disease outcomes such as myocardial infarction and stroke. HRT was
never authorised for the purpose of reducing cardiovascular risk, but
in the 1980s and 1990s, on the basis of results from observational
studies and much pharmaceutical company promotion, it was widely
used for this purpose. The fundamental problem in performing such
studies is that women using HRT may be healthier to start with and it
is difficult to address all possible confounding factors (see Glossary) in
the design and analysis of observational studies. Another important
point is that the outcome in question is a benefit (i.e. a reduction in
risk) and, because of such biases (see Glossary), observational studies

rarely provide convincing evidence of benefit. It is generally accepted
that randomised trials are needed to establish efficacy and benefit.
Eventually, large randomised trials of HRT were set up (e.g. the
Million Women Study), but some studies had to be stopped early
because they showed the opposite of what was expected – an increase
in cardiovascular risk. Warnings were then issued by regulatory
authorities and, because there is no major downside to suddenly stop-
ping HRT, communication was intrinsically easier than with OCs.
Indeed, the intended effect of the warnings was that women who were
inappropriately using long‐term HRT should stop taking it. However,
conveying the right messages was not straightforward because there
were multiple risks involved, and they are time‐dependent and cannot
simply be expressed as a proportion (e.g. 1 in 100). In 2007, the UK
authorities published a report on HRT which included estimates of
risk for several adverse outcomes, expressed in clear language. Since
then, further studies of HRT have been published and discussion of
the risks and benefits of these products continues, and is likely to for
some time to come.

­Selective Serotonin Re‐uptake Inhibitors
Selective serotonin re‐uptake inhibitors (SSRIs) are antidepressants
which were brought to the market in the late 1980s and have since
largely replaced older, tricyclic antidepressants such as amitriptyline.
The main reason why they have done so – apart from effective mar-
keting – is that they are less toxic to the heart in overdose (i.e. there is
a greater margin of safety in relation to dose). Depressed patients are
at risk of taking an overdose and therefore this is potentially an impor-
tant advantage.
There have been two controversial issues with SSRIs: withdrawal
reactions and a possible increase in the risk of suicide. Problems expe-
rienced by patients when they stop treatments are often quite difficult
to assess because they could possibly be related to recurrence of the
disease. Nevertheless, the potential for SSRIs to produce withdrawal
reactions was identified during their development, and when sponta-
neous reports were received post‐marketing it was hardly a new signal
(see Glossary). There were very large numbers of such reports
received, but few were serious and the level of usage of the drugs
was high. Over a period of years it became clear that the problem was
13

occurring much more commonly than initially thought, particularly
in users of paroxetine (Seroxat), a fairly short‐acting drug. Ultimately,
greater care was needed in withdrawing patients more gradually from
these drugs. Suggestions have been made that SSRIs are drugs of
dependence but most scientists do not accept this because features
such as craving and dose‐escalation are generally absent. Importantly,
it emerged that the nature of some of the more unpleasant symptoms
patients experienced – such as ‘electric shock’ sensations in the
head – was being lost in the data processing systems. This was often a
result of inadequate coding. Such cases often became ‘paraesthesia’
(a tingling or prickling sensation), something that hardly conveys how
unpleasant such sensations can be. Thus, it was recognised that we
needed better ways to capture unusual patient experiences and this
gave considerable impetus to allowing patients to report their adverse
reactions to the authorities. That approach had been used in the USA
and some other countries for many years, but hardly at all in Europe
until the early years of the twenty‐first century.
The possibility that any drug might increase the risk of an outcome
associated with the disease it is being used to treat is invariably diffi-
cult to evaluate. Suicidal feelings and actions are relatively common in
depressed patients and it is not surprising when they occur in a patient
who has recently started treatment. Nevertheless, around 1990, a cli-
nician in the USA saw several patients treated with fluoxetine (Prozac)
who had suicidal thoughts and he published a case series suggesting
that the drug might be responsible. This prompted a review of all the
clinical trial data for the drug which did not support the proposition,
but it was never completely refuted.
Over the years more clinical trial data accumulated for various
drugs in the class and studies were conducted in children and adoles-
cents, the latter being a high‐risk group for suicide. Even in severely
depressed patients, completed suicides are rare in clinical trials and
therefore the evidence available relates mostly to attempted suicide
(also uncommon in trials) and thoughts of suicide measured on vari-
ous scales. Trials of paroxetine in children produced adverse find-
ings – an increased risk of suicidal behaviour and hostility – which for
some time were known only to the manufacturer. When the regula-
tory authorities eventually received the data, they issued warnings
against the use of this drug in children. The company was investigated
and prosecution considered, but the law was found to be insufficiently
clear that the company was obliged to submit concerning clinical trial

data immediately to the authorities when a trial was being conducted
outside the authorised indication. Again, this issue pointed to the
potential importance of clinical trials in the assessment of safety and
raised concern about a lack of transparency with clinical trial data.
Considerable steps have since been taken towards making clinical trial
data publicly available through mechanisms other than publication in
the literature which is slow and selective. There is still some uncer-
tainty as to whether SSRIs directly increase the risk of suicide in
adults, but there is general agreement that the early phase of treat-
ment is a high‐risk period and that careful monitoring of patients is
required.

­COX‐2 Inhibitors
What have been the most prominent drug safety issues of the twenty‐
first century? One of the most important has been the increased risk
of cardiovascular outcomes associated with selective COX‐2 inhibi-
tors (coxibs). This possibility was first uncovered in basic research but
not followed through. The first clinical indication of a problem came
from the VIGOR trial which was published in 2000. At the time, two
drugs in the class – rofecoxib and celecoxib – had just been author-
ised. The VIGOR study was a randomised comparison of rofecoxib
with naproxen (a standard NSAID), designed to establish whether
there was a difference in the rates of serious gastrointestinal adverse
effects (e.g. bleeding) of these two drugs. In that respect, rofecoxib
was clearly preferable and the trial results led to rapid uptake of cox-
ibs, on the basis that they were supposedly safer. However, the VIGOR
study also found an important difference in the rate of cardiovascular
events such as myocardial infarction which were five‐fold more com-
mon in patients taking rofecoxib than with naproxen. This informa-
tion was included in the original publication but lacked prominence
and was presented as a fivefold reduction with naproxen rather than
an increase with rofecoxib. The paper was subsequently the subject of
extensive criticism.
Over the years there have been suggestions that standard NSAIDs
reduce the risk of cardiovascular outcomes (as aspirin does) and a
potential explanation for the finding in the VIGOR study put forward
was that naproxen is cardioprotective whereas rofecoxib is not.
15

Ultimately, it took a large clinical trial comparing rofecoxib with
­placebo to establish beyond any doubt that this was an adverse effect
of rofecoxib (rather than a lack of benefit) and the findings of that
study led to the drug being withdrawn from the market in late 2004.
This event sent shockwaves around the world leading people to ques-
tion why such a trial had not been carried out much earlier, before
millions of people had used the drug. It also left a big cloud hanging
over the remaining drugs in the class; some were later withdrawn but
some remain on the market. At one stage, the proposition that coxibs
might be given to people at high risk of gastrointestinal bleeding and
low risk of cardiovascular disease seemed reasonable, but it has since
been discovered that, to a considerable extent, risk factors for these
problems overlap in individual patients. To make matters even more
complicated, it appears that some standard NSAIDs also increase the
risk of cardiovascular events and the ability to assess the relative safety
of drugs in the same class remains rather limited. This issue was a
major driver of the considerable increase in post‐marketing regula-
tion, and focus on post‐authorisation safety studies, which came to
fruition in Europe in 2012 and is discussed in Chapter 5.
Two other notable drug safety issues of recent years are also impor-
tant: the differing hazards associated with three glitazone drugs used
to treat type 2 diabetes, and the association of pandemic flu vaccine
with narcolepsy.

­Glitazones
Troglitazone was the first of the three glitazones to be marketed in the
late 1990s. These drugs are oral hypoglycaemics which work by
­activating peroxisome proliferator‐activated receptors (PPARs). Soon
after marketing, a considerable number of case reports of severe hepa-
toxicity with associated liver failure were received and the drug was
rapidly withdrawn in Europe. At the time, the next in class, rosiglita-
zone, was in the later stages of development and regulatory authori-
ties therefore considered very carefully whether it might also be
associated with a similar level of hepatotoxicity. They concluded (and
were eventually proven right) that it was probably different in this
regard. Rosiglitazone became a very widely used drug in the first
few years of the twenty‐first century and it was soon followed by

pioglitazone. Studies of cardiovascular risk were performed with these
drugs in the expectation that an effective anti‐diabetic drug would
reduce the risk. However, when these studies were brought together
in a meta‐analysis (which combines the results of multiple studies; see
Chapter 3) published in 2007, the opposite appeared to be the case for
rosiglitazone. This concern was the subject of considerable debate and
further study but, within a couple of years, it led to the demise of the
drug. Much of that debate was about its relative cardiovascular safety
compared with pioglitazone.
Given that the benefits of the two drugs appeared broadly equal,
and that most of the available evidence suggested that pioglitazone
was safer, it was allowed to remain on the market. Interestingly, piogl-
itazone also appears to be associated with its own particular impor-
tant safety problem, bladder cancer. This was originally identified in
animal studies and in the last few years has been confirmed in humans.
However, the level of risk is quite low, and considered manageable and
to be outweighed by the benefits of the drug in effectively treating
type 2 diabetes. The safety issues experienced with glitazones are
remarkable. Despite the apparent similarities of the drugs, they appear
to be associated with different important adverse effects affecting
­different organs.

­Pandemrix
In 2009, there was an influenza pandemic reflecting the global spread
of a new strain of human flu H1N1 virus. In many countries, mass vac-
cinations were undertaken with Pandemrix. In Finland and Sweden,
case reports of a vaccinated children and adolescents developing nar-
colepsy – a brain disorder causing episodes of sudden onset of sleep at
inappropriate times – were soon received. Formal studies have since
confirmed this as a rare risk but only in young people, and the mecha-
nism for this effect remains unclear. The effect has therefore been rec-
ognised in the product information and it has been recommended
that this vaccine should no longer be used in patients under 20 years
unless no other suitable vaccine is available. This example illustrates
the effectiveness of the intensive ADR monitoring systems which were
put in place to cover mass vaccinations during a pandemic in picking
up an unusual and important adverse reaction.
17

Main Lessons Learned from Recent Major Safety Issues

●●The need for vigorous follow‐up of safety signals with appropriate
studies.
●●That drugs within the same class can have markedly different risks
and the need for studies that address this possibility.
●●The difficulty of assessing outcomes that are related to the drug
indication.
●●The potential value of randomized controlled clinical trials in
assessing safety and the importance of the choice of comparator
drug(s).
●●Important safety data can emerge from clinical trials performed for
other purposes.
●●The need for greater transparency and increased availability of clin-
ical trial data.
●●The potential importance to safety of off‐label use (e.g. in
children).
●●There is a need to evaluate medicines adequately in children and
adolescents.
●●The need for greater patient involvement in drug safety.
●●The complexity of evaluating and communicating multiple risks
(and benefits).
●●The need for regulatory authorities to have sufficient powers to
ensure that companies have adequate pharmacovigilance systems
and proactively investigate potential risks with marketed products.­Conclusions
The issues discussed are necessarily selective and our discussion of
them is broad. The intention is primarily to illustrate that pharma-
covigilance experienced many teething problems in its early years and
that most of its developments have been in response to quite specific
lessons learned from landmark safety issues. In this chapter, we have
tried to illustrate what pharmacovigilance is and, by describing impor-
tant examples, how it has progressed over a period of more than half
a century. Despite that progress, no one should doubt that there is still
a long way to go. The current limitations of the discipline and how we
might eventually overcome them are considered in Chapter 9.
19
2

Basic Concepts

The two most important concepts in pharmacovigilance are opposites: harm and safety. The usual term for harm related to a medicine is an adverse drug reaction (ADR). As pharmacovigilance is fundamentally about preventing and managing ADRs, this concept is considered first through a summary of relevant definitions, classification systems that have been proposed, their nature and mechanisms and predisposing factors. Subsequently, the concept of safety is defined and discussed, particularly in the context of balancing harms with benefits. Finally, we consider the issue of causation how we go about deciding whether or not a patient has experienced an ADR or whether a medicinal product really is responsible for an apparent safety problem.

­Adverse Drug Reactions
Definitions

Standard, internationally agreed definitions of side effect, ADR and adverse event can be paraphrased as follows:

●● A side effect is an unintended effect of a medicine. Normally, it is undesirable but it could be beneficial (e.g. an anxiolytic effect from a beta‐blocker prescribed for hypertension).

●● An adverse drug reaction (ADR) is an unintended and noxious effect that is attributable to a medicine when it has been given within the normal range of doses used in humans.An Introduction to Pharmacovigilance, Second Edition. Patrick Waller
and Mira Harrison-Woolrych.
© 2017 John Wiley & Sons Ltd. Published 2017 by John Wiley & Sons Ltd.

●●An adverse event (AE) is an undesirable occurrence that occurs in
the context of drug treatment but which may or may not be causally
related to a medicine.
The difference between an ADR and an AE is crucial and yet these
terms are widely misused. In practice, determining whether a drug
is responsible for a particular AE in an individual patient is often
­difficult and a judgement has to be made (for an explanation of the
principles on which this judgement is based see Causality Assessment
in Individual Cases). When the judgement is that the drug is a possible
cause, this should be called a suspected ADR. Reports of such suspi-
cions form the basis of spontaneous ADR reporting schemes and the
key point about such data is that they are a subset of all the AEs occur-
ring during drug treatment which someone (generally a health profes-
sional who has seen the patient) has identified as possibly being
drug‐related. It is the clinician’s experience and professional judge-
ment that enables him or her to suspect a drug as the cause but, of
course, that suspicion may not be correct.
Proper use of the term AE should imply that a more systematic data
collection process has been used so that events will be included,
regardless of whether anyone believes they might be caused by a drug.
In most clinical trials it is a standard practice to document all AEs and
the best way of determining whether a drug is responsible for a par-
ticular type of event from such data is by comparison with a control
group. For example, if 10% of patients exposed to an active drug expe-
rienced headache compared to 2% on placebo, then this is an estimate
that headache attributable to the drug occurs in 8% (i.e. 10% minus
2%) of patients using it. In such trials it is also common to ask investi-
gators whether they believe that individual events are related to the
drug. This is effectively another way of collecting suspected ADRs,
although such data are likely to be more complete if the patient is in a
clinical trial rather than being treated in ordinary practice. It is impor-
tant to realise that relying on clinical judgement is a methodologically
weaker approach. Providing that the estimated 8% difference is not
based on very small numbers, then it would be more persuasive evi-
dence that the drug causes headache.
Thus, the three terms should be applied in the following contexts:
●●Use ADR to mean that it is now generally accepted that drug x may
cause effect y rather than in relation to individual cases. Qualify the
term with ‘possible’ if there is doubt.
Basic Concepts21

●●Use suspected ADR when a health professional or investigator
­indicates that a drug may have been responsible for an event in an
individual case. A valid case submitted as a spontaneous report to
a company or regulatory authority (see Chapter 5) is, by definition,
a suspected ADR.
●●Use AE only in the context of systematic data collection when no
element of judgement is involved in determining whether a case is
counted.

Classification Systems

Since the 1970s, ADRs have traditionally been classified into two
broad categories: Types A and B. The usual characteristics of
these different types of reactions are contrasted, followed by some
examples:

1. Type A (Augmented) reactions are generally:
   ●● Dose‐related

●● Predictable from drug pharmacology

●● Common

●● Reversible

●● Manageable with dose adjustment.

Classic examples of Type A reactions are bleeding with warfarin,
hypoglycaemia with oral anti‐diabetic agents and headache with
nitrates. 2) Type B (Bizarre) reactions are generally:
●● Not dose‐related

●● Unpredictable

●● Uncommon

●● Serious/irreversible

●● Indicative that the drug needs to be stopped.

Classic examples of Type B reactions are anaphylaxis with penicillins,
hepatitis with halothane and agranulocytosis with clozapine.
Additional categories of ADRs have also been suggested, as
follows:
●●Type C (Chronic), e.g. adrenal suppression with corticosteroids.
●●Type D (Delayed), e.g. tardive dyskinesia with neuroleptics.
●●Type E (End of use), e.g. withdrawal reactions with benzodiazepines.

DoTS Classification

In 2003, a system of classification was proposed by Aronson and
Ferner based on dose‐relatedness, time course and susceptibility; this is
known as DoTS. The main ways in which ADRs can be classified
within each of these three categories is given in Table 2.1.
In terms of dose‐relatedness, ‘toxic’ means that reactions occur as a
result of drug levels being too high, ‘collateral’ means that reactions
occur at drug levels that are in the usual therapeutic range and
‘­hypersusceptibility’ means that reactions can occur even at very low,
sub‐therapeutic doses. The terms ‘early’, ‘intermediate’ and ‘late’ have
not been precisely defined; the main difference between ‘late’ and
‘delayed’ reactions is that the latter can occur long after treatment is
stopped (e.g. cancer, which can occur years after exposure to a causal
agent). A withdrawal reaction means one that is specifically precipi-
tated by stopping the drug.
If suitable estimates of risk are available, it may be possible to draw
three‐dimensional DoTS diagrams of the probability of an ADR occur-
ring in sub‐groups over time and as a function of dose. When this is
not possible, qualitative classification may still be useful, as shown by
the following examples.

DoTS Classification: Examples

1. Osteoporosis due to corticosteroids: this reaction occurs at
   ­
   therapeutic doses, usually after some months of treatment.
   Females and older people are at the greatest risk. Hence, it would
   be ­classified as:

Table 2.1 Summary of dose‐relatedness, time course and susceptibility (DoTS)
categories.

Dose Time Susceptibility

Toxic IndependentAge
CollateralDependent:Gender
Hypersusceptibilityrapid administrationEthnic origin
first doseGenetic
early, intermediate, lateDisease
delayed
withdrawal
Basic Concepts23

●●Dose: collateral effect
●●Time: late
●●Susceptibility: age, sex. 2) Anaphylaxis due to penicillin: this reaction can occur with very
small doses and within minutes of taking the first dose of a course,
but true anaphylaxis only occurs when the drug (or a closely related
agent) has been used previously. Hence, it would be classified as:
●● Dose: hypersusceptibility

●● Time: first dose

●● Susceptibility: requires previous sensitisation.

The DoTS approach is useful because it addresses the limitations of
the Type A/B scheme into which many ADRs do not clearly fit and in
providing pointers as to how specific ADRs can be avoided.

Nature and Mechanisms of ADRs

The adverse effects of medicines usually mimic diseases or syndromes
that occur naturally and have a variety of non‐drug potential causes
(e.g. hepatitis or aplastic anaemia). As a general rule, considering
other potential causes is an important part of the assessment of a
potential adverse effect (see Causality Assessment). However, there
are a few unique syndromes that, as far as we yet know, seem to be
caused only by specific drugs. Four examples of this are:

1. Vaginal cancer in young women caused by maternal exposure to
   diethylstilboestrol
2. Oculomucocutaneous syndrome caused by practolol (see Chapter 1)
3. Eosinophilia‐myalgia syndrome caused by some l‐tryptophan
   products
4. Fibrosing colonopathy induced by large doses of high‐strength
   pancreatic enzymes in children with cystic fibrosis.
   In broad terms, there are at least four mechanisms for ADRs:
5. Exaggerated therapeutic response at the target site (e.g. bleeding
   with warfarin)
6. Desired pharmacological effect at another site (e.g. headache with
   glyceryltrinitrate)
7. Additional (secondary) pharmacological actions (e.g. prolongation
   of the QT interval on the electrocardiogram – many drugs)
8. Triggering an immunological response (e.g. anaphylaxis due to
   many drugs).

Particularly at the time they are first identified, the mechanism
of many ADRs is unknown or incompletely understood. Some have
a pharmacokinetic basis e.g. impaired hepatic metabolism due to a
genetic polymorphism or the effect of another medication taken con-
currently, leading to increased plasma concentrations. Understanding
genetic predispositions is likely to be an important factor in determin-
ing how we might prevent ADRs in the future (see Chapter 9).

Predisposing Factors for ADRs

The main clinical factors that increase the chance that patients will
experience an adverse reaction are as follows:
●●Age – the elderly and neonates are at greatest risk.
●●Gender – women are generally at higher risk.
●●Ethnic origin – can affect drug metabolism because of genetic
predisposition.
●●Impaired excretory mechanisms – reduced hepatic and/or renal
function.
●●Specific diseases – e.g. asthma and beta‐blockers1.
●●Polypharmacy –use of multiple drugs simultaneously, increasing
the potential for drug interactions (see next section).
●●Any previous history of an ADR.

Drug Interactions

Drug interactions occur when the presence of one drug affects the
activity of another. This occurs either because both drugs act through
the same pathway(s) – these are called pharmacodynamic interac-
tions – or through effects on absorption, distribution, metabolism or
excretion – pharmacokinetic interactions. The result may be an
adverse reaction or modified effectiveness. Some specific examples
are given as follows:
●●Pharmacodynamic – concomitant use of two drugs with similar
effects. For example, an angiotensin converting enzyme (ACE)
inhibitor plus a potassium‐sparing diuretic can result in hyper-
kalaemia and cardiac arrhythmias.
1
This is a very important example because the effect of beta‐blockers in patients with
asthma is to constrict the airways and to counteract some of the treatments that the
patient may be taking (e.g. beta‐agonists). Giving a beta‐blocker to an asthmatic patient
can prove to be fatal.
Basic Concepts25

●●Absorption – orlistat, a drug used to treat obesity, impairs the
absorption of some medicines (e.g. anticonvulsants) and its use in
this context could lead to convulsions.
●●Distribution – protein‐bound drugs (e.g. phenytoin, aspirin) can
displace each other, resulting in an increased unbound (i.e. active)
fraction of drug in plasma.
●●Metabolism – many medicines (e.g. cimetidine and omeprazole),
drugs that reduce gastric acid by different mechanisms, inhibit the
metabolism of warfarin and thereby increase its anticoagulant
effect, leading to bleeding reactions.
●●Excretion – amiodarone, an anti‐arrhythmic drug, reduces excre-
tion of, and therefore the dosage requirements for, digoxin – a drug
widely prescribed to patients with cardiac disease.
Many drugs are metabolised by hepatic cytochrome P450 (CYP450)
enzymes, the activity of which may be induced or inhibited by a wide
variety of drugs. There are several subgroups of CYP450 enzymes and
their activity can also be affected by:
●●Herbal medicines – e.g. St John’s wort is an enzyme inducer and can
reduce the effectiveness of various drugs including ciclosporin.
●●Dietary products – e.g. grapefruit juice is an enzyme inhibitor and
increases plasma concentrations of some calcium channel blockers,
drugs that are used to treat hypertension and angina.
Drugs can also interact with alcohol – for example, metronidazole
(an antibiotic) blocks part of the metabolic pathway for alcohol
and concomitant use, which is not recommended, leads to intense
vasodilatation.

­The Concept of Safety
Definition

Safety can be defined as relative absence of harm. When using the
word ‘safety’ we often mean something else. For example, safety data
often means collection of reports of harm. Safety departments in the
pharmaceutical industry are generally focused much more on harm
than safety. And yet how safe something is a key question for the user
and one that pharmacovigilance is gradually becoming more targeted
at. To establish safety, it is not enough to sit around and hope that

nothing much happens. Active processes are required to generate data
in large numbers of users – this is one of the main challenges facing
people working in the field.
In practice, there is no such thing as absolute safety because, even if
something is completely harmless, it is impossible to demonstrate that
with complete certainty. For example, if a drug were given to 999 999
people without any problem occurring, it would be very unlikely that
the millionth person to use it would be harmed, but it is not impossi-
ble. In any case, we know that all pharmacologically active substances
have the potential to cause harm. When we say that a drug is ‘safe’, we
mean that there is a low probability of harm which, in the context of
the disease being treated and the expected benefits of the drug, can be
considered acceptable. Disease context is important because patients
with more serious illnesses are much more likely to be prepared to
accept potentially harmful treatments than those who have minor or
self‐limiting illnesses. ‘Acceptability’ is a subjective judgement which
ultimately is made by comparing both the positive and the negative
consequences of one course of action (e.g. a drug) with another (which
could be any form of treatment or no treatment). We will return to
this point in more detail in the section on risk–benefit balance.
Safety is a moving ball – there is a need to re‐evaluate it as experience
accumulates. Treatments previously considered acceptably safe may
become ‘unsafe’ in the light of new evidence or the discovery of safer
alternatives. An example of the latter was the antihistamine terfena-
dine which was widely used in the treatment of hay fever until the early
1990s. It was then discovered that it could, very rarely, cause serious or
fatal ventricular arrhythmias through the mechanism of prolonging
the QT interval. Terfenadine is a pro‐drug (i.e. precursor of the active
substance) which is normally completely metabolised on the first‐pass
through the liver. It is the parent drug terfenadine that prolongs the QT
interval (when its metabolism is inhibited) but the metabolite is
responsible for the beneficial effects. Thus, the metabolite, known as
fexofenadine, was developed for this indication and rapidly accepted to
be a safer alternative, following which terfenadine became obsolete.

Measuring Risk

To assess how safe something is we need to identify and measure the
risks of harm associated with it. Risk is the probability of an adverse
outcome. It may be expressed in the following terms:
Basic Concepts27

●●Absolute risk – an absolute risk must have a numerator and a
denominator but it may be a proportion (e.g. 1 in 100) or a rate
which includes time (e.g. 1 in 100 per year). The null value (i.e. no
increased risk) is zero.
●●Relative risk – a relative risk is a ratio and makes comparison with a
specified alternative (e.g. a twofold increase compared to no treat-
ment is a relative risk of 2). The null value is one.
Absolute risk provides more useful information than relative risk
but the latter is often easier to measure. Interpreting a relative risk is
difficult without knowledge of the baseline rate (i.e. the background
probability of the effect occurring in the absence of any intervention).
Several times a very small number is still a small number, whereas a
small increase in the relative risk of something common could be
important. This is illustrated by the comparison made in Table 2.2,
showing that many more extra cases will occur in the situation where
the baseline risk is high.
The fundamental problem with measuring safety is that it is much
more difficult to determine that an effect is absent than to measure
one that is present. We may be hoping or expecting to observe no
effect but if nothing goes wrong, does that mean everything is
all right?
The rule of three is a simple and useful tool when zero cases have
been observed in a defined population (NB it cannot be used if any
cases have occurred). Simply dividing the size of population by 3
approximates an upper 95% confidence limit. In practice, this is the
highest value that, statistically, is reasonably likely to represent the
truth. For example, if 900 patients use a new antibiotic and 0 allergic
reactions occur, then it is statistically unlikely that such reactions will
occur more frequently than 1 in 300 patients (i.e. 1 in 900/3).
The rule of three works very well provided the size of the population is
at least 30 and thus, in the context of drug safety, it usually is applicable.

Table 2.2 Comparison between the number of extra cases produced by differing
relative risks according to the level of baseline risk.

Baseline risk Relative riskExtra cases per million

1 in 100 (common)1.1 (small increase)1000
1 in 1 000 000 (very rare)10 (large increase)10

Safety in Practice

There are two basic components to safety:
●●Intrinsic safety – some drugs are intrinsically and obviously safer
than others at therapeutic doses. For example, the adverse reactions
produced by paracetamol compared with cytotoxic drugs.
●●User‐dependent safety – the safety of a drug can also depend on how
it is used. For example, monitoring white blood cell count in users
of clozapine can completely prevent reduction in white blood cells
to a level that would potentially have fatal consequences. Using
the drug without such monitoring is therefore clearly less safe than
following the recommended procedure. Another example of safety
being user‐dependent would be giving penicillin to someone who is
allergic to it, perhaps because that information has been ignored or
is not available. In such a case, the safeguard (i.e. means of minimis-
ing the risk) is avoidance of a specific drug in a particular individual.
Using an appropriate dose of medicine is an example of practising
risk minimisation that applies to most therapeutic situations.
The amount of safety knowledge available for a drug depends on
how much it has been studied and used. Broadly, there are four cate-
gories of safety in respect of the amount of knowledge available:

1. Well‐established – drugs that have been widely used for many
   (~ 20+) years for which it is unlikely that completely unidentified
   safety issues will emerge.
2. Established – drugs for which there is a substantial body of evi-
   dence of safety in clinical use but not enough to meet level 1.
3. Provisional – all newly authorised drugs until they have been used
   fairly extensively in ordinary practice over a period of at least
   5 years. During this period such drugs are normally under addi-
   tional monitoring (see Glossary) and their safety in ordinary prac-
   tice needs to be studied proactively.
4. Limited – all investigational drugs and the following situations
   where the drug might be authorised on limited safety information:
   ●● Small populations eligible for treatment (e.g. rare diseases, treat-

ments for which are known as orphan drugs). An example is
Gaucher’s disease, a lysosomal storage disorder, which is usually
treated with a recombinant glucocerebrosidase.
●● Drugs with important benefits or where there is great clinical

need (i.e. situations where potentially large risks might be
­acceptable, such as in advanced cancer).
Basic Concepts29

A logical principle following from this categorisation is that all use
of drugs in category 4 should be associated with systematic collection
of safety information.
It is important to recognise that drugs in the well‐established
­category are not necessarily safer than those in lower categories (and
so on), only that more information is available about their safety.

Risk–Benefit Balance

As absolute safety is an unattainable goal, the aim is to use medicines
with an acceptable level of safety. Various factors need to be consid-
ered in judging whether safety is or is not acceptable:
●●The level of absolute risk(s) and the potential health consequences.
●●The benefit(s) expected, also measured in absolute terms.
●●The seriousness of the disease for which treatment is given.
●●The risks and benefits of alternative approaches.
●●The perspective and circumstances of the individual who is to be
exposed.
In practice, therefore, whether safety is acceptable cannot be
divorced from efficacy and expected benefits. The harms and benefits
of a medicine are balanced at two levels:

1. Population level – this is a regulatory and research‐based task and
   a question of whether, overall, the benefits that will accrue from
   availability of a medicine will exceed the expected harms.
2. Individual level – this is made by the clinician in consultation with
   the patient and takes into account factors such as the patient’s pre-
   vious treatment, disease severity and the patient’s circumstances
   and preferences.
   The process of balancing harms and benefits is a judgemental one
   and an element of judgement is always likely to remain, despite
   promising attempts that have been made to develop mathematical
   tools to aid the process at the population level. The term risk–­benefit
   ratio has often been used but is best avoided. A ratio implies one
   number divided by another and even if two simple numbers were
   available to summarise risks and benefits, what would a ratio of, say,
   1.5 mean? Conceptually it is preferable to use an additive process in
   risk–benefit assessment and the resulting balance becomes analo-
   gous to a financial balance, which is either positive or negative.
   Ideally, a balance sheet would be constructed and the debits

(i.e. the ADRs) would be s­ubtracted from the credits (i.e. the
expected benefits), it is to be hoped leaving a positive balance.
The problems are that the credits and debits are not usually measur-
able in the same way and there is often uncertainty about the size of
some of the entries. Nevertheless, such an analogy is helpful in
assessing whether to achieve these ­benefits it is reasonable (or not)
to accept these risks of harm.

Lack of Benefit

The efficacy and effectiveness of drugs is not considered in any detail
in this book because pharmacovigilance is primarily about clinical
safety of medicines. However, the expected benefits of a drug are an
important factor when considering whether safety is acceptable, and
the overall balance of risks and benefits for at least one indication
must be considered positive if a drug is to remain on the market.
Conversely, when a drug is initially launched there must be evidence
of efficacy and potential benefit, but this does not mean that the drug
will be beneficial to all patients (many drugs do not work in surpris-
ingly high proportions of patients) or that its ‘real world’ level of effec-
tiveness will be sufficient for the risk–benefit balance to be considered
positive, or remain constant over time.
The development of resistance to antibiotics is a good example
of diminishing effectiveness. If there is no longer any expectation of
­benefit, then there can be no level of safety that will lead to a positive
risk–benefit balance. At the individual level, lack of efficacy can
sometimes be regarded as having serious safety implications (and
therefore potentially reportable as a suspected ADR), for example if
contraceptive products or devices fail, resulting in unintended
pregnancies.

­Causation – Was the Drug Responsible?
Deciding whether a drug is responsible for an AE is very often the most
important question facing scientists working in the field of pharma-
covigilance. Yet, it is rarely completely straightforward, whether the
­matter is being considered at the level of an individual patient or in
terms of study data for various populations. As in the case of risk–­
benefit assessment, a judgement is often necessary and there are
Basic Concepts31

some ­principles to be applied. There are some similarities in approach
between the two levels mentioned, although they are considered
­separately here.

Causality Assessment in Individual Cases

Many causality algorithms and categorisation systems have been
­proposed but none has gained universal acceptance, and the value of
assessing this for each individual report of a suspected ADR has been
questioned. It may be more efficient to reserve such assessment for a
series of cases which might represent a new and/or important safety
issue. Systematic assessment of causality in individual cases occurring
in clinical trials is generally a weaker approach to assessing causality
than comparison of numerical counts. However, in post‐marketing
surveillance, and especially in prescription‐event monitoring (PEM)
studies (see Chapter 3), causality assessment of individual AEs can be
important in determining which may be related to the medicine and
which represent background clinical events.
When individual case causality assessment is to be performed, there
are usually four categories into which a case might be placed following
analysis of all available clinical information:

1. Probable – the balance of information available supports causa-
   tion. Usually, evidence of a ‘positive rechallenge’ (reoccurrence of
   the AE on readministration of the same dose of the suspect medi-
   cine) is required for this category.
2. Possible – some of the available information is in favour of and
   some against causation. For this category, usually evidence of a
   ‘positive dechallenge’ (resolution of the AE symptoms after stop-
   ping the suspect medicine) is required.
3. Unlikely – the balance of information available is against causation.
   For example, it is more likely that other factors (e.g. the patient’s
   condition) have caused the AE.
4. Unassessable – a reasonable judgement cannot be made, often
   because key information is missing.
   In making such judgements there are four broad areas to consider:
5. Temporal relationships – what was the time relationship between
   starting treatment and the onset of the event. If treatment was
   stopped (‘dechallenge’) or restarted (‘rechallenge’), did the event
   abate and/or recur?

6. Alternative causes – are there concomitant diseases and other
   medications or non‐drug exposures that could explain the event?
7. Nature of the event – some clinical events are often caused by drugs
   and immediately suggest a relationship (e.g. certain types of skin
   reactions such as toxic epidermal necrolysis; see Chapter 7).
8. Plausibility – is the reaction already recognised with this drug (or
   similar drugs) or can a biological mechanism be postulated based
   on the pharmacology of the drug?
   In terms of temporal association, sometimes causation can be defi-
   nitely excluded; for example, ADRs cannot start before the drug is
   given (although drugs can worsen existing diseases). On the other
   hand, a positive rechallenge in the absence of alternative causes is
   ­generally considered to be strong evidence for causation. While most
   ADRs start early on in treatment this is not invariably true, as reflected
   in the time course element of the DoTS classification already
   discussed.
   Merely because an alternative cause can be identified does not mean
   that it was responsible. Possible other causes are often called
   ‘­confounding factors’ and when they are present, cases are said to
   be ‘confounded’. This is rather loose use of the word (see Figure 2.1)
   and best avoided.
   The issues of nature of the event and plausibility need to be consid-
   ered with some caution – these factors may add to the arguments for
   causation, but a clinical event that is not normally known to be drug‐
   related or the absence of any information supporting plausibility is not
   strong evidence against it. Absence of evidence is not the same as
   ­evidence of absence.

Assessing Causality from Clinical Trial Data

One of the main reasons why data from randomised controlled trials
are considered to be the gold standard is that, in principle, observed
differences between randomised groups should be attributable to the
different treatments (i.e. causal). Other explanations are still possible,
for example differences could simply be due to chance or caused by
various biases, particularly in relation to what is being measured.
Problems with the randomisation may also occur – such as that it may
not have been carried out properly. Sometimes, as a result of bad luck,
randomisation may not have worked to produce groups that were
adequately balanced at baseline in terms of important factors that may
Basic Concepts33

predict the outcome of interest. While all these alternative explana-
tions need to be considered, when a difference that looks important is
observed in a randomised trial, causation is the most likely explana-
tion. If the trial has adequate statistical power (and the observed dif-
ference is statistically significant), the groups were well‐balanced at
baseline and the measurements are objective or blinded, then no great
element of judgement is required to accept that such a difference
between treatments is likely to be real.

Causality in Non‐Randomised Studies – The Problems of
Bias and Confounding

For study data that are not randomised, assessing causation requires
much more judgement and is often a source of debate. When such
studies find a difference, this is known as an association. In terms of
chance, the issues are much the same as for randomised trials, but
there are many more types of biases that may be relevant. In the real
world, people tend to do things for a reason and patients who are
given particular treatments may be selected according to factors that
are relevant to the outcome of interest. For example, patients using
coxibs (see Chapter 1) are often selected on the basis of being at higher
baseline risk of gastrointestinal bleeding than patients using tradi-
tional anti‐inflammatory drugs. Non‐randomised comparative stud-
ies that did not address this bias would therefore be likely to (wrongly)
observe the opposite of what is found in trials. A further potential bias
is that losses to follow‐up are more likely than in trials and the reasons
why people are ‘lost’ from studies may not be random. For example,
patients could be lost from follow‐up because they have died from
an ADR.
Aside from the greater problem of bias, there is also the problem of
confounding in non‐randomised studies. A confounder has a triangu-
lar relationship with an exposure (usually a drug) and outcome (AE of
interest; Figure 2.1). When it is present, the risk of the outcome is
affected and whether or not it is present also varies according to the
exposure status. Age is a good example of a perennial confounder – in
very simple terms, older people tend to use more drugs and have more
adverse outcomes. Therefore there is a need to be sure that any
observed association is not simply a consequence of that. A ran-
domised study will, unless it is small, tend to balance the groups for
age – or indeed any confounder – largely circumventing this problem.

Confounder (e.g. age)
Exposure (e.g. drug)Outcome (e.g. ADR)

Figure 2.1 The triangular relationship between a confounder, an exposure and
an outcome. By influencing both the probability of being exposed and the
probability of the outcome occurring, a confounder distorts the relationship of
interest (i.e. between the exposure and outcome).

In principle, confounding can be dealt with, either in the study design
(e.g. by matching patients or groups so that relevant factors are bal-
anced) or in the analysis by statistical adjustment. However, to do so
requires that all potential confounders are identified and adequately
measured. Smoking is another common confounder and knowledge
of smoking status in terms of (say) current, ex‐ or non‐smoker is fairly
crude given that there may be a close relationship between the precise
amount smoked and the risk of the outcome. The possibility that con-
founding has not been fully addressed is called residual confounding
and this is often a possible alternative explanation to causation when
data come from non‐randomised studies.

Using the Bradford Hill Criteria to Assess Causality

When chance, bias and confounding are considered unlikely, causa-
tion is possible but still cannot be assumed as an explanation for an
association based on non‐randomised data. Often, there are a series of
studies or various types of data that bear on this question. In this con-
text, nine criteria first described by Bradford Hill in the 1960s are still
used. Five of these can be summarised as follows:
●●Strength – the stronger an association is, the less likely it is to be
explained by other factors.
●●Consistency – repeated observation of an association in different
studies and under different conditions support causation.
●●Specificity – a few ADRs are completely unique syndromes (some
examples were given earlier) and their specificity means that
­causation is hardly in doubt.
Basic Concepts35

●●Temporality – exposure to the suspect medicine must precede
­outcomes in a consistent manner.
●●Biological gradient – is there evidence of dose‐ or duration‐related
risk?
The final four criteria are plausibility, coherence, supportive experi-
mental evidence and analogy. These are related by a theme of whether
the association fits with existing scientific knowledge and beliefs. If so,
then causation is more likely but newly identified associations may
not fit, so absence of any (or all) of these criteria does not preclude an
association being causal.
In general terms, the more criteria that are met, the more likely an
association is to be causal. However, there is no simple formula for
adding up these criteria and coming to a definitive answer. Professional
judgement is required for such assessments and Bradford Hill’s ­criteria
are merely a conceptual framework for making such a judgement. It is
worth noting that some of the criteria (e.g. temporality, dose–response,
plausibility) are analogous to what was described for the assessment of
causality in individual cases.

­Conclusions
This chapter has considered the most fundamental concepts in phar-
macovigilance: what is an adverse effect of a medicine, how do we
know that it really is an adverse reaction, what is safety and on what
basis do we consider a treatment to be safe? We have discussed the
concept of measuring risk and the differences between relative and
absolute risk. The concept of the balance of risk and benefit is impor-
tant because a key goal of the pharmacovigilance process is to ensure
that the risks of drug treatments are outweighed by the benefits.
Finally, we have covered the concepts behind causality assessment, a
basic and vital tool in pharmacovigilance practice. The next step is to
consider in more detail the various kinds of data that help us to answer
such questions in relation to specific medicines and safety issues.
37
3

The Process of Pharmacovigilance

­Overview – A Risk Management Process
As indicated in Chapter 1, pharmacovigilance is essentially a risk
management process for medicines. The process starts with identifi-
cation of a possible hazard, which is then evaluated and investigated
and, if necessary, some action is then taken with a view to minimising
risks. Implementation requires tools for communicating with pre-
scribers and users and the final step should be an assessment of the
effectiveness of this process. The whole process of risk management is
iterative because new evidence may emerge, or the measures taken
may turn out to be insufficient. Rarely can a drug safety issue be
­considered completely and permanently resolved.
The start of the process is usually a ‘signal’ (something that needs to
be looked at further), which may not turn out to be a true hazard.
Before that can happen, there is a need to identify the signal.

­Signal Detection
What is a Signal?

The World Health Organization (WHO) has defined a signal as:

Reported information on a possible causal relationship between
an adverse event and a drug, the relationship being unknown or
incompletely documented previously. Usually more than a sin-
gle report is required to generate a signal, depending upon the
seriousness of the event and the quality of the information.
An Introduction to Pharmacovigilance, Second Edition. Patrick Waller
and Mira Harrison-Woolrych.
© 2017 John Wiley & Sons Ltd. Published 2017 by John Wiley & Sons Ltd.

This definition seems mainly focused on spontaneous ADR report-
ing data. A broader approach would be to consider a signal as simply
an alert from any available data source that a drug may be associated
with a previously unrecognised hazard or that a known hazard may be
quantitatively (e.g. more frequent) or qualitatively (e.g. more serious)
different from existing knowledge. This approach is in line with the
Council for International Organizations of Medical Sciences (CIOMS)
VIII report (see Chapter 6), which defines a signal as:

Information that arises from one or multiple sources (including
observations and experiments), which suggests a new poten-
tially causal association, or a new aspect of a known associa-
tion, between an intervention and an event or a set of related
events, either adverse or beneficial, that is judged to be of
­sufficient likelihood to justify verificatory action.

In practice, most signals will relate to previously unrecognised
­ azards, but a striking example of a signal that a known hazard was
h
more serious than previously thought occurred in the mid‐1990s. The
non‐steroidal anti‐inflammatory drug, tiaprofenic acid, had been
known to cause cystitis for over a decade, but a series of cases was
then reported indicating that, if the reaction was not recognised and
the drug was continued in the long term, severe chronic cystitis might
occur. The outcome was that surgical resection of the bladder was
often necessary, leading to permanent disability.
While some signals may be detected passively (e.g. from the medical
literature), the process of signal detection should be fundamentally an
active one. In terms of finding signals in large databases, it has been
suggested that this is akin to looking for a needle in a haystack,
although there are likely to be lots of needles to find. The term data
mining (actively searching for patterns in large datasets) is now widely
used in this context, particularly in relation to systematic detection of
signals from large spontaneous ADR databases.

Processes for Signal Detection

In the context of spontaneous ADR reporting, a signal is normally a
series of cases of similar suspected ADRs reported in relation to a par-
ticular medicinal product. When the suspected ADR is a condition
that is rare in the general population (e.g. aplastic anaemia, toxic
The Process of Pharmacovigilance57

e­ pidermal necrolysis), a very small number of cases associated with a
single drug is unlikely to be a chance phenomenon, even if the drug
has been used quite widely. Except for certain types of event that are
particularly important and likely to be drug related (e.g. anaphylaxis),
a single case is not usually sufficient to raise a signal. Three cases are
generally considered to be the minimum number of cases needed.
The amount of drug usage (i.e. some drug exposure data) is helpful
in providing context to a series of reported cases, but it is not usually
critical in determining whether there is a signal that needs to be evalu-
ated. The strength of evidence for the individual cases will be impor-
tant to consider later but, initially, the key issue is whether there is an
unexpectedly large enough number of cases.
In the past, various methods have been used to detect signals using
spontaneous reporting data. Calculating reporting rates based on
usage denominator data, as prescriptions dispensed or defined daily
doses (or less accurately from estimated sales figures), may enable a
signal of a particular ADR to be derived by comparison with alterna-
tive treatments. As spontaneous ADR reporting schemes are subject
to a variable and unknown degree of under‐reporting and denomina-
tor data derived from sales data can be very inaccurate, such compari-
sons are crude. They may also be biased, particularly if the drugs being
compared have been marketed for different indications or durations,
or if there has been significant publicity about the adverse effects of
one of the drugs.

Disproportionality Approaches or Signal Detection

The other principal approach that has been for making comparisons
between drugs is to use the proportions of all ADRs for a particular
drug that are of a specific type – perhaps within an organ system class
of reactions (e.g. gastrointestinal or cutaneous). This is known as
­profiling, a method that has an advantage over reporting rates in that
it is independent of the level of usage. The data can be displayed
graphically as ‘ADR profiles’. This proportionate approach forms the
basis of statistical methods which have been developed since the mid‐
1990s and are now widely used. One important advantage of these
methods is that no external data (e.g. usage) are required – they are
entirely based on information present on a single database.
The basic concept behind such measures of ‘disproportionality’ is
whether more reports have been received for a particular drug–­reaction

combination than might have been expected as background noise.
When all drugs are considered together, large ADR databases tend to
have fairly stable proportions of particular reactions over time. That
proportion is used as a baseline for comparison –to determine what
would be expected if there was no signal. For example, in the UK
Yellow Card database in the mid‐1990s, there were nearly 600 000
­suspected reactions which had been reported to any drug over a
period of 30 years. Almost 800 of these (about 0.13%) were classified
as ‘uveitis’ (inflammation of the middle layer of the eye). A few years
earlier, a new anti‐tuberculous drug,rifabutin, had been introduced
and some 41 cases of uveitis were reported as suspected ADRs to this
drug. In total, only 55 reactions of any kind had been reported with
rifabutin by that time (i.e. 75% of them were uveitis). In this example,
the expected proportion of uveitis reports (derived from placing all
other drugs together) was 0.13% but the observed value for rifabutin
was 75%. Dividing 75/0.13 yields a number well over 500 – this is
known as the proportional reporting ratio (PRR). The ‘null value’ of a
PRR is 1 and the calculation is made from a two‐by‐two table, as
shown in Table 4.1.
As can be seen from the statistical tests, this was very unlikely to
have occurred by chance and is a very extreme finding. In fact, this
signal was quite obvious without using mathematics. The approach is
more likely to be useful in identifying signals that might otherwise
be missed when the PRR is much lower – say in the range of 1–10.
In general, experience has shown that a PRR of 3 or more represents a
degree of disproportionality worth looking into further, providing it is

Table 4.1 Example of proportional reporting ratio (PRR) calculation: rifabutin
and uveitis.

RifabutinAll other drugs Totals

Uveitis41 754795
All other ADRs14 591 958 591 972
Totals55 592 712 592 767

Proportion of ADRs that are uveitis with rifabutin = 41/55 (i.e. 0.75).
Proportion of ADRs that are uveitis for all drugs 754/592 712 = 0.0013.
PRR = 0.75/0.0013 = 556.
Chi‐squared (1 degree of freedom) = 22 000, P ≪ 0.00001.
The Process of Pharmacovigilance59

unlikely to have occurred by chance, that is, the value of chi‐squared
exceeds 4 (roughly the 5% level of statistical significance).
Going back to the point about generally needing three cases, it
is therefore possible to regard the following as cut‐off points for a
minimum signal:
●● PRR >3
●● Chi‐squared >4
●● N = 3 or more.
Using such criteria, whole databases can be screened regularly by
calculating two‐by‐two tables for all drug–reaction combinations to
identify those that most need further attention.
A useful way of visualising the data is to plot, on logarithmic scales,
the PRR against the value of chi‐squared using the number of reports
(N) as the symbol (Figure 4.1). The vertical and horizontal lines
­represent the cut‐off points and everything in the upper right‐hand
quadrant is a signal of an unexpected degree of disproportionality.
Note that the 41 cases of uveitis reported with rifabutin appear in this
quadrant as one of the most extreme data points.
Another useful way of looking at the data is to plot the PRR over
time (Figure 4.2). In the historical example given in Figure 4.2, the
angiotensin converting enzyme (ACE) inhibitor captopril was first
marketed in 1982 but it took until 1986 before cough was recognised

10 000
Proportional reporting ratio
1000

100

10

1110 100100010 000
Chi-squared

Figure 4.1 Plot of proportional reporting ratio (PRR) vs. chi‐squared (from UK
spontaneous ADR reporting data); the number of reports is used as the symbol.

30

107
97
96
90
68
66
66
54
20 4448
44
34
31
28
25
PRR
61213 21
21
16613
13 15 18
11113141516
13
1466 15
14466777889
1
101
1
12
12
11
1111

0
1982 198419861988
Calendar time

Figure 4.2 Plot of PRR over time for captopril and cough (from UK spontaneous
ADR reporting data); the number of reports is used as the symbol.

as an adverse reaction with this class of drug. Like thalidomide and
practolol, the first indication of this association appeared in the pub-
lished medical literature. By the beginning of 1986 there were at least
15 reports in the UK ADR database and the criteria discussed earlier
would have been met some 2 years earlier when there were four
reports and a PRR above 10. Note how the PRR fluctuates over
time – ADR databases are dynamic – and that the increase in the
period 1986–1988 is most likely to have been an effect of publicity
about the reaction.
The PRR is just one of several measures of disproportionality that
have been used. A reporting odds ratio (ROR) can be calculated from
the same two‐by‐two table and has been mostly used in the
Netherlands. The WHO Uppsala Monitoring Centre (UMC) uses
the information component (IC) and the US Food and Drugs
Administration (FDA) the Multi‐Item Gamma Poisson Shrinker
(MGPS), both of which are more complex measures based on Bayesian
statistics. These measures tend to produce less extreme values than
PRRs when the number of cases is very small. However, when the sen-
sitivity, specificity and predictive power of these measures were com-
pared using Dutch data in 2002, no important differences were found
provided at least three cases had been reported. In addition to PRRs,
the UK regulatory authority now uses the empirical Bayes geometric
mean (EBGM).
The Process of Pharmacovigilance61

A number of points about these methods are worth emphasising.
First, although the numbers are calculated in a similar way to relative
risks, they do not represent a meaningful calculation of risk. While it is
true that the greater the degree of disproportionality, the more reason
there is to look further, the only real utility of the numbers is to decide
whether there are more cases than might reasonably have been expected.
Indicators of disproportionality are measures of association and
even quite extreme results may not be causal. The next step is detailed
clinical review of the relevant individual case reports and to assess any
other relevant information which may be available. Many pharma-
covigilance experts do not regard mathematical disproportionality
alone as sufficient to raise a ‘signal’. Thus, use of the terms ‘statistical
signal’ and ‘signal of disproportionate reporting’ has emerged.
Aside from such semantic considerations, the underlying nature of
the data and various potential biases inherent in spontaneous ADR
reporting must not be forgotten. A specific problem arising from pro-
portionate methods is that large effects may swamp and therefore mask
smaller ones. For example, it is fairly obvious that PRRs calculated for all
the other suspected reactions reported with rifabutin (the example
given earlier) are going to be less than 1 but it is quite possible that some
of these reactions would also be worth looking into further.
The data mining approach to signal detection has been questioned
by some practitioners who believe that relying on clinical experience
alone is preferable and that there are too many limitations to the
­disproportionality methods. It is generally agreed that detailed assess-
ment of individual case reports (preferably by those with clinical
experience) should be a key component of signal identification, but in
databases where there are large numbers of ADRs, data mining may be
seen as a useful first step to raise possible issues to examine further,
or to add supporting evidence when assessing and investigating
­individual case reports. Hence, data mining should not be seen as a
replacement for clinical assessment of reports, but rather an aid to it.

­Evaluation and Investigation
Signal Prioritisation

Systematic use of data mining tools in a large spontaneous ADR data-
base will identify large numbers of statistical signals. Evaluating all of
them in detail would have major resource implications as many will

turn out not to be real or to require no action. Possible signals
have often been evaluated or dismissed on the basis of subjective
judgements, but two more formal methods of prioritisation have been
developed.

1. Triage (used by the WHO UMC) analogous to a process used in
   emergency medicine to decide on priorities. Essentially, it is a
   quick look at the most important features of a case series (e.g. seri-
   ousness, outcome) to decide on the urgency of further assessment
   relative to other cases.
2. Impact analysis (used by the UK MHRA) more quantitative and
   involves calculating two scores which are then used to decide an
   overall priority:
   Evidence score:
   ●● Based on the degree of disproportionality (e.g. value of PRR)

●● Strength of evidence

●● Biological plausibility.

Public health score:
●● Based on number of reported cases per year

●● Expected health consequences

●● Reporting rate in relation to level of drug exposure.

The overall categories derived from these scores are as follows:
●● High priority – prompt further evaluation is required

●● Need to gather more information

●● Low priority

●● No action.

It is important to recognise that these scores are only a means of
deciding whether further evaluation is currently warranted and that
impact analysis can – and should be – repeated if more evidence
emerges.

Principles of Signal Evaluation

The data giving rise to the signal – whether arising from a series of indi-
vidual cases or a formal study – should be evaluated in detail first. It is
also important to consider what other immediately available data might
be relevant, to obtain them and to include them in the evaluation.
For example, are there any other cases of the putative ADR (or similar
clinical events) in randomised clinical trials, or are there any relevant
The Process of Pharmacovigilance63

pre‐clinical findings? Are there any epidemiological data that might
help, or is there anything of relevance in the published literature?
When evaluating a signal the key issues are:
●●Causality – does the balance of evidence support cause and effect
(see Chapter 2)?
●●Frequency – if this is a real effect, how often is it occurring? Can we
make any estimate of the likely level of absolute risk (see Chapter 2)?
●●Seriousness of the ADR – are there any fatal cases, is the reaction
potentially life‐threatening, can it result in long‐term disability?
●●Other clinical implications – even if the ADR is not serious (as
defined here and in Chapter 2), are there other important effects for
patients and healthcare systems (e.g. need for extensive investiga-
tions or inability to work)?
●●Preventability – are there any factors that, even at this stage, suggest
a potential means to prevent the adverse reaction or serious out-
comes arising from it?
In terms of frequency, the descriptors originally proposed by a
CIOMS working group (see Chapter 6) are generally used, based on
orders of magnitude and expressed as a simple proportion of patients
affected (Table 4.2).
When evaluating signals from spontaneous reporting data, it is
often difficult to obtain denominator or exposure data which are
accurate enough to make a more precise estimate of expected ADR
frequency than suggested earlier. We have already mentioned that
sales data have limitations and provide only a rough estimate of usage.

Table 4.2 Descriptors originally proposed by a Council for International
Organizations of Medical Sciences (CIOMS) working group.

CIOMS descriptorFrequency

Very common More than 1 in 10
Common1 in 10 to 1 in 100
Uncommon 1 in 100 to 1 in 1000
Rare1 in 1000 to 1 in 10 000
Very rare Less than 1 in 10 000

The most accurate way to estimate frequency of ADRs in post‐­
marketing use is from more formal pharmacoepidemiology studies,
for example PEM studies (see Chapter 3) where cohorts of patients are
established from prescription records.
The outcome of signal evaluation is often that there is a need for
further investigation, but there can also be enough evidence and con-
cern to take action without waiting for confirmatory studies. If several
deaths or serious ADRs had been reported and causality assessment
suggested a ‘definite’ or ‘probable’ relationship with a specific medi-
cine (see Chapter 2), it would not be ethical to wait for more formal
studies to be designed, conducted and analysed. Also, in some cases,
it may not be feasible to conduct further studies because no suitable
resource is available with data on enough patients.

Further Investigation

Primarily, signals are further investigated to provide more informa-
tion about the key issues in signal evaluation – to try to gain better
evidence on whether the drug really does cause the effect, how com-
mon it is, how serious it is and how it might be prevented. In respect
of the latter, this is often a question of trying to identify who is at
particular risk of the adverse effect (i.e. what are the risk factors?; this
is discussed further in Chapter 7). Thus, as discussed in Chapter 3,
pharmacoepidemiological studies are the main way in which signals
are further investigated.
Another common avenue of investigation is through mechanistic
studies (i.e. through the application of basic science in the laboratory,
can we understand the biological mechanism of the ADR?) Knowing,
for example, that an adverse effect mostly occurs in people who are
poor metabolisers of specific hepatic cytochrome substrates could
be important in developing preventive measures.­Taking Action
Potential Options

The ultimate purpose of pharmacovigilance is prevention and there-
fore the actions that are taken will generally be intended to help
­prevent occurrence of ADRs in the future. There are many factors that
The Process of Pharmacovigilance65

can impact on the potential for prevention of ADRs. Broadly, these
can be classified into characteristics of the user or the drug:

1. User characteristics:
   ●● Demographics: age, sex, race

●● Genetic factors: polymorphisms (e.g. acetylator status)

●● Concomitant diseases (e.g. impaired hepatic or renal failure)

●● History of previous ADRs (e.g. allergy)

●● Compliance and use of other medicines.

2. Drug characteristics:
   ●● Route of administration

●● Formulation (e.g. sustained vs. immediate release, excipients)

●● Dosage regimen

●● Therapeutic index (a measure of the intrinsic safety of a drug in

relation to dose)
●● Mechanisms of drug metabolism and route of excretion

●● Potential for drug interactions.

Based on these possibilities, a wide variety of potential actions can
be considered and in various combinations. For taking regulatory
action, it is useful to think of these in relation to the structure of the
Summary of Product Characteristics (SPC), sections 4.1–4.9, and the
potential amendments that might be made (Table 4.3). Thus, it can be
seen that every section of the clinical advice in the SPC might poten-
tially need to be modified in relation to a new drug safety issue.
Apart from amending the advice to users, there are two more
drastic types of regulatory action that might be considered. The
first is to take some steps, beyond mere recommendation, to ensure
that a key part of advice is implemented in practice. The second is
to remove the drug from the market. A good example of the former
is the scheme that was set up to ensure that users of the antipsy-
chotic drug clozapine have their white blood cell counts effectively
monitored (see Chapter 7). In essence, further supply of the drug
was linked to the availability of a blood test result (i.e. no blood, no
drug). The reason for this was that it had been demonstrated that
regular blood tests would generally pick up a falling white blood cell
count before patients developed serious infections and also that on
stopping the drug, the process was reversible. A further example of
a scheme that takes active steps to ensure that measures necessary
to minimise risks are taken by users are the pregnancy prevention
programmes set up for users of isotretinoin (a known teratogen).

Table 4.3 Potential for actions to improve safety related to sections
of the Summary of Product Characteristics (SPC).

Section of SPC Examples

Indications/usesLimiting the indications to particular conditions with
the greatest benefits by removal of indications: (a) for
which the benefits are insufficient to justify use; (b) for
which use is associated with a greater risk of the ADR
Dosing instructionsReductions in dose (may be applied to specific groups,
e.g. the elderly); limitations on duration or frequency of
treatment (especially for ADRs related to cumulative
dose); provision of information on safer administration
ContraindicationsAddition of concomitant diseases and/or medications
for which the risks of use are expected to outweigh
the benefits
Warnings/Addition of concomitant diseases and/or medications
precautionsfor which the risks of use need to be weighed carefully
against the benefits; additional or modified
recommendations for monitoring patients
InteractionsAddition of concomitant medications, alcohol or foods
that may interact; advice on co‐prescription and any
monitoring required
Pregnancy/lactationAddition of new information relating to effects on the
fetus or neonate; revised advice about use in these
circumstances based on accumulating experience or
other new data
Effects on driving orPractical advice on possible impairment of coordination
using machinery or other effects due to ADRs such as sleepiness
Undesirable effectsAddition of newly recognised ADRs; improving
information about the nature, frequency and severity of
effects already listed
OverdosageAdverse effects of overdosage; management, including
the need for monitoringIn both these examples, the drugs appear to have particular benefits
not shared by alternative treatments.
Over a period of many years, about 4% of drugs put on the market
have had to be withdrawn for safety reasons – a fairly low proportion.
This reflects reluctance to use this measure unless it is clear that, rela-
tive to alternative treatments, the risks outweigh the benefits despite
maximum attempts to minimise the risks (and maximise the benefits).
The Process of Pharmacovigilance67

Withdrawal from the market is particularly problematic for drugs that
are used chronically by large numbers of patients. If the adverse
effect tends to occur early in treatment, established users will have a
relatively low risk of the ADR – the main need is to prevent new start-
ers. Existing regulatory systems do not readily address this dilemma
although in some instances it is possible for patients using a with-
drawn medicine to continue it on a ‘compassionate use’ basis.
When considering such decisions in the face of uncertain data it
may be necessary to take into account the impact of the precautionary
principle. While, scientifically, it may seem unsatisfactory to act deci-
sively on unconfirmed risks – the need being for more data – some
decisions may have to be made in advance of definitive data, and the
precautionary principle is well‐established in many areas of regula-
tion. In particular, patients should not be expected to take a possible
additional risk when there is no evidence of possible advantage in
doing so. On the other hand, removing a drug from the market may
mean that it becomes almost impossible to study it further and that
clear answers will never be forthcoming.

Making a Decision

The first step in making a decision about how to manage an important
drug safety issue is to bring together all the relevant evidence into a
single document. This is usually called a benefit–risk report and there
is an internationally agreed structure which has been defined in a
report published by the CIOMS IV working group (see Chapter 6).
Both companies and regulatory authorities use the report format and
both usually use experts, often in the form of a committee, to review
the report and help formulate the decision. Lay representation on
regulatory committees has become increasingly common as such
decisions are not purely technical and scientific, they involve value
judgements and consideration of the impact of such decisions on
patients’ lives. In most countries, regulatory decisions are overseen
and sometimes directly made by politicians who are not necessarily
bound by the scientific advice they receive.
The following is a suggested basic approach or framework for
­making decisions on drug safety (i.e. a structured list of the issues that
should be taken into account):

1. What is the nature of problem?
2. What is the evidence of benefit?
3. What is the evidence for risk?

4. How strongly would we wish to avoid the risks and obtain the ben-
   efits in terms of the nature of the potential harms and expected
   positive effects?
5. What assumptions have we made and how valid are they?
6. What areas of uncertainty remain and what evidence is missing?
7. What are the options for action?
8. What are the expected consequences of each option?

Implementation

Unless the medicine is to be withdrawn from the market, most regula-
tory actions that could be taken will involve a change to the marketing
authorisation and product information. Occasionally, the existing
product information is considered satisfactory and the problem is
merely that the recommendations within it are frequently not being
followed. In these circumstances, ‘reminder’ communications may be
issued, often directly by regulatory authorities and through regular
bulletins by which the authorities communicate with health profes-
sionals. However, the extent to which these influence the behaviour of
prescribers is unclear.
An important consideration is how quickly information needs to be
made available to health professionals and patients. A new life‐­
threatening ADR requires immediate communication, whereas the
addition of a symptom that does not appear to be associated with seri-
ous consequences (e.g. nausea) to the undesirable effects section of
the product information could be part of the next routine revision of
the SPC. Most issues come between these two extremes and a judge-
ment needs to be made about the speed of action and the most
­appropriate method of communication.
An issue that is particularly difficult relates to communication of
signals to users of medicines. In the past, unconfirmed signals have
rarely been communicated actively by regulatory bodies because of
the uncertainty involved and because it is often difficult to make clear
recommendations to users. However, in recent years expectations
have changed and appearing to ‘sit’ on potentially worrying informa-
tion which then leaks out can damage confidence in the system and
lead to perceptions that the data are worse than is really the case. In an
important example, in 2007 the WHO UMC published a signal of
approximately 10‐fold disproportionate ADR reporting identified
The Process of Pharmacovigilance69

from their spontaneous database related to statins and amyotrophic
lateral sclerosis (a life‐threatening neurological condition) despite
much uncertainty about cause and effect. This was picked up and
­covered by the general media but, despite the very wide use of statins,
it did not appear to create a major ‘scare’. Subsequently, the signal was
effectively disproved by further investigation. It is likely that informa-
tion about signals will increasingly be actively communicated in the
future, for example through social media.

Other Methods of Implementing Changes in Practice

Once a signal has been identified, it is primarily the responsibility of
regulators to take action and implement changes in prescribing and
use of medicines, using the methods described. However, this part of
the pharmacovigilance process can also be supported and enhanced by
other professional bodies, international organisations and also patient/
consumer groups to achieve effective results. An example relates to the
contraceptive device Implanon. In the early 2000s, more than 200
unintended pregnancies following insertion of Implanon devices were
reported to the Australian national regulatory body, the Therapeutic
Goods Adminstration (TGA). This signal was investigated by the TGA
in collaboration with an academic researcher and published as a case
series in 2006. It transpired that many of the devices had not been cor-
rectly inserted and changes were subsequently made to the Implanon
product information. In addition to the work carried out by the TGA to
resolve this issue, professional bodies in Australia assisted the sponsor
company with providing additional training to inserters of Implanon.
Following these actions, the numbers of unintended pregnancies with
Implanon in Australia fell significantly.

­Communication
Principles

Communication is a vital stage in the pharmacovigilance process, but
one that is hard to get right, particularly if there is an urgent need to
act. The example of oral contraceptives and ‘pill scares’ discussed in
Chapter 1 led to much more attention to this aspect and discussion of

the principles involved. Since the late 1990s, risk communication has
developed as a sub‐specialist area of pharmacovigilance (with an
increasing number of publications in academic journals) and it is now
recognised that a particular set of skills is required to achieve effective
communication.
The main requirements for a successful drug safety communication
are that it is accurate, balanced, open, understandable and targeted.
These can be remembered by the mnemonic ABOUT (Table 4.4).

Practical Issues

The ABOUT criteria are considerations that can be used to formulate
the process of developing a communication. A draft should be tested
against these requirements by a review process which includes both
individuals who are experts in the field and those who are generalists.
Communications intended for patients should be written in plain lan-
guage and reviewed by lay people. Information should be prepared in
the appropriate languages of the target populations in the countries
affected. In urgent situations it is vital to spend enough of the time
that is available ensuring that these requirements are met.Table 4.4 Key requirements for a successful drug safety communication (ABOUT).

Requirement Comments

Accurate Are the facts and numbers correct? Is all the
information that the reader needs to know included?
Balanced Have both risks and benefits been considered? Is the
overall message right?
OpenIs the communication completely honest about the
hazard without any attempt to hide or minimise it?
Have any conflicts of interest been declared and
explained?
UnderstandableShould be as straightforward as possible using lay
language without jargon – the reader is more likely
to respond appropriately if the message is simple
and clear
Targeted This involves considering who is the intended
audience and their specific information needs
The Process of Pharmacovigilance71

It is particularly important in any communication about drug safety
to ensure that essential information is clearly conveyed and not
obscured by other less important information. The key facts and
advice should be placed in a prominent early position (as many people
will only read the first paragraph) with use of highlighting where
needed. A clear lay‐out with sub‐headings, a large enough font, use of
bolding/colour and inclusion of appropriate pictures or diagrams can
make a huge difference to readability and effective communication.
It is vital that the level of the risk is made very clear by expressing it in
absolute rather than relative terms (see Chapter 2). The need for clear
and simple language is vital – a good tip when drafting is to read the
communication out loud and listen to how it sounds.
Table 4.5 represents a basic model for any drug safety communica-
tion, whether it is to be targeted at health professionals or at a lay
audience (e.g. the general media).
Information sent to health professionals should be clearly labelled
‘Important safety information’ and, if appropriate, ‘Urgent’. It is also
useful to prepare answers to ‘Frequently asked questions’ as these are
often placed on relevant websites.

Methods of Communication

Today there are many different ways in which drug safety messages
can be conveyed to the target audience (which must be clearly defined),
from hard copy letters through to electronic methods including social
media and text messaging. It is important to consider which means
will be most effective in the local environment and also which are
the most appropriate. These aspects of risk communication are still
evolving.

Table 4.5 Basic model for a drug safety communication.

Short heading which includes the drug and hazard

1.  Nature of the problem: drug, hazard, precipitating factor(s)
2.  Summary of the evidence for the hazard
3.  What is being done: for example reviewing, investigating, new studies,
    changing labelling and so on
4.  What are the implications for: (a) health professionals; (b) patients?
5.  Overall balanced view of risks and benefits
6.  Where to get further information/contact details

­ easuring the Effectiveness of the Risk
M
Minimisation Process
Measuring the success (or failure) of actions taken to minimise risk is
an important step in the overall process, but one that is often over-
looked or poorly done. Broadly, the possible methods of evaluating
the effectiveness of actions taken are as follows:
●●Testing the effectiveness of the communications – have they been
received and understood (e.g. using market research techniques)?
●●Analysing the effect on prescribing – the extent to which prescribing
habits may have been modified and whether these changes consist-
ent with revised recommendations in the product information (e.g.
using longitudinal patient databases).
●●Monitoring spontaneously reported cases – to see whether serious
cases continue to be reported. The numbers of cases reported may
be difficult to interpret because of publicity bias, but it can be useful
to see, for example, whether any of the reported cases reflect con-
traindicated use.
●●Observation/formal study of prescribing and events – has the action
resulted in reduced morbidity/mortality from the ADR in practice?
This will require use of a longitudinal patient database, performance
of clinical audits or an epidemiological study. A formal pharma-
coepidemiological study is perhaps the ideal but has been the least
frequently undertaken of these activities.

­Crisis Management
Every drug safety issue is different and an important step in dealing
with one is to determine the level of urgency, using the principles
­discussed (broadly, the public health impact taking into account the
absolute frequency of the hazard, number of users and seriousness).
Major, newly identified hazards result in a need to re‐evaluate the
overall risk–benefit balance of a product. The highest level of urgency
occurs when new evidence emerges suggesting that the risks of a
­medicine may outweigh the benefits, either for all users or in specific
circumstances (e.g. a particular indication). Thus, a potential or
defined need to withdraw a drug on safety grounds is inevitably a
The Process of Pharmacovigilance73

c­risis ­situation for all those involved in its management. In these
­circumstances, any delay can result in damage to patients and reason-
able haste is necessary.
Crisis management in drug safety is not fundamentally different
from dealing with other types of crisis. A standard operating proce-
dure for crisis management needs to be in place beforehand defining:
●●What will be considered a crisis
●●Composition of the crisis team and responsibilities
●●Stakeholders and need for interactions with them.
The first task of the crisis team is to draw up a specific crisis
­management plan which will define the following:
●●Key objectives
●●Expected timelines (likely to be days to a few weeks at most)
●●Resources required
●●Responsibilities.
The key tasks for the drug safety crisis team are likely to be the
following:
●●Evaluation of the evidence
●●Decision‐making
●●Practical arrangements for implementation
●●Developing the external communication materials.
Progress towards the objectives needs to be reviewed daily and
effective internal communication is vital. Because a regulatory author-
ity or company (or other organisation) needs to deal with a crisis does
not mean that routine work and other obligations can be ignored.
Therefore, personnel who continue to deal with routine work should
ideally be kept entirely separate from the crisis team.

­Conclusions
This chapter has considered the process of pharmacovigilance from a
signal of possible hazard through to remedial action, including
­effective risk communication. The outlined principles apply to phar-
maceutical companies, regulatory authorities, researchers and
other professionals involved in the practice of pharmacovigilance

worldwide, including those who can support implementation of
changes in clinical practice in order to achieve safer use of medicines.
Good communication, both within organisations and with external
stakeholders, is essential in achieving the best results from the ­process.
Chapter 5 considers how companies and regulators should interact to
ensure that the pharmacovigilance process is appropriately applied.
75
5

Regulatory Aspects of Pharmacovigilance

The need for medicines regulation and pharmacovigilance became
widely recognised in the 1960s as a consequence of the thalidomide
tragedy. The role of regulatory authorities worldwide is to protect
public health by promoting the safe and effective use of medicines. In
general terms, these activities are also in the interests of pharmaceuti­
cal companies, but industry has an additional, commercial driver – the
needs to recoup investments in products and to satisfy shareholders.
As health and financial drivers sometimes conflict, the authorities
have compulsory powers to act on grounds of safety. However, these
powers are only used when necessary and most of the time regulatory
authorities seek and gain voluntary agreement from companies for
the necessary measures.
Legally, both the authorities and manufacturers are responsible for
the safety of medicinal products. In the European Union (EU), both
parties are obliged to operate pharmacovigilance systems, to exchange
data and, where necessary, to take appropriate action to protect
patients. The responsibilities of the authorities generally cover all
medicinal products – and there are many thousands of them.
Therefore, in practice, they have to focus particularly on issues that
are the most important for public health. As the early post‐marketing
phase is invariably a period of considerable uncertainty about safety
and the time when important new hazards are most likely to be identi­
fied, most regulatory pharmacovigilance activity is concentrated on
newer drugs.
In this chapter, ‘regulation’ is considered from both sides of
the fence: that is, from the perspective of both the regulator and
industry. The regulatory obligations of pharmaceutical companies are
An Introduction to Pharmacovigilance, Second Edition. Patrick Waller
and Mira Harrison-Woolrych.
© 2017 John Wiley & Sons Ltd. Published 2017 by John Wiley & Sons Ltd.

e­ xtensively laid out in legislation and guidelines, but it is important to
appreciate that merely meeting these obligations does not ensure the
safety of medicinal products. Rather, they should be seen as an essen­
tial baseline from which an acceptable safety standard can potentially
be achieved. Since the beginning of the twenty‐first century it has
been formally recognised that the whole process was previously too
passive, that more and better post‐authorisation safety studies are
needed, and that proper planning is required if adequate safety
­knowledge is to be gained. This has led to the introduction of risk
management planning to underpin the whole process.

­Legislation and Guidelines
Despite ongoing attempts at international harmonisation (see
Chapter 6), legislative requirements for the regulation of medicines
continue to differ around the world. Most countries have a medicines
regulatory body, which usually operates from within the relevant
­government department. Pharmaceutical companies are obliged to
submit applications to it in territories in which they wish to market
their products. In this section, we focus on the EU where, as in many
countries around the world, medicines legislation is supported by
guidance to give practical advice on how to comply with the law.
Following guidelines is generally a good practice, but it may not always
be possible or appropriate. Guidelines are much more easily amended
than legislation and tend to increase in size as issues of interpretation
are addressed.

­Key Elements of European Legislation
EU medicines legislation has two broad aims: protection of public
health and the creation of a single market for pharmaceuticals. EU
legislation is initially proposed by the European Commission, goes
through extensive consultative and political processes and emerges
via the European Parliament to be put into force by the Commission.
In principle, if there is an apparent conflict with any national legisla­
tion, EU law takes precedence. However, this does not necessarily
mean that national authorities cannot enforce additional require­
ments in their own territory. A centralised system of authorisation
Regulatory Aspects of Pharmacovigilance77

(i.e. one licence valid throughout the EU) was introduced in 1995 and
in recent years its use has been obligatory for all new drugs. Many
older products have national authorisations in some individual or all
Member States. For such medicines, product information may still
differ, but when important safety issues arise procedures are available
to ensure that harmonised action is taken across the EU.
The legislation defining the centralised system of authorisation is in
the form of Regulations, which are directly effective in all Member
States. Other relevant EU legislation is contained in Directives, which
oblige Member States to implement national laws having specified
effects. Until 2010, EU pharmacovigilance legislation occupied short
sections within each of the broad legislative documents covering
medicines regulation in general:
●●Regulation 2309/93, articles 19–26
●●Directive 2001/83, Title IX, articles 101–108.
These articles briefly defined the need for both Member States and
pharmaceutical companies to operate pharmacovigilance systems
and were largely focused on adverse reaction reporting systems.
They were supported by quite extensive guidance which had been
developed over many years and was known as Volume 9A.
In 2010, after extensive consultation and development, two major
pieces of pharmacovigilance legislation were enacted and came into
force in mid‐2012:
●●Regulation 2010/1235, and
●●Directive 2010/84
which amend the previous Regulation and Directive to introduce
­substantial new requirements, and greatly increase the volume of
pharmacovigilance legislation. There is also an implementing
Regulation 520/2012 which covers various practical aspects of the
regulatory pharmacovigilance process, for example the contents of
key documents such as the pharmacovigilance system master file,
risk management plan and periodic safety update report.
The ‘recitals’ at beginning of the main new legislation explain the
reasoning behind it and define three broad objectives:

1. Strengthen post‐authorisation regulation of medicines
2. Improve efficiency, both within the pharmaceutical industry and
   through reduced duplication of effort between the Member States
3. Increase transparency.

To underpin these developments, a Pharmacovigilance Risk Assess­
ment Committee (PRAC) was formed consisting of representatives of
Member States, healthcare professionals, patient organisations and
independent experts. It meets monthly at the European Medicines
Agency (EMA). The pharmacovigilance legislation that came into
effect in 2012 also mandated the development of good pharmacovigi­
lance practice (GVP) to replace existing guidance.
When required, regulatory action is taken through the European or
national marketing authorisations. The options available are suspen­
sion, revocation or variation. These powers are specified in article 116
of Directive 2001/83 (which is not part of the section on pharmacovig­
ilance) and an unfavourable risk–benefit balance (section 117 (c))
­provides the most usual basis for compulsory withdrawal from the
market. Suspension is temporary and usually put in place as a matter
of urgency. Revocation leads to permanent removal of the product
and this decision is taken over a longer time scale. In either case, the
marketing authorisation (MA) holder is usually given the opportunity
to make representations to the authorities. As discussed in Chapter 4,
variation of the authorisation is the most common mechanism
for dealing with pharmacovigilance issues and, if urgent, there is a
mechanism for making safety restrictions within 24 hours. Both the
authorities and companies can initiate such restrictions.
Aside from the above legislation, the Regulation covering clinical
trials (Regulation 2014/536) is relevant to pharmacovigilance for
investigational drugs (i.e. those that are not yet authorised) and
Annex 3 specifies the safety reporting requirements.
The most important principles specified in the EU legislation that
came into effect in 2012 can be summarised as follows:
●●Pharmacovigilance is based largely on existing national systems.
●●Member States are responsible for conducting pharmacovigilance
in their own territories.
●●The EMA is responsible for coordination, and maintenance of
(a) the central pharmacovigilance database (EudraVigilance) and
(b) a web portal, the purpose of which is to promote transparency in
pharmacovigilance by disseminating defined information about
medicines authorised in the EU.
●●The key advisory forum is the PRAC on whose recommendations
the handling of pharmacovigilance issues is based.
●●MA holders have defined responsibilities.
Regulatory Aspects of Pharmacovigilance79

­Guidelines
Over the past few years, EU guidance has been extensively changed
by the genesis of GVP. As with legislation, there are consultation
­processes involved in the development of guidelines. At the time of
writing, 12 modules of GVP have been developed and published on
the EMA’s website (Box 5.1). The titles of these modules are shown
in Table 5.1. As well as the general procedural considerations
addressed by these guidance documents, a GVP series addressing
product or population‐­specific considerations is being developed
with chapters relating to: (i) vaccines, (ii) biologicals, (iii) pregnancy
and breast ­feeding, (iv) children and (v) the elderly, either published
or in preparation.
There is additional pharmacovigilance guidance on the EMA web­
site which is not part of GVP. For example, these cover requirements
specific to the centralised system and provide questions and answers
in relation to company pharmacovigilance systems. Also relevant to
pharmacovigilance are guidelines on the Summary of Product
Characteristics (SPC) and Package Leaflet (in Volume 2 of the Rules
Governing Medicinal Products), and, for investigational drugs, clini­
cal trial guidelines (Volume 10 of the Rules Governing Medicinal
Products, Chapter II). These are part of Eudralex and can be found in
the public health section of the European Commission’s website
(Box 5.1).

Box 5.1 Key website references.
EudraVigilance: http://www.ema.europa.eu/ema/index.jsp?curl=pages/
regulation/general/general_content_000679.jsp&mid=WC0b01ac
05800250b5
European Commission’s legislation pages (Eudralex): http://ec.europa.eu/
health/documents/eudralex/index_en.htm
European Medicines Agency’s Good Pharmacovigilance Practice
pages: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/
document_listing/document_listing_000345.jsp&mid=WC0b01ac
058058f32c
European Network of Centres for Pharmacoepidemiology and
Pharmacovigilance: www.encepp.eu

Table 5.1 Good pharmacovigilance practice (GVP) Modules.

No.Title

IPharmacovigilance systems and their quality systems
IIPharmacovigilance system master file
IIIPharmacovigilance inspections
IVPharmacovigilance audits
VRisk management systems
VIManagement and reporting of adverse reactions to medicinal products
VIIPeriodic safety update report
VIIIPost‐authorisation safety studies
IXSignal management
XAdditional monitoring
XVSafety communication
XVIRisk minimisation measures – selection of tools and effectiveness
indicators

Addenda
Module VIAddendum IDuplicate management of adverse reaction
reports
Module VIIIAddendum IMember States’ requirements for transmission
of information on non‐interventional
post‐authorisation safety studies
Module XVIAddendum IEducational materials

Note: The following GVP Modules were originally planned but are no longer
considered necessary given that other guidance has since been made available:
Module XI on public participation; Module XII on safety‐related action; Module
XIII on incident management and exchange of information exchange within the
EU regulatory network; and Module XIV on international collaboration.
Source: Produced from material published on the European Medicines Agency’s
website (© EMA [1995–2016]).

­Regulatory Pharmacovigilance Systems
Broadly, there are two functions to pharmacovigilance from the per­
spective of a regulator: (i) the protection of public health by measures
to promote safe and effective use of medicines and prevent serious
adverse drug reactions (ADRs), and (ii) regulation of the industry.
Regulatory Aspects of Pharmacovigilance81

Medicines regulatory authorities do not regulate health professionals,
who are potentially able to prescribe medicines outside the terms
of the authorisation (and unlicensed medicines) on their own
responsibility.
In terms of protecting public health, regulators are active at every
stage of the pharmacovigilance process described in Chapter 4: in the
regulatory environment this means from the time a new medicine
starts being studied in humans, through to post‐marketing surveil­
lance, which may continue for many years. In particular, regulators are
concerned to ensure that signals are identified as rapidly as possible
and are appropriately managed. They also aim to ensure that any
actions taken are appropriate, communicated effectively and that their
impact is measured.
In terms of regulating industry, the principal issue is one of com­
pliance with the legal requirements. Formal monitoring of industry
compliance with pharmacovigilance obligations through inspec­
tions is a fairly recent development. These inspections may be
undertaken routinely, or at any time if the authorities have a reason
to believe there may be non‐compliance. There is a three‐level
approach to dealing with non‐compliance. Relatively minor trans­
gressions can be dealt with by educative measures or, in more
­serious cases, warnings are issued. In very serious or persistent
cases, prosecution can be undertaken against the marketing author­
isation holder. Offences are determined nationally but include
­substantial fines and even imprisonment, with both the company
and the qualified person (see Company Pharmacovigilance Systems)
being held responsible.
It should also be noted that regulators have obligations towards
industry, in particular the timely availability to the MA holder of
spontaneous ADR reports which they receive from health
­professionals. This is facilitated through the EudraVigilance database
(Box 5.1). They are also obliged to audit their pharmacovigilance
systems.
In order to provide the particular focus on new drugs alluded to, in
2013, EU regulators introduced an additional monitoring scheme
which was mandated in the legislation. This is primarily for new drugs
and usually lasts for 5 years after first authorisation. In order to pro­
mote ADR reporting for these products, they are identified by a black
triangle symbol in the product information. This is essentially a modi­
fication of a scheme that has been in use in the UK since the 1980s.

The EMA publishes on its website lists of products under additional
monitoring and, as well as new drugs, the lists include established
ones with new safety concerns which are under investigation
(e.g. domperidone, see example given later).­Obligations of Pharmaceutical Companies
Broadly, the pharmacovigilance obligations of companies can be
­summarised as follows:
●●To operate a pharmacovigilance system with documented proce­
dures (known as the pharmacovigilance system master file) and to
regularly audit it
●●To nominate a qualified person for pharmacovigilance
●●ADR reporting
●●Periodic safety update reporting
●●To inform regulatory authorities of any information that may
change the risk–benefit balance of a specific product
●●To respond to requests for information from regulatory authorities
●●To maintain a system to manage and minimise risk(s) with their
medicines
●●To keep the product information (including Patient Information
Leaflets, PILs) up‐to‐date
●●To comply with regulations for marketing and advertising pharma­
ceutical products.­Company Pharmacovigilance Systems
The qualified person for pharmacovigilance (QPPV) takes personal
responsibility for organisation and management of the pharmacovigi­
lance ­system within the company. They need to be always available
and therefore most large companies also nominate a deputy. It is
essential that documented quality procedures are put in place in the
form of a pharmacovigilance system master file. Effective pharma­
covigilance requires a properly functioning database containing accu­
rate up‐to‐date data. All personnel within the department must be
appropriately trained. General system compliance with these princi­
ples is now monitored by regulatory authorities through inspections.
Regulatory Aspects of Pharmacovigilance83

­ADR Reporting
We have described the principles of spontaneous ADR reporting in
Chapter 3 and how the data are used in the pharmacovigilance p­ rocess
in Chapter 4. Next, we consider the principal activities undertaken by
company pharmacovigilance departments: ADR reporting, periodic
safety update reporting, post‐authorisation safety studies and risk
management planning. It should be self‐evident that the purpose of
company ADR reporting obligations is to ensure that regulators have
prompt access to reports which are submitted directly to companies.
This led to the concept of the ‘expedited’ report – in essence this is a
report of a serious (as defined in Chapter 1) suspected ADR and the
obligation is to submit it to the authorities within 15 calendar days of
receipt. Non‐serious reports should be submitted within 90 days. In
the EU, the use of the Medical Dictionary for Regulatory Affairs
(MedDRA) for coding is mandatory and reporting electronically
via EudraVigilance is expected to become mandatory for MA holders
in 2017.
EudraVigilance is the EU regulatory network’s system for manag­
ing information on suspected ADRs reported with authorised
­medicines, managed by the EMA. It supports safety monitoring by
facilitating the electronic exchange of suspected ADR reports among
the EMA, national competent authorities, MA holders and sponsors
of clinical trials.
The principal use of EudraVigilance is in the early detection and
evaluation of possible safety signals for human medicines. It includes
an automated message processing mechanism and a large pharma­
covigilance database with query, tracking and tracing capabilities.
The EMA publishes data from EudraVigilance as the European
­database of suspected ADR reports. A public website allows users
to view the numbers of serious individual case reports submitted to
EudraVigilance for centrally authorised medicines. On their website,
the EMA also publishes reports for common drug substances
­contained in nationally authorised medicines.
There are two further important principles for pharmaceutical
companies. The first is that serious (see Glossary) and fatal reports
should be followed‐up and the information obtained also reported
within 15 days. Companies should also follow‐up incomplete ADR
reports and any that represent an event of special interest for the
product concerned (e.g. reports of pregnancy for a medicine that is

used in women of reproductive age). Secondly, companies should be
proactive in searching the medical literature, media (including social
media) and the internet to identify potential case reports of ADRs that
are not well recognised to occur with their drugs. Assuming they are
valid and have been assessed by the company as serious, these should
also be submitted within 15 days. A valid individual case safety report
meets four criteria:
1)At least one identifiable reporter
2)One single identifiable patient
3)At least one suspected adverse reaction and
4)At least one suspected medicinal product.
Prior to authorisation, in relation to products being investigated in
clinical trials, ADR reporting requirements are different. The key
principles here are that serious and unexpected (meaning not listed in
the Investigator’s Brochure for that specific trial) suspected ADRs
(SUSARs) should be expedited, and that such reports should be
unblinded for this purpose. Steps should be taken to ensure that per­
sonnel directly involved in the trial remain blinded. Companies are
required to submit SUSARs both to regulatory authorities and to the
ethics committee(s) that approved the trial. They must also ensure
that all investigators are kept informed about SUSARs so as to meet
the key objective of protecting the safety of trial participants.
The practice of ADR reporting by companies has many complexities
which are best learned ‘on the job’ and by applying the available
­regulatory guidelines. These principles give an overview of current
practice and it is the responsibility of industry to keep up‐to‐date
with changing guidance and discuss cases of doubt with the relevant
regulatory authority.

­Periodic Safety Update Reporting
The concept of, and format for, periodic safety update reporting was
developed in the early 1990s by the Council for International
Organizations of Medical Sciences (CIOMS) working group (see
Chapter 6) and rapidly implemented into legislation in many parts of
the world. The objective of producing Periodic Safety Update Reports
(PSURs) is to facilitate regular, systematic review of the global safety
data available to the manufacturer of marketed products. Over time,
Regulatory Aspects of Pharmacovigilance85

the scope of the PSUR has tended to broaden and the overall goal of
such review is to identify any change in the benefit–risk profile of the
product that might require further investigation or action. Following
the adoption of International Council on Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use (ICH) guideline
E2C (see Chapter 6), PSURs are now also known as Periodic Benefit–
Risk Evaluation Reports (PBRERs), reflecting this broadened scope
from safety to benefit–risk.
Production of PSURs starts when a drug is first approved for
­marketing anywhere in the world (international birth date, IBD) and,
initially, reports are produced on a 6‐monthly basis. The period
­covered becomes longer once the drug is established in the market but
precise requirements have varied over time and between countries.
In the EU, the new legislation seeks to make the requirements
­proportionate to the risks. For example, it no longer routinely requires
PSURs for generic products containing drugs the safety of which is
well established.
The main body of data in each PSUR covers a defined period of
time, starting either at the IBD or when data for the previous report
were ‘locked’ (i.e. the point at which further information received can­
not be included in the report). The contents and structure of a PSUR
is summarised in Table 5.2. The ‘reference’ or ‘core’ safety information
is also included as an appendix. This is a minimum standard of infor­
mation which is considered essential for safe use and will be included
in all product information worldwide.
Key sections of the PSUR are those that evaluate signals, the inte­
grated risk–benefit evaluation and the overall conclusions and actions
proposed. These sections are where any important newly identified or
ongoing safety issues are assessed and proposals made to address them.
PSURs are routinely reviewed by regulatory authorities around the
world. In the EU, they are submitted in electronic format and the
EMA undertakes a single assessment which is reviewed by the PRAC
who make recommendations for any action to be taken through the
MA. Meeting all the global requirements is complex and resource
intensive, despite a fair degree of harmonisation. A format for safety
update reporting in relation to investigational drugs in development
(Development Safety Update Report, DSUR) has also been proposed
by CIOMS (see Chapter 6), and adopted internationally. In the EU,
guidance suggests that DSURs should be submitted annually to
­regulatory authorities.

Table 5.2 Structure of the Periodic Safety Update Report (PSUR).

Executive Summary
1Introduction
2Worldwide marketing authorisation status
3Actions taken in the reporting interval for safety reasons
4Changes to reference safety information
5Estimated exposure and use patterns
6Data in summary tabulations
7Summaries of significant findings from clinical trials
during the reporting interval
8Findings from non‐interventional studies
9Information from other clinical trials and sources
10 Non‐clinical data
11 Literature
12 Other periodic reports
13 Lack of efficacy in controlled clinical trials
14 Late‐breaking information
15 Overview of signals: new, ongoing or closed
16 Signal and risk evaluation
17 Benefit evaluation
18 Integrated benefit–risk analysis for authorised indications
19 Conclusions and actions
20 Appendices

Source: produced from material published on the European Medicines Agency’s
website (© EMA [1995–2016]).­Post‐authorisation Safety Studies
Companies started to conduct these studies in the 1980s, but in the
early days they were often seen as covert marketing exercises intended
to promote use of a new medicine. Of course, it is impossible to study
safety in ordinary practice if a drug is little used, but nevertheless it
is important that post‐marketing studies have clear safety objec­
tives and do not interfere with prescribing practice. The emergence
of databases such as the Clinical Practice Research Datalink in the
Regulatory Aspects of Pharmacovigilance87

UK has lessened the need for studies that start by recruiting prescrib­
ing doctors and build up a cohort of users (see Chapter 3). From a
scientific point of view, single cohort studies based on use of a par­
ticular drug have some limitations. They can measure the frequency
of a particular event, but they may not provide any indication of the
expected or background frequency, leading to judgements about cau­
sality being made from the individual cases. This problem is best
addressed by including a comparison cohort of patients using an
alternative treatment.
A frequent limitation of post‐authorisation safety studies (PASS) is
the sample size. Historically, 10 000 patients has often been a fairly
arbitrary target for a drug that is likely to be widely used – this is based
on the notion that it is about one order of magnitude more than the
average number of patients studied in clinical trials. In terms of study­
ing ADRs, which are rare or very rare, this will mean that there are
only likely to be a few or possibly no cases observed in the study. In
general, such studies will measure events rather than suspected ADRs,
but any serious events that are suspected by investigators to be drug‐
related should be submitted to regulatory authorities as an expedited
report.
Companies undertaking PASS will need to submit a draft protocol
for review and endorsement by PRAC. They will also need to plan to
provide data from the study to the regulatory authorities. The need for
undertaking such studies will usually be specified in the risk manage­
ment plan for the product (see Risk Management Planning). As well as
studying ADRs, PASS can provide valuable information about drug
utilisation. Who is using a medicine – and how – is an extremely
important component of safety.
In recent years, the EMA has overseen the development of the
European Network of Centres for Pharmacoepidemiology and
Pharmacovigilance (ENCePP). Members of this network are public
institutions and contract and research organisations involved in
research in pharmacoepidemiology and pharmacovigilance.
Research interests are not restricted to the safety of medicines, but
include the benefits and risks of medicines, disease epidemiology
and drug utilisation. ENCePP states that its aims are to strengthen
the monitoring of the benefit–risk balance of medicinal products in
Europe by:
●●Facilitating the conduct of high quality, multi‐centre, independent
post‐authorisation studies with a focus on observational research.

●●Bringing together expertise and resources in pharmacoepidemiol­
ogy and pharmacovigilance across Europe and providing a platform
for collaborations.
●●Developing and maintaining methodological standards and
governance principles for research in pharmacovigilance and
­
pharma­coepidemiology.
ENCePP has produced publicly accessible resources which include
a database of available European research resources, a register of post‐
authorisation studies, a code of conduct which aims to promote trans­
parency and scientific independence and guidance on methodological
standards in pharmacoepidemiology.
An example of an important study undertaken through ENCePP is
one that was undertaken to assess the rare risk of sudden cardiac
death in association with domperidone, a drug widely used for gastro­
intestinal symptoms such as nausea and vomiting. This case–control
study (see Glossary) found an approximately twofold increased rela­
tive risk of sudden cardiac death which appeared to be dose‐related.
In 2014, taken in conjunction with other relevant data, the results of
this study led PRAC to recommend restrictions on its use, strength­
ened warnings (particularly in relation to use of interacting drugs) and
revocation of the MA for high dose products. In the UK, action was
also taken to make the drug a prescription‐only medicine.

­Risk Management Planning
In the past, the pharmacovigilance process often lacked a clear start­
ing point and an active plan to gain further safety knowledge and min­
imise risks. In recent years, considerable efforts have been made by
regulatory authorities and companies to improve existing systems of
risk management. It is now recognised that there is a need to focus
more on safety, rather than harm, and to actively plan to demonstrate
the safety of newly authorised products. An important development
introduced into European regulatory processes in 2005 is risk man­
agement planning. In the EU, submission of a risk management plan
(RMP) is now required with all new applications for MAs (not only all
new active substances, but also generic products for example) and for
changes to existing authorisations that are likely to significantly extend
usage of the product. Plans may also be requested by the authorities at
a later stage if an important new safety issue emerges.
Regulatory Aspects of Pharmacovigilance89

The basic structure of an EU RMP, as defined the relevant GVP
module, is shown in Table 5.3. The RMP should contain three key
sections:

1. Safety specification
2. Pharmacovigilance plan
3. Risk minimisation plan.
   The purpose of the safety specification is explicitly to consider the
   level of safety that has been demonstrated so far. It should identify
   what is and what is not yet known about safety and the latter (i.e.
   what is not known) should be a major driver of the pharmacovigi­
   lance plan. The purpose of that plan is essentially to attempt to find
   out what is not yet known, largely because of the limitations of
   ­clinical trials.Table 5.3 Structure of an EU risk management plan.

Part IProduct(s) overview
Part IISafety specification
Epidemiology of the indication(s) and target population(s)
Non‐clinical part of the safety specification
Clinical trial exposure
Populations not studied in clinical trials
Post‐authorisation experience
Additional EU requirements for the safety specification
Identified and potential risks
Summary of the safety concerns
Part IIIPharmacovigilance plan
Part IVPlans for post‐authorisation efficacy studies
Part VRisk minimisation measures (including evaluation of the
effectiveness of risk minimisation measures)
Part VISummary of the risk management plan
Part VIIAnnexes

Source: produced from material published on the European Medicines Agency’s
website (© EMA [1995–2016]).

RMPs should be particularly focused on known or potential risks
that cannot simply be managed through routine measures described
in the product information.
Until recently, post‐marketing safety activities in pharmaceutical
companies mainly concerned satisfying the regulatory requirements
outlined earlier in this chapter (i.e. spontaneous reporting and peri­
odic safety update reports). While these are important, they do not in
themselves ensure that medicines are safe and often they do little to
demonstrate safety. They may also encourage a tendency towards
focusing on bureaucratic requirements rather than public health. As it
is impossible to know that a medicine is acceptably safe until it has
been used in ordinary practice, it is reasonable to argue that demon­
strating safety should be a key goal in the post‐marketing period and
therefore logical that it is necessary to plan how to achieve it.

Safety Specification

In the rest of the chapter we consider the key principles on which the
key parts of the RMP are based. Any new medicine that has been
authorised can be considered to have a level of safety which, in rela­
tion to its potential benefits and the disease being treated, is
­provisionally acceptable. The safety specification section of the RMP
should document the basis of this judgement by considering the five
broad areas set out next. The best starting point conceptually is to
consider the disease that is to be treated or prevented and the charac­
teristics of the target population.

Epidemiology of the Indication(s)
This should include the descriptive epidemiology of the disease
indication(s): incidence, prevalence and demographic considerations,
prognosis, likely co‐morbidity and co‐prescribing, plus medical events
associated with the indication that could be mistaken for ADRs. Such
information will be helpful for setting spontaneous ADR reports in
context.

Extent of Current Clinical Safety Experience
This can be summarised in the form of graphs or tabulations, with
calculations of the statistical power to detect ADRs according to dura­
tion of treatment and potential latency (i.e. time to onset), based on
the following information:
Regulatory Aspects of Pharmacovigilance91

●● Overall numbers of patients studied for various durations of treat­
ment and lengths of follow‐up in all pre‐marketing trials.
●● Numbers of patients in different sub‐groups, for example, split by
age, gender, dose and other characteristics relevant to the disease
being treated (presented by duration of treatment and length of fol­
low‐up). Both overall numbers (and sub‐groups where feasible) are
best shown graphically using plots of exposure over time (Figure 5.1).

Confirmed Adverse Reactions
The main focus here should be on ADRs identified in clinical trials
described and quantified by system organ class. Analyses should be
based on statistically significant differences seen between treated and
control groups. This may be best presented as absolute excess risks
with 95% confidence intervals.

Signals of Potential Adverse Reactions
These might include the following:
●● Serious events that are not statistically significantly different
between groups in clinical trials, but that constitute potential s­ ignals
requiring further evaluation, based on a relative risk of at least 2 or

Time in study for drug and dose
20 000

15 000
Patients
10 000

5000

0
0102030
Time (months)

drug1 dose1 drug1 dose2drug2

Figure 5.1 Drug exposure versus time, demonstrating the usual situation that,
while quite large numbers of patients are exposed in pre‐marketing trials for a
few months, very few have been observed for more than 2 years.

at least one case that was thought to be related to the medicine
(either by the investigator or the company following a formal cau­
sality assessment).
●●Unconfirmed signals of potential toxicity (e.g. potential teratogenic­
ity) found in pre‐clinical data.

Areas of Safety Knowledge that are Incomplete
The main areas that are relevant here are:
●●Special populations not studied in clinical trials (unless these are to
be absolute contraindications to use of the drug), where experience
is limited (e.g. children, pregnant women) or for which the safety
profile might be expected to be different.
●●Rare ADRs not yet observed with the drug, but which are recog­
nised to occur with other drugs in the class, or which are possible
based on knowledge of the molecular structure.
●●Consideration of the potential for safety concerns based on off‐label
use, medication errors and intentional overdose.

Pharmacovigilance Plan

The marketing of a medicine represents both an opportunity and a
need to demonstrate an acceptable level of safety. The pharmacovigi­
lance plan should indicate how this will be achieved in practice, cover­
ing both routine pharmacovigilance activities (i.e. those required in
legislation for all medicines) and any additional activities that are spe­
cific to the product (e.g. PASS). The plan might contain the following
types of information:
●●Expected levels of use of the product over time (worldwide)
●●Strategies to address existing and potential safety signals
●●Strategies to monitor recognised serious ADRs to ensure that their
incidence is not greater than expected
●●Strategies to address areas where safety knowledge is incomplete,
for example in special populations
●●Proposed milestones at which a greater level of safety experience is
expected to have been demonstrated.
Most safety milestones (e.g. PSURs) are based on arbitrary meas­
ures of time. When they are reached, safety knowledge may or may
not have been extended, in part depending on the level of usage of the
product. A conceptually more logical way of defining milestones
Regulatory Aspects of Pharmacovigilance93

would be to base them on levels of exposure to the product. They can
be derived using the expected level of use, taking into account power
calculations indicating the known level of safety at authorisation.
Milestones would then be reached when a specified number of
patients had been studied (possibly for a specified length of time) or
when particular safety studies are complete.

Risk Minimisation Plans

RMPs are particularly important when product information alone (i.e.
SPC and PIL) is considered to provide insufficient safeguards against
known or serious potential hazards. The additional risk minimisation
measures that may be contained within them vary from providing
general education (e.g. ‘Dear Health Professional’ communications)
through specific training of users in safe administration, to restric­
tions on use‐linked documentation of safe practice (e.g. ensuring that
users of clozapine actually have acceptable white cell counts before a
further prescription can be dispensed). There may also be additional
risk minimisation measures for specific medicines or populations,
for example pregnancy prevention programmes for medicines known
to be teratogenic and likely to be used by women of childbearing
potential (e.g. isotretinoin).
Whatever level of activity is envisioned, good communication is
essential and it is important to consider and test the feasibility of the
proposed measures. The most common form of activity is promotion
of safe use and it is important that this is not confused with mere
promotion of use. Regulators generally expect there to be clear day­
light between the two activities and are unlikely to accept company
representatives as the only vehicle for delivery of risk minimisation
measures.
The final step in the process of pharmacovigilance is to assess the
extent to which risk minimisation has been successful and if, neces­
sary, to refine or change the measures. This is something that in
the past has generally not been performed well, but is now part of
the legislation and is receiving much more attention from the
authorities.
Potential methods for measuring the success of risk minimisation
(see Chapter 4 for further details) include:
●●Testing the effectiveness of the communications
●●Analysing the effects on prescribing

●●Monitoring spontaneously reported cases
●●Formal studies of measurable outcomes (e.g. analysing rates of
ADRs in defined patient cohorts before and after risk minimization
measures).
Simply monitoring spontaneous ADR reports is normally insuffi­
cient for the purpose of studying the effects of risk minimisation, but
much can be learned from studies of drug utilisation and in particular
from studying the characteristics of users and how a medicine is used.
It is relatively easy, for example, to use a prescription database to
examine concomitant use of interacting drugs, which might perhaps
be contraindicated. Ideally, studies should measure hard and quantifi­
able outcomes, so that we can learn whether ADRs are being pre­
vented by the measures put in place.

­Conclusions
In this chapter, we have outlined the principles underpinning regula­
tory pharmacovigilance, focusing on the EU. Legally, both the regula­
tory authorities and manufacturers are responsible for the safety of
medicinal products. Both are obliged to operate pharmacovigilance
systems and, where necessary, to take appropriate action to protect
patients. Key elements of the process are ADR reporting, periodic
safety update reporting, PASS and risk management planning. Much
of what we have described in this chapter relating to the EU has been
developed through wider international cooperation. How and why
this has happened, and the roles of the relevant international bodies is
described in the next chapter.
95
6

International Collaboration

Pharmaceuticals are used by patients worldwide so global pharma-
covigilance activities are needed to monitor the safety of medicines in
all countries where they are marketed. There are many reasons for
apparent international variations in the safety of medicines. The pop-
ulation in which a drug is used might be different in terms of ethnicity,
demographic factors or the indication(s) for use. The need for a
­specific medicine and the way in which it might be used may differ
(e.g. in terms of dose or monitoring), as might perceptions of risks and
benefits in relation to alternative treatments. Despite the legitimacy of
all such possible reasons, historical variations in safety recommenda-
tions and practice have undoubtedly exceeded what can be explained
by them. There are many examples of drugs withdrawn or restricted
in one part of the world remaining available in another for no rational
reason. Such irrational international variations reflect uncertainty in
the relevant data or differing views of experts who advise regulatory
authorities on safety. In order to achieve patient safety across the
globe – and consistency in practice – it has long been recognised that
international harmonisation and cooperation are very important
aspects of pharmacovigilance.
International collaboration in pharmacovigilance has advanced
greatly in recent years. In medicines regulation, authorities around
the world increasingly communicate about global regulatory issues
and the pharmaceutical industry has been proactive in requesting
international harmonisation for many processes, including adverse
drug reaction (ADR) reporting. Non‐governmental international
organisations such as the World Health Organization (WHO), the
Council for International Organizations of Medical Sciences (CIOMS)
An Introduction to Pharmacovigilance, Second Edition. Patrick Waller
and Mira Harrison-Woolrych.
© 2017 John Wiley & Sons Ltd. Published 2017 by John Wiley & Sons Ltd.

and the International Council on Harmonisation (ICH) have contin-
ued to develop important pharmacovigilance services and guidelines
on practice. Professional bodies – such as the International Society
of Pharmacovigilance (ISoP) and the International Society for
Pharmacoepidemiology (ISPE) – have become more global. In this
chapter we give an overview of the activities and roles of the key
international pharmacovigilance organisations and describe how
­
they have developed and collaborated.

­International Regulatory Collaboration
In Chapter 5 we described medicines regulation in the EU, with respect
to pharmacovigilance. By developing centralised and harmonised
processes, the European Medicines Agency (EMA) has addressed
many differences in pharmacovigilance practice which previously
existed between different member states – for example, products that
had been withdrawn for safety reasons in one country, but not in
another. The EMA has also developed centralised databases for ADR
reporting, European guidelines on pharmacovigilance practice and
expert advisory committees with representatives from all Member
States (see Chapter 5). In these ways, the EMA has put international
collaboration into active regulatory practice.
Outside Europe, most developed nations – and an increasing ­number
of emerging and low and middle income countries – have their own
medicines regulatory body. Countries with authorities ­covering the
highest population size in the WHO Programme for International Drug
Monitoring (WHO‐PIDM) include those in Africa (e.g. Nigeria), the
Middle East (e.g. Egypt), Asia (e.g. India, China and Japan), Central
America (e.g. Mexico), South America (e.g. Brazil) and the Russian
Federation. In most countries, pharmacovigilance activities are con-
ducted by the national regulatory authority, which usually sits within
the government’s health department. However, there are notable excep-
tions, including in Japan, Korea, the Netherlands and New Zealand,
where the pharmacovigilance centre lies outside the government regu-
latory body, collecting and providing data for the national authority.
The US Food and Drug Administration (FDA) is the oldest regula-
tory authority in the world. The FDA was established in 1906 and
their remit has always included monitoring the safety of medicines
and food products. This remains a key difference between the FDA
and some other national regulatory authorities, including the UK
International Collaboration97

Medicines and Healthcare products Regulatory Agency (MHRA),
which does not cover food (this is monitored by another UK govern-
ment agency). However, many other national regulatory authorities
(including several Asian authorities; for example, China FDA, Thai
FDA, Philippines FDA) regulate food products in addition to drugs.
The US FDA covers vaccines, blood products, medical devices,
tobacco products, cosmetics and veterinary products, and so has a
very wide scope.
By 2010, the US FDA employed nearly 15 000 people and in 2012
its annual budget was over $4 billion. The size and resources of the
US FDA enabled it to lead the way in medicines regulation worldwide
for many years, especially licensing of new medicines. Today, most
other countries have their own regulatory authority but many coun-
tries still follow guidance developed in Europe (see Chapter 5) or the
USA. Regarding pharmacovigilance, the FDA’s primary tool is its
­spontaneous reporting programme, MedWatch, which was estab-
lished in 1993. In more recent years, the FDA’s requirements for post‐
marketing risk management have been increasing, as in Europe (see
Chapter 5). In 2007, US legislation was amended, mainly as a conse-
quence of concerns about rofecoxib (see Chapter 1) and the following
year the FDA launched the Sentinel Initiative, a proactive electronic
system for post‐marketing surveillance.
In 2014, the UK MHRA and US FDA led discussions to establish
a global regulatory authority which resulted in the formation of
the International Coalition of Medicines Regulatory Authorities
(ICMRA). The purpose of this voluntary organisation is to allow the
heads of national regulatory authorities around the world to develop
shared strategic leadership in order to address current and emerging
global regulatory challenges, including safety issues. An example of
this is that the ICMRA collaborated with the WHO in 2015 to help
deal with the Ebola virus outbreak which affected many countries.
The ICMRA has set up several working groups to examine issues such
as rapid sharing of information and generic medicines.

­World Health Organization
The WHO’s international collaborative programme on drug safety was
originally set up in 1968 and since 1978 the Uppsala Monitoring Centre
(UMC) in Sweden has provided scientific leadership and t­echnical
support to this expanding worldwide pharmacovigilance network.
­

The WHO programme began with only a handful of participating
countries but, by 2016, the number of countries included had risen to
153 (124 full members and 29 associate members). Some national
centres with particular pharmacovigilance expertise have become
WHO Collaborating Centres. More recently established Collaborating
Centres include Ghana (2009), Morocco (2012) and Lareb in the
Netherlands, which provides additional expertise in the areas of
patient reporting and pharmacovigilance curriculum development.
The main WHO‐UMC programme activities of today are as
follows:

1. Programme for International Drug Monitoring (PIDM) All coun-
   tries that are members of the WHO‐PIDM provide their post‐­
   marketing individual case safety reports to the UMC, where the
   data are entered into the global reference source, VigiBase. By
   December 2015, there were over 12 million reports in VigiBase,
   accessible to all national pharmacovigilance centres through
   UMC’s web‐based search and analysis tool, VigiLyze. Data requests
   can also be made by anyone with a legitimate interest in the reports
   contained in VigiBase, although charges may be levied on those
   outside national centres.
2. Training and support for participating countries The UMC and
   its Collaborating Centres offer training and support to any coun-
   try wishing to set up and develop a national pharmacovigilance
   centre. Examples of newly established centres since 2000 include
   Sri Lanka (2000), Ghana (2001), Peru (2002), Sudan (2008),
   Jamaica (2012) and Swaziland (2015); a full list can be found on
   the UMC website (Box 6.1). Many countries – especially develop-
   ing nations – start with little resource, few staff and a low number
   of reports submitted, but once in the WHO programme many
   develop into larger and more productive centres. In addition to
   on‐the‐ground support, regular training and education sessions
   are provided to WHO programme members, and there is also an
   annual WHO National Centres meeting which is held at different
   locations around the world. Some of these annual meetings are
   timed to run back‐to‐back with the annual ISoP conference, with
   joint sessions on an overlapping day to encourage greater interna-
   tional collaboration.
3. Providing products and commercial services More than 70
   WHO programme members use the web‐based data management
   International Collaboration99

Box 6.1 Key website references.
Council for International Organizations of Medical Sciences: www.
cioms.ch
Drug Information Association: www.diaglobal.org
International Council on Harmonisation: http://www.ich.org/
home.html
International Society of Pharmacoepidemiology: www.pharmacoepi.
org
International Society of Pharmacovigilance: http://isoponline.org/
about‐isop/
United States Food and Drug Administration Sentinel Initiative:
http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149340.htm
World Health Organization Uppsala Monitoring Centre: www.
who‐umc.orgsystem, VigiFlow, developed by the UMC. Commercial services
offered by the UMC include the WHO Drug Dictionary Enhanced,
which is offered mainly to industry and research organisations.
The UMC no longer provides subscriptions to the WHO Adverse
Reaction Terminology (WHO‐ART), but continues to provide the
WHO‐ART to MedDRA Bridge, which is intended to help coun-
tries migrate to MedDRA (see Glossary). 4) Pharmacovigilance analysis and research For signal detection
and investigation, the UMC uses a data‐mining approach (see
Chapter 4) supported by additional triage algorithms, and clinical
assessment provided by UMC experts and a panel of reviewers.
The UMC’s research department undertakes methodology
research, including data mining of electronic healthcare records
and structured benefit–risk assessment. 5) Communicating drug safety information worldwide Information
is exchanged within the WHO programme network through the
publication of the WHO Pharmaceuticals Newsletter, and elec-
tronically through the VigiMed collaboration portal. The UMC
distributes the Signal document, containing summaries of signals
recently investigated, and publishes Uppsala Reports, a magazine
giving information on current pharmacovigilance topics and news
from centres around the world.
1

­ ouncil for International Organizations of
C
Medical Sciences
The CIOMS is an international, non‐profit, non‐governmental organ-
isation established jointly by the WHO and United Nations
Educational, Scientific and Cultural Organization (UNESCO) in 1949.
It has served as a forum for discussions between regulators and indus-
try on a variety of pharmacovigilance topics since the late 1980s and
reports from CIOMS working groups have been highly influential
in shaping legislation and guidelines around the world. In 2013,
­membership of the CIOMS included 49 international and associate
member organisations.
The activities of CIOMS can be broadly divided into three areas:

1. Drug development research
2. Human ethics, particularly in medical research
3. Working groups to produce guidance on drug safety issues.
   Here, we focus on the CIOMS working groups as these have the
   most direct relevance to pharmacovigilance. Between 1990 and 2015
   10 formal CIOMS working groups have been established, the topics
   and broad vision of each are summarised next.

CIOMS I: International Reporting of ADRs (1990)

Before the mid‐1980s, reporting requirements to regulatory authori-
ties related almost entirely to ADR reports occurring on each national
territory. Some countries then started to introduce requirements for
submission of ‘foreign’ reports. This working group was convened to
discuss the principles of what should be reported and how. The key
output was that ‘foreign’ reports should be of suspected reactions
which were both serious and unexpected (i.e. unlabelled) and should
be submitted within 15 days.
This CIOMS group also developed a reporting form – the ‘CIOMS
form’ – which became the international standard. In 1995, the work-
ing group reconvened (as CIOMS Ia) and made proposals for the data
elements to be included in electronic transmission of reports. Today,
this form, known as the CIOMS 1 form, is still used for ADR report-
ing, although the current international standard for reporting is now
the ICH E2B format, which was developed based on the data elements
described in CIOMS Ia.
International Collaboration101

CIOMS II: International Reporting of Periodic Safety Update
Summaries (1992)

This report made the original proposals for the format and content of
Periodic Safety Update Reports (PSURs). Since 1992, requirements for
PSURs have been widely implemented as a regulatory requirement
and there is now a European GVP Module covering this subject
(see Chapter 5). A harmonised guideline has also been adopted
through the ICH.

CIOMS III: Guidelines for Preparing Core Clinical‐Safety
Information on Drugs (1995)

The third CIOMS report addressed the problem of variations in safety
labelling around the world by proposing that manufacturers should
develop ‘core clinical‐safety information’ which contains all the rele-
vant safety information that needs to be included in all countries
where the drug is marketed. This is effectively a minimum stand-
ard – additional information may be included in some countries –
and it also serves as the basis for deciding whether a specific adverse
reaction is ‘listed’ (i.e. expected).

CIOMS IV: Benefit–Risk Balance for Marketed Drugs –
Evaluating Safety Signals (1998)

This report proposed a standard format and content for a benefit–risk
evaluation report and also laid down the principles for good decision‐
making practices. The CIOMS IV working group recommended a
harmonised approach to the analysis, reporting and decision‐making
steps involved in any re‐evaluation of benefit–risk that is required
when safety issues arise.

CIOMS V: Current Challenges in Pharmacovigilance – Pragmatic
Approaches (2001)

CIOMS V covered good case management and reporting practices,
both in terms of individual cases and summaries. It included specific
recommendations and was intended to be used as a handbook in
pharmacovigilance departments. A general recommendation was that
the ultimate goal should be a single, global, shared dataset.
1

CIOMS VI: Management of Safety Information from Clinical
Trials (2005)

The aim of this report was to enhance awareness of the ethical and
technical issues associated with safety in clinical trials. The working
group proposed a systematic approach to managing safety during
clinical development. The CIOMS VI report was wide ranging, cover-
ing ethical issues, statistical approaches to identifying risks and com-
munication of safety information from clinical trials.

CIOMS VII: The Development Safety Update Report –
Harmonising the Format and Content for Periodic Safety
Reporting During Clinical Trials (2006)

This report proposed the content and format for a Development
Safety Update Report (DSUR), a means of regular and timely review,
appraisal and communication of safety information during the clinical
development of drugs. The working group suggested that the DSUR
and PSUR could be integrated into a single harmonised safety report
that would cover a product throughout its life cycle.

CIOMS VIII: Practical Aspects of Signal Detection in
Pharmacovigilance (2010)

This working group looked at how electronic capture of data was result-
ing in the accrual of large datasets with much potential for complex
analyses. The CIOMS VIII report gave practical recommendations
for how such datasets could be managed for signal detection and how
pharmacovigilance systems and practices could be strengthened.

CIOMS IX: Practical Approaches to Risk Minimisation
for Medicinal Products (2014)

The CIOMS Working Group IX was set up in 2010 to develop a prag-
matic consensus publication that would contain a harmonised list of
tools for managing the risks of medicinal products, as well as consid-
erations governing the potential application of these tools. Following
review, drafting and wider consultation, the group’s report was pub-
lished in 2014.

CIOMS X: Meta‐analysis

The 10th CIOMS working group was set up to consider how good
meta‐analysis practices could be applied to clinical safety data
International Collaboration103

within the biopharmaceutical regulatory process. Meta‐analyses
(see Chapter 3) have been increasingly used to examine risks and
benefits of medicines and there is continuing debate as to the value
of this approach. The report from this working group was expected
to be published during 2016.

Other Activities of CIOMS

In addition to the projects discussed, CIOMS working groups have
also addressed the following issues:
●●Vaccine pharmacovigilance
●●Pharmacogenetics
●●Drug development research and pharmacovigilance in resource‐
poor countries.
CIOMS has also been involved in developing definitions of ADR
terms and, in particular, definitions for the frequencies at which
ADRs are reported to occur (see Chapter 4).­International Council on Harmonisation
Formerly known as the International Conference on Harmonisation,
which was established in 1990, the organisation was renamed the
International Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use (ICH) in 2015. The aim of the
ICH is to bring together regulatory authorities and the pharmaceuti-
cal industry to discuss scientific and technical aspects of drug regis-
tration. It is a more formal group than CIOMS, which is more an ideas
‘think tank’ which produces reports, and has a wider remit for harmo-
nisation across the drug development process.
The ICH has also been influential in shaping current regulatory
requirements relating to pharmacovigilance, particularly through its
guidance documents. It was previously tripartite in terms of regions,
covering the EU, the USA/Canada and Japan, but is now open to any
country fulfilling the requirements set out in the ICH Articles of
Association. In addition to representatives from regulation and indus-
try, there are various observers including the WHO and International
Federation of Pharmaceutical Manufacturers and Associations. The
main purpose is to harmonise existing guidelines related to develop-
ment and registration of medicines.
1

ICH guidelines have a five‐step development process:

●●Step 1 – Preliminary discussion by relevant experts and production
of a draft
●●Step 2 – The draft is considered and signed‐off by the Management
Committee
●●Step 3 – Wider consultation and revision
●●Step 4 – Final sign-off by the Management Committee
●●Step 5 – Implementation into the relevant legislation and guidelines.

In principle, the authorities in each territory are committed to
implementing ICH guidelines, although in practice the timing and
extent of implementation have been variable.
There are four broad categories of ICH guideline:

1. Quality – for example, guidelines on the conduct of stability
   studies.
2. Safety – covering pre‐clinical risks such as genotoxicity, reproduc-
   tive toxicity and carcinogenicity. A notable ICH safety guideline
   examined non‐clinical testing to assess the risk of QT prolongation
   with certain medicines.
3. Efficacy – these guidelines cover the design, conduct, safety (note
   that ICH includes pharmacovigilance in the ‘Efficacy’ guidelines
   group) and reporting of clinical trials.
4. Multi‐disciplinary – these cover topics that do not fit neatly into
   any of the above three categories – for example, the ICH medical
   terminology (MedDRA), the Common Technical Document
   (CTD) and the development of Electronic Standards for the
   Transfer of Regulatory Information (ESTRI).

In relation to pharmacovigilance, the key ICH guidelines are
E2A‐E2F (included in the Efficacy group above) and the dates at which
they were implemented were as follows:

●●E2A: Definitions and Standards for Expedited Reporting (1994)
●●E2B: Data Elements for Electronic transmission of Individual
Case Safety Reports (1997)
●●E2C: Periodic Safety Update Reports for Marketed Drugs (1996)
●●E2D: Post‐approval Safety Data Management (2003)
●●E2E: Pharmacovigilance Planning (2005)
●●E2F: Development Safety Update Report (2010).
International Collaboration105

ICH guideline E2E had a significant international impact, its key
message being that additional methods to spontaneous reporting are
required to monitor the safety of medicines adequately in the post‐
marketing period. In the years that followed publication of E2E, the
US FDA developed the Sentinel Initiative for additional monitoring of
medicines and the EU worked towards introducing more regulatory
requirements for risk management planning (see Chapter 5).

­International Scientific Collaboration
Earlier chapters of this book discuss basic methods and tools for phar-
macovigilance (see Chapter 2) and the types and sources of data that
are used in the scientific investigation of drug safety issues (see
Chapter 3). It is worth noting here that the science and methodology
of pharmacovigilance has developed substantially in recent years, and
that much of this has been a result of international collaborative
efforts. In addition to the work carried out by regulatory bodies and
the international organisations, a significant amount of pharmacovigi-
lance and pharmacoepidemiology research has been performed by
academic institutions around the world. Many studies have been
international multi‐centre studies, especially investigations of less
common outcomes, where large numbers of patients need to be
included to obtain meaningful results. Researchers, academics and
clinicians worldwide have collaborated with national pharmacovigi-
lance centres, WHO collaborating centres and other non‐governmen-
tal organisations to develop scientifically robust methods for the
practice of pharmacovigilance (see Chapter 4).

­International Professional Societies
Much international collaboration in pharmacovigilance occurs
through professional societies which support their members in
encouraging sharing of information and ideas and promoting research.
Collegial networking in these societies is valued by those working in
the different areas where pharmacovigilance is practiced (e.g. regula-
tion, industry, academia/research, clinical work) and over many years
has resulted in numerous professional collaborations.
1

There are several professional bodies for people working in pharma-
covigilance and some are based on the members’ qualifications (e.g.
pharmacists’ associations in different countries) or their employment
role (e.g. the Regulatory Affairs Professionals Society). There are three
broader international professional societies, which do not require spe-
cific qualifications or employment roles for membership, as follows.

International Society of Pharmacovigilance (ISoP)

IsoP began in 1993 as the European Society of Pharmacovigilance
(ESoP) and for the first few years activities and meetings were mainly
for those working in Europe. However, in 2001, ESoP became ISoP
and there has since been a strong focus on increasing the international
reach of the society. There are now several regional chapters of ISoP
including the Western Pacific, Latin American, Middle Eastern and
African chapters, in addition to several European chapters.
ISoP organises an annual research‐based conference (held alternate
years in Europe and outside Europe) and also offers training courses
for members throughout the year. Abstracts from ISoP conferences
are published in the international journal Drug Safety. ISoP also runs
several special interest groups (SIGs) including Risk Communication
and Women’s Medicines. It describes itself as a society that is ‘profes-
sional, independent, non‐profit and open to anyone with an interest in
the safety and effectiveness of medicines’.

International Society for Pharmacoepidemiology (ISPE)

ISPE began in 1989 as a North American and European society and
includes those working in the broader field of pharmacoepidemiol-
ogy in addition to pharmacovigilance. Like ISoP, ISPE has become
more international in recent years and has regional chapters. It also
now holds an annual pharmacoepidemiology conference in Asia, in
addition to its other meetings. Abstracts from ISPE meetings are
published in the international journal Pharmacoepidemiology and
Drug Safety.
ISPE also has several SIGs, including those covering drug utilisation
research, medical devices and vaccines. It is a larger society than ISoP
and there is some collaboration and networking between the two
­societies. Both ISoP and ISPE have links with CIOMS and ICH, and
many working in pharmacovigilance worldwide are members of more
than one group.
International Collaboration107

Drug Information Association

The Drug Information Association (DIA) was founded in 1964 as a
‘neutral global membership association’ which aimed to provide a
forum for all those working in healthcare product development
(­especially in industry and regulation) to discuss pertinent issues. Its
goals of communication and collaboration in the area of drug develop-
ment remain the same and issues relating to safety of medicines and
benefit assessment still fall under the DIA umbrella. However, mem-
bers of DIA are more likely to be those working in pre‐licensing drug
­
development, rather than post‐marketing pharmacovigilance and
pharmacoepidemiology.

­Conclusions
Pharmacovigilance is an international activity and collaboration and
communication are needed more than ever before to monitor the
safety of products marketed worldwide. Much pharmacovigilance and
pharmacoepidemiology research and monitoring is conducted all
around the world. While the USA and Europe continue to play a major
part in regulation, research and development, other countries outside
these regions have much to contribute in the area of post‐marketing
surveillance.
There is a continuing need for practical pharmacovigilance in all
countries where medicines are marketed, and the WHO worldwide
pharmacovigilance programme includes over 150 countries. Other
international bodies, including the CIOMS and ICH, have made
­significant contributions to pharmacovigilance guidance and con-
tinue to provide forums for international discussions. Three interna-
tional professional societies – ISoP, ISPE and the DIA – also provide
members with opportunities for communication, discussion of
research and collaboration across the world.
109
7

Clinical Aspects of Adverse Drug Reactions

In clinical practice, prescription of a medicine is the most common
intervention. Prescribing rates have increased in many countries in
recent years: in England, the number of prescriptions dispensed
increased between 2006 and 2013 from approximately 15 to 19 per
person per year. In 2013, over 1 billion items were prescribed in
England alone, costing £8.63 billion during that year. The monetary
costs of prescribing such large numbers of medicines are only one
aspect of the impact of this frequent clinical intervention. Equally
­significant are the consequences for patient safety. A report by the
American Institute of Medicine, ‘To Err is Human’, identified adverse
drug reactions (ADRs) as the most common clinical adverse event. In
the UK, which has a population of around 60 million, the total number
of spontaneously reported ADRs has increased in recent years. In
2015, a total of 39 046 reports were received by the MHRA compared
to 21 419 in 2006. In everyday practice, side effects to medicines result
in high mortality and morbidity rates and cause much clinical burden.
Pharmacovigilance has its roots in clinical practice – this is where
the majority of ADR reports originate – and the most important aim
of all pharmacovigilance activities should be to improve patient safety
in every clinical setting. People take medicines in a wide variety of
environments, most often in the community where they live, but also
in hospitals and other care facilities, in schools, residential homes
and prisons. Others volunteer to take medicines as part of a clinical
trial or research study, either as healthy participants or for a specific
condition. It is important to understand the clinical context in which
medicines are used and how medicines have many benefits. Some

An Introduction to Pharmacovigilance, Second Edition. Patrick Waller
and Mira Harrison-Woolrych.
© 2017 John Wiley & Sons Ltd. Published 2017 by John Wiley & Sons Ltd.
1

treatments have completely changed the prognosis or quality of life
for patients; for example, statins for the primary and secondary
­prevention of cardiovascular disease and isotretinoin for the treat-
ment of severe acne. However, all medicines have side effects and
in earlier chapters we have discussed benefit–risk evaluation in the
processes and practice of pharmacovigilance. Nowhere is this assess-
ment more important than in the clinical setting, where health profes-
sionals need to communicate the potential benefits and harms of
medicines directly to patients and their caregivers.
In this chapter we give an overview of the clinical aspects of adverse
drug events and some examples of important ADRs encountered in
medical practice. We then consider some specific patient populations
and discuss how patient safety could be improved in the clinical
environment.

­Clinical Burden of ADRs
ADRs are an important cause of morbidity and mortality in many
clinical settings and continue to place a major demand on public
health services worldwide. In 2004, a British study reported that 6.5%
of hospital admissions were directly a result of an ADR, with a
­projected annual cost to the National Health Service of £466 million.
A systematic review which included 25 observational studies (with a
total of more than 100 000 patients) reported that about 5% of hospital
admissions were associated with an adverse drug event. Thus, the
burden of ADRs on hospital systems – and the associated costs – is
significant.
Data on the prevalence of ADRs in patients in the community are
more difficult to find. A prospective cohort study of over 1200 patients
attending four primary care practices in Boston, USA, found that
about one‐quarter of people who responded to the survey experi-
enced an adverse drug event and about 13% of all events identified
were classified as serious. The effects of ADRs on patients (and
­healthcare professionals and systems) in general practice can be wide‐
reaching. In addition to the mortality and morbidity directly caused
by ADRs, there may be indirect clinical effects; for example, issues
affecting medication adherence. A patient experiencing clinically sig-
nificant adverse events related to a medicine (e.g. gastro‐intestinal
Clinical Aspects of Adverse Drug Reactions111

effects caused by metformin prescribed for diabetes) may be less
compliant and even stop taking the medicine completely. In the
­
­example of a patient prescribed metformin this may lead to poor
blood glucose control and worsening diabetes, with more clinical
consequences.
ADRs are an important form of iatrogenic (i.e. doctor‐induced)
­disease. Many of the serious reactions that occur are well‐recognised and
potentially preventable; for example, bleeding with warfarin, or the
upper gastro‐intestinal effects of non‐steroidal anti‐inflammatory drugs
(NSAIDs). In public health terms, it is not newly introduced drugs that
are responsible for most of the population effects of adverse drugs
­reactions, but those whose safety profile is ‘well‐established’.
The burden of ADRs on people’s lives can extend far outside the
clinical environments in which they are treated. There are many less
measurable impacts of illness; for example, dependency on family or
other carers, lost working hours (and hence financial cost), time away
from education or training opportunities and reduced quality of life.
For older patients – a group at high risk of ADRs – the last point is
especially important. It could be argued that there is little point
­prescribing medicines to extend the number of years of life if those
years are of such poor quality that they cannot be enjoyed.

­Important ADRs and Minimising Risk
The most important ADRs in clinical practice are those that cause
serious morbidity and mortality – that is, those that are potentially
life‐threatening. There are many examples of such ADRs – from gen-
eral anaphylaxis to serious adverse events affecting any body system.
It is beyond the scope of this book to describe them all and so instead
we have chosen some examples of important ADRs and discuss how
the risks of these serious events can be minimised in clinical practice.

Gastro‐intestinal Bleeding

Bleeding from the gastro‐intestinal tract is a recognised side effect of
some of the most commonly prescribed medicines, including NSAIDs,
selective serotonin re‐uptake inhibitors (SSRIs), warfarin and the
newer novel oral anticoagulants (NOACs), alendronate and other
1

­ isphosphonate medicines, and corticosteroids such as prednisolone
b
(or prednisone in the USA and Oceania). Long‐term users of NSAIDs
(e.g. patients with arthritis, other inflammatory conditions or chronic
pain) have a 1–4% annual risk of gastro‐intestinal bleeding and it has
been estimated in the UK that this causes 12 000 emergency admissions
and 2200 deaths per year.
Gastro‐intestinal bleeding can occur from any region of the
tract – from the mouth, teeth and gums down to the rectum and anus –
and may range from relatively minor, to major life‐threatening
haemorrhage. Commonly affected areas are the stomach and small
intestine, where gastro‐intestinal bleeding may present as
haematemesis (vomiting blood). Gastro‐intestinal haemorrhage
­
may also present as melaena (dark stools) or rectal bleeding. Patients
most at risk include the elderly, those taking anticoagulants,
patients with pre‐existing disorders of coagulation and those on
multiple medicines, especially other medicines known to cause
­gastro‐intestinal bleeding.
The pharmaceutical industry has attempted to reduce the risk of
gastro‐intestinal bleeding associated with many medicines by devel-
oping new products; for example, enteric‐coated NSAIDs, more
­
selective cyclo‐oxygenase 2 (COX‐2) inhibitors and combination
products (e.g. tablets containing a NSAID and a prostaglandin), and
some of these have been successful. Other ways of minimising the risk
of drug‐related gastro‐intestinal bleeding in clinical practice include
the following:
●●Identifying patients at high risk by taking a thorough family history,
reviewing all clinical details for each patient including a full medica-
tion history, including herbals and other over‐the‐counter (OTC)
medicines such as aspirin, and alcohol intake.
●●Reducing drug use in high‐risk patients, for example older people.
●●Prescribing the lowest possible dose for the shortest possible time
period.
●●Prescribing the medicine with the lowest risk; for example,
­ibuprofen as the NSAID with the lowest risk of gastro‐intestinal
bleeding.
●●Consider co‐prescribing acid secretion blocking medicines.
●●Informing patients of the risk of gastro‐intestinal bleeding and
encouraging them to present early to medical services if such side
effects occur (this is important for reducing fatalities).
Clinical Aspects of Adverse Drug Reactions113

Agranulocytosis and Other Blood Dyscrasias

Some medicines have adverse effects on blood cells, including granu-
locytes (white blood cells) which are a vital component of the immune
system. An example of a medicine that can affect the number of
­neutrophils (the most common type of granulocyte) is clozapine, an
atypical antipsychotic prescribed for treatment‐resistant schizophre-
nia. Clozapine has an important place in clinical practice as it is very
effective in some patients who do not respond to other antipsychotic
medicines, or who have specific symptoms which are difficult to con-
trol with other medicines. It has been reported that approximately
30–60% of patients with schizophrenia resistant to other treatments
will respond to clozapine.
While clozapine is clinically effective in a group of patients who
have limited other options, it is also associated with serious side
effects including myocarditis (inflammation of the heart muscle),
­
gastro‐intestinal dysmotility (causing severe constipation in some
patients) and serious haematological effects. The frequency of neutro-
penia (defined in most countries as a neutrophil count of less than
1.5 × 109/L) in clozapine‐treated patients is 2% and of agranulocytosis
(defined as a neutrophil count of less than 0.5 × 109/L) is 0.8%.
Agranulocytosis may be life‐threatening, or even fatal, as the patient’s
immune system is severely compromised.
For some medicines, identification of such a serious ADR – with
associated deaths reported –have resulted in permanent withdrawal
from the market if the risks were thought to outweigh the benefits of
treatment. However, the importance of clozapine in clinical practice
was recognised and pharmaceutical companies – working in collabo-
ration with clinicians, researchers and regulators – developed a risk‐
minimisation solution which allowed clozapine to be authorised for
schizophrenia resistant to other treatments. In several countries, clo-
zapine manufacturers have developed mandatory monitoring pro-
grammes in which patients’ blood samples are regularly tested to
detect haematological adverse effects.
In clinical practice, clozapine is started by the patient’s psychiatrist
and should only be prescribed if the patient has not responded to
other antipsychotic medications. Blood tests are performed before
clozapine is started (a normal white cell count is required) and then at
least weekly for the first 18 weeks of treatment. After that time, blood
tests are required at 2‐week intervals during the first year and then at
1

4‐week intervals for the remainder of the time on treatment (and also
for 4 weeks after stopping treatment). Pharmacists have an important
role in clozapine risk management programmes, as they check that
blood tests have been performed before dispensing the patient’s next
dose of clozapine. Some schemes have a ‘red, amber, green’ approach
to guide prescribers and pharmacists, with a ‘red’ result indicating
that clozapine should not be prescribed if white cell counts have fallen
too low. Community psychiatric nurses also play an important part in
supporting patients on clozapine.

­Common Clinical Scenarios
These examples outline how potentially serious ADRs can be man-
aged effectively in clinical practice and how life‐threatening outcomes
can be prevented, but there are many other examples in everyday
practice where management of patients is not as clear‐cut. In Box 7.1
we describe a common clinical case scenario involving management
of a patient concerned about side effects from statins.
This case reveals some of the complexities of identifying and man-
aging ADRs in real‐life clinical practice. Muscle aches and worsening
memory are both common complaints in older patients and there
may be other factors (e.g. increased physical activity) that may be
responsible for the onset of new symptoms. It is also possible that new
symptoms represent new‐onset disease (e.g. polymyalgia rheumatica
or polymyositis) rather than an ADR. Physical examination and blood
tests help the doctor exclude or confirm certain conditions, but as
seen in the case history, often there is not a specific blood test for a
particular symptom or ADR and results can be equivocal rather than
giving an exact diagnosis. In this case, the positive dechallenge and
rechallenge suggested that the patient’s muscle symptoms were likely
caused by the first statin, but in practice it is not always easy to get
such evidence – for example, if a patient is unwilling to restart a medi-
cine that caused them to have unpleasant symptoms. Finally, in the
case in Box 7.1, changing to another statin helped the patient’s muscle
symptoms (while theoretically myalgia is a class effect of statins, in
practice many patients find they do not get symptoms with another
medicine of the same class) but did not give as effective control of her
blood lipids. This shows that in real life, often a compromise position
has to be reached.
Clinical Aspects of Adverse Drug Reactions115

Box 7.1 Case history.
Mrs X, a 61‐year‐old woman, visits her GP for a review of her statin
medication and a repeat prescription. A year earlier, she had been
invited to have a cardiovascular risk assessment with the practice
nurse and was found to have hyperlipidaemia (increased levels of fats
in the blood) which gave her an elevated cardiovascular risk score. She
was advised to make dietary changes, but these did not significantly
alter her cholesterol ratio, so Mrs X was commenced on a statin
­medication (HMG‐CoA reductase inhibitor).
At her medication review, Mrs X mentions to her GP that she has
read on the internet about ‘muscle problems’ and memory loss with
statins. She feels her memory has deteriorated in the past year and that
she has been experiencing more general aches and pains. Mrs X asks
her GP if these symptoms could be caused by the statin. On further
discussion, she also reports that she has recently retired, has been
redecorating her house and has been much more active in her garden.
Her GP checks that she is not on any other concomitant medications,
including herbal treatments and over‐the‐counter products.
The GP examines Mrs X and finds no evidence of muscle tenderness
or weakness. Blood tests are performed for creatine kinase (an enzyme
marker of muscle breakdown) and serum cholesterol. A few days later
Mrs X is told her tests show her cholesterol levels are under good con-
trol on the present dosage of statin. Although her creatine kinase is
slightly raised, it is not enough to indicate rhabdomyolysis (muscle
breakdown) or myositis (muscle inflammation). Mrs X is still concerned
about her symptoms and so it is agreed that she will stop the statin for
2 weeks (dechallenge) to see if her symptoms improve and then restart
the medicine at the same dose (rechallenge).
After stopping the statin, Mrs X notices a marked improvement in
her muscle pains, but no change in her memory. On restarting the
medicine, her muscle pain returns (positive rechallenge) so her GP
advises trying a lower dose. Mrs X reduces the dosage but still experi-
ences muscle symptoms and after further discussion her GP switches
her to another statin. She tolerates this drug without muscle side
effects, but her blood lipids are not as well controlled as with the first
statin. Mrs X is unwilling to try a higher dosage of the new statin, so it
is agreed she will remain on this dosage and accept the risks of less
tightly controlled hyperlipidaemia.
1

Other common clinical scenarios are less complicated – for ­example,
a patient who presents with a drug rash, which is easily identified
through taking a clear history and clinical examination. Skin ADRs are
among the most commonly reported group of reactions reported to
regulatory authorities and fall into several groups:
●●Erythematous (redness), maculo‐papular (flat and raised redness)
or exanthematous (blotchy redness)
●●Urticarial (sometimes known as hives or nettle rash)
●●Angioedema (swelling of the face, lips, oral cavity and upper
­respiratory tract)
●●Photosensitivity (skin reaction to sunlight)
●●Purpuric (bruising or bleeding under the skin)
●●Fixed drug eruption (recurrence at same site)
●●Bullous (blistering) conditions (e.g. bullous pemphigoid or sub‐­
epidermal blistering)
●●Widespread skin reactions (e.g. Stevens–Johnson syndrome, SJS;
toxic epidermal necrolysis, TEN).
Most skin ADRs are not serious and resolve on cessation of the
medicine and symptomatic treatment, but some require biopsy by a
specialist. However, some skin reactions are very serious – for exam-
ple, SJS or TEN (Figure 7.1) – and can affect the whole body. Such
reactions are life‐threatening and require intensive treatment, despite
which they are sometimes fatal.­Important Patient Populations
While it is important to remember that any patient can experience an
ADR to any medicine at any time (not all ADRs occur in the first days
or weeks of treatment), some patients are at higher risk of ADRs:
●●Women – in every age group, women take more medicines than men
(including contraceptive products, herbals and OTC medicines),
may metabolise medicines differently and experience more ADRs.
In the UK, in 2015, more spontaneous ADR reports were received
for women (56%) than men (39%), with gender unspecified in
some cases.
●●Older patients – the elderly are prescribed more medicines than
younger patients, take medicines for longer periods, have more
Clinical Aspects of Adverse Drug Reactions117
Figure 7.1 Photograph of patient with toxic epidermal necrolysis (TEN).
© DermNet New Zealand. We are grateful to DermNet New Zealand for
permission to reproduce the image under the terms of this license:
https://creativecommons.org/licenses/by‐nc‐nd/3.0/nz/legalcode.

pre‐existing disease (including deteriorating hepatic and renal
­
function) giving more chance of ADRs and drug interactions.
Recent UK data show that the age band with the highest number of
spontaneous ADR reports per year was 61–70 years (note that these
are absolute numbers of reports and not frequencies of ADRs).
●●Patients with chronic (long‐term) conditions – examples include
those with diabetes, autoimmune conditions, epilepsy, arthritis or
other joint conditions, schizophrenia and other chronic psychoses,
hypertension, heart disease, and chronic lung disease. These
patients are likely to be on long‐term medications, may be taking
several medicines and there may also be aspects of their conditions
that make them more susceptible to ADRs.
●●Patients with genetic or other susceptibilities affecting how medicines
are metabolised – for example glucose‐6‐phospate dehydrogenate
deficiency (an X‐linked recessive enzyme deficiency which affects
about 400 million people worldwide) which alters metabolism of
several medicines including antibiotics and antimalarials.
1

In addition to the above groups, there are special populations where
exposure to medicines should be carefully considered, as follows.

Pregnant Women

Virtually all medicines cross the placenta, resulting in fetal exposure,
so it is important for clinicians and women to consider this risk,
­especially as many pregnancies are unplanned. However, it is also
important to remember that some women require medicines during
pregnancy, for example those with epilepsy or other chronic condi-
tions. The benefit–risk assessment of medicines in pregnancy may be
quite complex and it advisable to refer to specialist sources of
­information (see Chapter 10).

Breastfeeding Infants and Neonates

Babies may be exposed to medicines via their mothers’ milk and it is
important for clinicians to take a maternal drug history – including
herbals, OTC medicines and alcohol. Neonates can be at more risk of
ADRs because of their immature metabolic systems and dose adjust-
ment of medicines is crucial in this very young population, especially
for premature babies.

Children

While the number of medicines licensed for use in the paediatric pop-
ulation is increasing all the time, it may still be necessary for clinicians
to prescribe medicines to children ‘off‐label’ (i.e. outside the terms of
the marketing authorisation). Data are often lacking in patients under
18 years and, as for neonates, dosage adjustments may have to be
made in small children. Younger people may also be at risk of specific
ADRs (e.g. Reye’s syndrome with aspirin).

­Improving Patient Safety in Clinical Practice
We began this chapter by placing pharmacovigilance at the centre of
patient safety, not least because ADRs are the most common safety
event in clinical practice, both in community and hospital settings.
Patient safety is the ultimate goal of all pharmacovigilance practice
Clinical Aspects of Adverse Drug Reactions119

and in everyday clinical practice there are several steps that can be
taken to improve this outcome.

Better Prescribing

To reduce the clinical burden of ADRs, prescribers should discuss
four important questions with patients before reaching for the pre-
scription pad:

1. Is this medicine really needed? There may be non‐pharmaceutical
   alternatives which should be tried first – for example, dietary
   changes and exercise programmes before weight reduction medi-
   cines are prescribed.
2. Is this medicine suitable for this person and this condition? For
   example, antidepressant medicines are not usually an appropriate
   treatment for grief.
3. How effective is this medicine likely to be? It is generally not well
   understood by patients that most medicines are not 100% effec-
   tive – many products are only effective in around 50% of patients.
   This is an important consideration for benefit–risk discussions in
   the clinical setting.
4. How safe is this medicine? What are the most common and most
   serious ADRs associated with the medicine? Is the patient in a
   high‐risk group or in a special population requiring extra
   ­consideration? Most people understand that all drugs have some
   side effects, but may not understand that some of these may be
   life‐threatening.

Avoiding Medication Error

In all clinical settings, steps can be taken to reduce medication error,
which has been defined as ‘a failure in the treatment process that
leads to, or has the potential to lead to, harm to the patient’ and
includes different types of error, for example prescription of the
wrong drug or giving an incorrect dose. Protocols may involve ­several
different members of a multi‐disciplinary team, for example doctors,
nurses and pharmacists each making checks during the process
of prescribing and dispensing a medicine. In many countries,
­prevention of medication errors is now part of pharmacovigilance
practice and adverse events should be reported to national systems.
1

An important point is that these adverse events should be entirely
preventable with good clinical practice.

Use of Available Guidance

For many drugs or conditions (e.g. disease‐modifying anti‐­rheumatoid
drugs for rheumatological conditions) there are guidance documents,
checklists and treatment/monitoring protocols available to clini-
cians. These are drawn up by international, national or more local
­authorities. Using and adhering to such guidance has potential to
reduce ADRs and/or detect ADRs early in order to reduce harm to
patients on long‐term medicines.

Medication Reviews

For patients taking medicines in the long term, it is helpful for clini-
cians – ideally in collaboration with pharmacists and other members of
the patient’s healthcare team – to undertake regular medication
reviews. This is especially important in the elderly population or other
groups at high risk of ADRs. It is fairly common for additional
­medicines to be prescribed to older patients presenting with new
­problems, without considering whether any other medicines could be
discontinued. Regular medication review, involving the patient and
their carers, has much potential to improve patient safety and qual-
ity of life.

Good Communication

As in all other areas of pharmacovigilance practice (see Chapter 4),
good communication is essential in the clinical setting. Clear explana-
tions and discussions which consider the patient’s perspective are at
the heart of the clinical consultation. Use of diagrams, pictures and
charts can help explain risks of medicines in lay language. There are
also many useful resources to support the patient after the consulta-
tion – in particular, the product’s Patient Information Leaflet (PIL)
which should be provided to the patient when the medicine is
­dispensed. In most countries, the product’s PIL (known as the package
leaflet in the EU, package insert in the USA and consumer information
leaflet in some other regions) is assessed as part of the regulatory pro-
cess, to check it complies with the licensed product information in
accurately describing ADRs and other safety information, and is also
Clinical Aspects of Adverse Drug Reactions121

readable and useful to patients and their carers. There are many other
leaflets and online resources available for specific patient groups, or
for specific medicines, but it should be noted that not all are entirely
accurate (most online sites are not subject to expert review or regula-
tion) and some may be promotional for certain products.

Vigilant Practice

Clinicians are encouraged to develop a high level of suspicion con-
cerning evaluating clinical events which may be related to the patient’s
medicines. Some doctors have been defensive of the medicines they
have prescribed and unwilling to acknowledge that (inadvertently)
these products have harmed patients. In some countries, ADR report-
ing rates are thought to be low for this reason (and perhaps for other
reasons, such as fear of litigation). This perspective will not improve
clinical practice and patient safety in the longer term. In most
­countries, the mantra for reporting ADRs to national authorities is
‘if in doubt, report it’, as without reports, new signals will not be identi-
fied, clinical practice will not improve and the ultimate goal of
improved patient safety will not be achieved.

­Conclusions
Prescribing medicines is the most common intervention in everyday
medical practice and ADRs are frequent clinical events, placing a large
burden on health systems. In this chapter we have tried to give a snap-
shot of some clinical aspects of pharmacovigilance, with examples of
important and common ADRs. Understanding how medicines are
prescribed, taken and monitored in real life allows us to improve
pharmacovigilance practice with the ultimate aim of improving
patient safety.
123
8

Ethical and Societal Considerations

We now consider wider societal aspects of the safety of medicines, starting
by identifying the main stakeholders and their perspectives. There is an
important ethical dimension to pharmacovigilance – medicines are
supposed to be beneficial and yet we know that harms will occur
despite best efforts to prevent them. In the past, much information
about the safety of medicines remained within companies and was
only shared with regulators when required. Steps to improve transpar-
ency have been made both in terms of process and access to the
­relevant data, both in the pre‐ and post‐licensing phases of drug
development. Potential conflicts of interest are increasingly recog-
nised as very important and need to be handled appropriately. Ethics
committees continue to discuss the balance between benefit to society
and possible harm to individuals. At times, public confidence in gov-
ernment systems has not been high – there has been criticism that
regulators and industry are too cosy, and that patients’ interests do
not always come first. The media watch from a distance, waiting for
something interesting to happen.

­Stakeholders and Their Perspectives
The most important stakeholders in pharmacovigilance are patients
who use medicines – this is, after all, why the discipline exists. Health
professionals are also ‘users’ of the medicines they prescribe and both
probably have similar expectations of the process. Broadly speaking,
users of medicines expect them to have been adequately tested, to be

An Introduction to Pharmacovigilance, Second Edition. Patrick Waller
and Mira Harrison-Woolrych.
© 2017 John Wiley & Sons Ltd. Published 2017 by John Wiley & Sons Ltd.
1

effective and ‘safe’ in the sense that serious harms are unlikely to occur,
and to be provided with appropriate and understandable information
about their use. These are in essence the goals of the regulatory pro-
cess, but because of limitations that largely have a scientific basis there
is a gap between expectation and reality. Patients know that side
effects can occur with medicines, but generally perceive these as likely
to be transient or reversible and non‐serious. When a life‐threatening
reaction occurs with a treatment given for a relatively trivial indica-
tion, they are shocked. The prescribing doctor might be too, because
he or she has unintentionally broken one of the first rules of medi-
cine – primum non nocere (first, do no harm). By contrast, personnel
working in drug safety, whether they are in industry, a regulator or in
academia, may be unsurprised.
Patients exist not only as individuals but in groups (i.e. patient
organisations) and such bodies have an important role in educating
and supporting individuals who develop specific (usually chronic)
­diseases. Generally, patient organisations are more focused on access
to treatments than on safety considerations and their perspective may
well be that the need for and potential benefits of treatments outweigh
quite major risks. Some patient groups are specifically based on the
victims of particular treatments (e.g. there is still a prominent thalido-
mide action group in the UK) and they may be seeking to achieve
­recognition of a problem, regulatory measures against the drug or
compensation for affected individuals.
Vaccines are a particularly sensitive area for understandable
­reasons – they are usually given to healthy individuals and often to
children. One of the reasons for administering them as widely as
­possible may also be a benefit to society rather than the individual
(i.e. ‘herd’ immunity). This raises an ethical dilemma if serious harms
are possible. Perhaps for such reasons vaccines are unusual in that
some attempts to compensate victims directly (i.e. without litigation)
have been made. In most countries, society does not compensate
­victims of adverse drug reactions (ADRs) unless they are prepared
to litigate. To win they are likely to have to prove individual causation,
to demonstrate they were personally harmed by the treatment (this
may be intrinsically difficult as was discussed in Chapter 2) and pos-
sibly also that the manufacturer did not take all reasonable steps to
identify and prevent such harm. Litigation about medicines is a major
industry in itself and extremely good business for lawyers who may
actively advertise for cases (there are many such sites online) and
Ethical and Societal Considerations125

­ ursue mass actions which are quite often settled out of court by com-
p
panies as a means of damage limitation. Government health ministers
are ultimately responsible for the overall system, but politicians gener-
ally avoid involvement – there is little in it for them but a potential
minefield.
When an unexpected major drug safety issue arises, it is good
copy and likely to receive a very high profile in the media. Hindsight
will be liberally applied – surely this could have been predicted or
avoided? – and the company and/or regulators are likely to be blamed.
The plight of individual victims is highlighted, but media and public
interest will generally be transient. The media see their role as to
inform and entertain and vary considerably in their approach, but
common to all is a focus on what they perceive will attract their cus-
tomers (i.e. what ‘sells newspapers’). Drug safety matters will usually
do so, but some elements of the matter (e.g. uncertainties and difficult
judgements) are often handled badly or ignored.
Media coverage may unnecessarily scare some people into inappro-
priate action (as in the Pill scares discussed in Chapter 1) but pharma-
covigilance personnel should not lose sight of the potential positive
power of their influence. Indeed, better handling of the media should
be on their agenda. It is certainly worth sitting down with more
responsible sections of the media and explaining what the problem is
and discussing how they can help. Ultimately, anything that may lead
to well‐balanced coverage and clear, appropriate messages is worth
pursuing.
In terms of trying to prevent unnecessary drug safety scares, it is
worth bearing in mind recognised ‘fright factors’ – these are aspects
of a particular risk that will tend to make most people more risk‐
averse. In particular, we tend to be more frightened by risks that are:
●●Involuntarily taken
●●Man‐made
●●Irreversible
●●Poorly understood.
Many serious ADRs will meet all of these criteria, meaning that it is
very easy for the public to become more scared than is appropriate
and to lose sight of the balancing benefits. For example, following
­concerns that use of human insulins might mask the symptoms of
hypoglycaemia in the early 1990s, some patients stopped taking
­insulin altogether.
1

All the parties mentioned are stakeholders in the process of
­ harmacovigilance, but usually lawyers and the media only become
p
involved when a problem has already occurred. Industry personnel, reg-
ulators, researchers, non‐governmental organisations (see Chapter 6)
and individual users (i.e. patients/health professionals as discussed in
Chapter 7) between them have the potential to prevent some specific
problems occurring – the ultimate purpose of pharmacovigi-
lance – whereas other stakeholders may influence the system or
endeavour to promote change later in the process.

­Ethical Principles
As should be clear from the discussions above, there are many poten-
tial tensions in the drug safety system – such as risk versus benefit,
individual versus population good, potential therapeutic gain from
innovation versus uncertainty. These are set against a background of
commercial and political imperatives, the latter largely being the eco-
nomics of healthcare. The need for an ethical approach and ethical
safeguards is therefore manifest.
In terms of researching the safety of medicines in human subjects,
there is an overarching code of ethical principles – the Declaration of
Helsinki – which was originally developed under the auspices of the
World Medical Association (WMA) in 1964. Since that time there have
been several significant revisions to the Declaration and the current
version (2013) is the only official one, replacing all earlier versions.
The Declaration of Helsinki is based on principles outlined in the
WMA Declaration of Geneva which binds the physician with
the words, ‘The health of my patient will be my first consideration’, and
the International Code of Medical Ethics which declares that ‘A physi-
cian shall act in the patient’s best interest when providing medical care.’
In the context of safety, the most important of the 37 points
­currently included in the Declaration of Helsinki are as follows:
●●While the primary purpose of medical research is to generate new
knowledge, this goal can never take precedence over the rights and
interests of individual research subjects.
●●All medical research involving human subjects must be preceded
by careful assessment of predictable risks and burdens to the
­individuals and groups involved in the research in comparison with
Ethical and Societal Considerations127

foreseeable benefits to them and to other individuals or groups
affected by the condition under investigation.
●●Measures to minimise the risks must be implemented. The risks
must be continuously monitored, assessed and documented by the
researcher.
●●Medical research involving human subjects may only be conducted
if the importance of the objective outweighs the risks and burdens
to the research subjects.
These have an underlying theme: individual patient safety is para-
mount. However, another key theme in the Declaration of Helsinki is
consideration of the balance between the likely common good (future
benefit to society) and the risk of harm to the individual when under-
taking medical research. In pharmacovigilance, risk–benefit trade‐
offs made at the population level usually accept that some individuals
will lose out. Essentially, a judgement is being made that more good
than harm will occur in the population in the full knowledge that
some harms cannot be prevented.

­Informed Consent
When experimental research is being conducted (i.e. there is an
intervention that would not occur in ordinary practice), informed
consent is essential. On this point, the Declaration of Helsinki states
‘Participation by individuals capable of giving informed consent as
subjects in medical research must be voluntary. Although it may be
appropriate to consult family members or community leaders, no
individual capable of giving informed consent may be enrolled in a
research study unless he or she freely agrees.’ Issues become more
complex when an individual is unable to give informed consent to be
involved in research; for example, if they are too young, have a condi-
tion impeding their competency to consent or have died. Protocols
involving these situations are usually referred to ethics committees
for advice.
For non‐interventional research (i.e. observational studies), consent
of individuals has generally not been required and often may not be
feasible, for example in large data‐linkage studies. However, in today’s
environment of increasing importance of individual rights, most ethics
committees will ask researchers to justify why informed ­consent
1

should not be obtained for observational research. In addition to feasi-
bility and methodological issues (e.g. if seeking consent would bias the
results as people who agree to consent may differ from those who
refuse) there is again the overriding ethical question of whether the
common societal good overrides individual perspectives and if so,
when? This is relevant, for example, to whether or not patient consent
is required for ADR reporting and epidemiological research. To date, it
has been generally agreed that individual consent is not required for
submitting ADR reports, as this is in the common good and is also part
of good clinical practice (so is not strictly ‘research’ although research
may later be performed on the anonymised population data). However,
during the clinical consultation most health professionals are likely to
inform the patient they are submitting the ADR report and the indi-
vidual has the right to opt out of this process if they so wish.

­Privacy and Confidentiality
The patient’s right to privacy is a key issue and individual patient data
need to be held securely and treated with respect. Research protocols
need to specify measures for keeping individual data private and
­confidential during studies and these principles also apply in post‐
marketing pharmacovigilance practice. Often it is necessary to
de‐identify personal data for research purposes and no individual
should be identifiable when results are shared with authorities or
­published. While there is a general statement about privacy and confiden-
tiality in the Declaration of Helsinki, it should be noted that legislation
varies considerably between countries and this needs to be considered
when performing international pharmacoepidemiology research.

­Ethical Issues for the Pharmaceutical Industry
There are various other specific ethical issues that face industry per-
sonnel and are relevant to safety. For example:
●●Ethical promotion of drugs, given the potential link between safety
and promotion.
●●Public representation of data (e.g. the temptation towards suppression
of unfavourable data or expert opinions).
Ethical and Societal Considerations129

●●Drug pricing and availability, especially in the developing world,
may lead to use of less safe medicines.
●●Control over publication of results that were unfavourable in terms
of efficacy or safety.­Ethical Safeguards in Relation to Safety
The safeguards in place to protect patient safety can broadly be con-
sidered on the following four levels.

Legislation, Voluntary Codes and Guidelines

Many of the issues discussed are addressed in the framework of medi-
cines legislation in each country, in international codes such as the
Declaration of Helsinki and ICH guidance (see Chapter 6) and in
national and regional ethical guidelines. The pharmaceutical industry
also has some voluntary codes (e.g. in relation to advertising prac-
tices), as do health professionals, whose professional bodies have
developed codes and guidelines for ethical practice.

Ethics Committees/Review Boards

Ethics committees operate nationally or regionally and the role of
such committees is to consider ethical aspects of specific research
proposals. Committee membership is usually comprised of both
expert (medical or scientific) and lay representatives and in many
countries meetings are open in order to increase transparency. Their
key task is to protect study participants by reviewing research proto-
cols and any amendments that may be necessary once the study is
under way.
Many studies presented to ethics committee involve evaluation of
the safety of medicines, either in pre‐licensing clinical trials or in
­studies of marketed medicines. Some of the key ethical issues in such
studies are as follows:
●●There may be no benefit to the study participant (especially for
first‐in‐man studies or other new indication studies) and this is
an important difference to benefit–risk assessment in clinical
practice.
1

●●The risks of the medicines to be administered in the study need to
be clearly stated and explained, including frequencies of ADRs (if
known from previous studies) and possible outcomes for the
participant.
●●Any risks to special or vulnerable populations (e.g. pregnant women,
children or the elderly) need to be clearly stated and justified.
●●Issues relating to participants who are unable to provide informed
consent for interventional studies (e.g. unconscious patients, those
with cognitive impairment).
●●Researchers need to outline what they will do to minimise risk to
the study participants.
●●Participants must be informed of the possible risks in clear informa-
tion sheets written in lay language.

Data Monitoring Committees

These should be set up for interventional studies in order to protect
subjects from safety hazards which might only become evident during
the course of the study. Depending on the study and the risks involved,
the data monitoring committee can be an informal local group or a
full external committee. These groups should be run independently of
the sponsor and operate separately from those involved in the day‐to‐
day operation of the trial. A data monitoring committee looks at the
safety data sequentially as it emerges and can recommend that the
trial be stopped on safety grounds if it becomes clear that patients
in one treatment arm are at greater risk of a serious hazard than those
in the other arm(s).

Publication

Much (but not all) medical research will eventually be published in the
scientific literature. The publication process for most international
journals involves peer review which thereby provides another ethical
safeguard for research practice. However, publication is selective (and
therefore biased) depending on:

1. What the results show – positive research is more likely to pub-
   lished than something that failed to observe a clear effect
   (­commonly referred to as publication bias).
2. Choices made by researchers and editors – as with other forms of
   media, decisions are made regarding what is topical and of interest
   to readers.
   Ethical and Societal Considerations131

Aside from the issue of non‐publication (or delayed publication) of
some research findings, there is also the problem of misconduct.
There are many potential types of misconduct relating to publication,
the most serious of which are plagiarism, fraud or fabrication. Steps
have been taken to address these problems in part through the setting
up of a Committee on Publication Ethics which now operates world-
wide. This has drawn up guidelines intended to encourage intellectual
honesty, prevent and deal with misconduct and provide advice on
when research papers should be retracted.

­Transparency
In the past, drug safety was, like many other processes involving
regulated industry, essentially non‐transparent. Users were
expected to accept that behind the scenes people were doing their
best and with the right motives. Commercial sensitivity was another
reason given for a lack of transparency in the pharmaceutical indus-
try. The move towards greater transparency which gained impetus
during the 1990s was not specific to this field, but part of a wider
societal desire to know more of what was going on. Governments
have also seen advantages in opening up such processes, in terms of
public confidence in systems and in increasing the credibility of
their decisions and advice. This change in approach has been facili-
tated by developments in electronic communication. Thus, general
public policy on freedom of information began to override the
potential commercial considerations that were for a long time the
main putative reason for secrecy. It is now generally accepted that
drug safety information rarely has real commercial value to
competitors.
The following is a list of some of the major types of safety data which
may now be freely available:
●●Published scientific literature
●●Warnings on specific issues (e.g. from companies or regulatory
bodies)
●●Drug safety bulletins (e.g. from regulators or other professional
bodies)
●●Press releases
●●Public assessment reports on specific issues (e.g. from regulatory
bodies)
1

●●Searchable ADR databases
●●Clinical trial protocols and data.
The ordering of the list is chronological in the sense that 50 years
ago only information published in the scientific literature was availa-
ble and that the others have been introduced at various time points
since then. The requirement for registration of clinical trials is sur-
prisingly recent (early 2000s) and there is still scope for further devel-
opment (e.g. only summaries of risk management plans have so far
been made public) and in most countries, regulatory discussions are
still held behind closed doors.
Timing of release of information is important because it is reason-
able to be concerned that premature release before considered recom-
mendations can be made could do more harm than good. There is also
concern that complex information might be misunderstood and there
is a need to improve delivery with the goal of aiding better under-
standing according the needs of the recipient.
Besides the information on which judgements and decisions are
based, there is a need for transparency of process. In this respect the
public need to know:
●●Who reached the decision?
●●What was the basis for the decision?
●●Was the decision challenged?
●●Why was another course of action not chosen?

­Conflicts of Interest
The realisation that we all have conflicts of interest and attempts to
deal with them is a surprisingly recent phenomenon. It was only at the
beginning of the twenty‐first century that one of the major journals in
the field introduced a clear policy in relation to the need for declara-
tion of such conflicts. Drug safety is now a very sensitive area in this
respect because difficult judgements have to be made about the risk of
serious harms and these have financial consequences for the company
involved. The public need to be convinced that those making the
judgements are uninfluenced by such considerations and yet aca-
demic experts in the field are ubiquitously associated with, and their
research is often funded by, the industry. In dealing with conflicts of
interest, transparency and public credibility are the key issues.
Ethical and Societal Considerations133

There is general agreement that financial conflicts of interest must
be disclosed and that persons with important conflicts should not
influence relevant decisions. All organisations conducting pharma-
covigilance work should have policies on how conflicts of interest
should be handled. A useful categorisation of financial conflicts
­developed by regulators is to consider whether they are:
●●Personal (consultancy fees, shares) or
●●Non‐personal (e.g. funding to a university department) and
●●Specific (to the drug/issue at hand) or
●●Non‐specific (e.g. related to other drugs made by the same
company).
Using such a system provides for four categories, and interests that
are both personal and specific represent the highest level of conflict.
These should result in exclusion of an expert from giving advice to
regulators. Conversely, a non‐personal, non‐specific interest is at the
lowest level and usually only requires declaration. Such systems are
necessary because, in practical terms, regulators or other authorities
may not have access to the necessary expertise if they simply excluded
all experts who had any kind of conflict.
Other competing interests (e.g. non‐financial) are also possible and
systems are less well developed in dealing with them. Involvement
with competitor products/companies, indirect potential conflicts via
personal associations (through family or work) and past interests
which might be considered lapsed, are examples of such grey areas.

­Conclusions
In this chapter we have outlined broad ethical and societal considera-
tions that impact on pharmacovigilance. We have discussed the per-
spectives of the relevant stakeholders and how they impact on aspects
of societal behaviour when drug safety issues occur. General ethical
principles and guidance are drawn from the Declaration of Helsinki
and a balance is required between protecting individuals and the
­common good. There are some specific issues for research studies
involving medicines, and ethics committees continue to be important
in protecting participants from harm. To support system credibility,
the need for transparency of drug safety information and processes is
generally accepted, while protecting the privacy of individuals.
135
9

Future Directions

­Current Limitations
Many new drugs have been introduced in recent decades, but there is
no evidence that this has reduced the overall burden of adverse drug
reactions (ADRs). Despite thorough clinical development, unexpected
and sometimes unexplainable ADRs become recognised at a fairly late
stage in the process. Furthermore, it is often not possible to under-
stand why a particular individual experiences an ADR while another
does not. Thus, ADRs remain an important cause of morbidity and
mortality around the world (see Chapter 7). Much of this harm is
potentially preventable and some of our inability to prevent it so far
reflects the limitations of existing systems.
When thinking about the future of pharmacovigilance, a useful
starting point is to consider the most important current limitations of
the discipline. It is to be hoped that future developments will be tar-
geted at overcoming at least some of them, although the challenges
are considerable. Broadly, these limitations might be characterised
under the following three headings.

1 Detecting New ADRs and Distinguishing Them
from Non‐causal Effects

Existing systems have many limitations for detecting new ADRs.
Under‐reporting is an important issue and spontaneous reporting
remains a passive system, in that it relies on reporters to submit their
suspicions of ADRs. More proactive methods of detecting and

An Introduction to Pharmacovigilance, Second Edition. Patrick Waller
and Mira Harrison-Woolrych.
© 2017 John Wiley & Sons Ltd. Published 2017 by John Wiley & Sons Ltd.
1

­ easuring the occurrence of ADRs (e.g. prescription‐event monitor-
m
ing; see Chapter 3) are available but there is still not enough use of
such methods and real‐time monitoring has been largely focused on
specific areas (e.g. vaccines).
As discussed in Chapter 2, judgement is required in deciding whether
reported or observed association are causal. Such judgements are often
hampered by the limitations of the available data; for example, there
may not be enough clinical information provided on spontaneous
reports to assess causality. Even when a causal effect appears likely,
educated guesses usually have to be made about the frequency of an
ADR (especially in post‐marketing use) or who is most at risk and the
applicability of the available data to a general population. Better use of
other data sources for detecting and measuring the frequency of ADRs
should also provide more detailed information on which to judge if
there is direct causal relationship with the medicine.

2 Extending Knowledge of Safety

The development of risk management planning has provided a
­mechanism for extending knowledge of safety (i.e. gaining greater
confidence that adverse effects are not remaining undetected).
However, this approach is highly dependent on sponsor companies or
other bodies conducting formal post‐authorisation studies and
remains under‐utilised to date. More careful estimation of baseline
risks in ­different groups within the population is also needed.

3 Preventing and Managing Known ADRs

Once an ADR is recognised and perhaps even well‐understood, our
ability to prevent it often remains imperfect for two broad reasons:

1. Few of the preventive tools used are 100% effective (e.g. monitoring
   liver function tests in a patient using a potentially hepatotoxic drug
   may only prevent some cases).
2. Most of the preventive measures available are recommendations
   which are imperfectly followed by clinicians and/or patients.
   In overall terms, difficulties we have in predicting, understanding
   and measuring ADRs hamper preventive efforts, but even if those
   limitations could be overcome, the mechanisms for minimising known
   risks still need to be improved (e.g. through better communication).
   Future Directions137

­Meeting the Challenges
Improving Collection of Pharmacovigilance Data

A logical approach to improving anything is to specifically target areas
of weakness. For example, it is notable that one of the most toxic class
of medicines, anti‐cancer drugs, tend to be associated with very few
ADR reports. Understanding the reasons for this (perhaps oncologists
consider the side effects of these medicines are well known and there-
fore feel there is no need to report ADRs to regulators) may help us
target and improve areas of under‐reporting. In the 1990s, there was a
particular difficulty in studying the then new anti‐HIV drugs, which
may have been related to concerns about confidentiality and the
underlying diagnosis. In the UK, a targeted reporting scheme was set
up which successfully allayed the concerns of reporters and gained
much important information about the safety of the class.
Regarding detection of ADRs and in particular, the problem of
under‐reporting, such weaknesses could be overcome by the use of
electronic systems at the point of prescribing. Use of reporting apps
on phones are likely to allow an increased number of suspected ADR
reports to be collected. The use of social media is another potential
source of data for detecting ADRs, but there are several challenges
with this method. It may be difficult to confirm that data refer to
actual ADRs that have occurred, rather than discussion of ADRs
occurring in other people (such as celebrities) or duplications of other
reports. Social media may be helpful in early detection of problems in
the future, but there are many aspects of this type of reporting that
need further investigation.
There is also potential to improve collection of ADR data from hos-
pital systems where, in many countries, reporting rates have been low
compared with those from primary care. In the developed world,
there have been hopes that electronic health record scanning could
eliminate the need for spontaneous reporting as a method to detect
new ADRs. However, this has proved to be difficult in practice and
even developing a complete electronic record for each individual
patient in a national health system has been challenging. It is to be
hoped that there will be improvements in this area and the ability to
test signals rapidly in large electronic systems like Sentinel in the USA
is likely to improve over time. If we are successful in increasing the
number of ADR reports submitted in the future, there will be a need
1

for improvement in the methods for processing of reports and
­efficiently distinguishing ADRs from non‐causal events.
One of the most striking areas of weakness has been in relation to
children, who until recent times were largely excluded from drug
development programmes and often had to be treated outside the
terms of marketing authorisations (known as ‘off‐label’ prescribing).
Since 2007, this has been partially addressed through the EU regulatory
requirement for paediatric investigation plans (with pharmacovigi-
lance being an important element of these) and, in the UK, also by
publication of a children’s British National Formulary which gives
specific advice for younger patients. While there are now more medi-
cines licensed for paediatric use and reporting of ADRs in children
has increased, there is still room for improvement.
Another area where pharmacovigilance data have been lacking is for
pregnant and breastfeeding women. Again, this special population
has been excluded from clinical trials and product information too
often states ‘no data are available’. However, some measures are being
taken to improve guidance in this area, with development of a
European GVP Module regarding medicines in pregnancy and
­lactation (see Chapter 5). In addition, healthcare databases (notably
the UK Clinical Practice Research Datalink and Danish national
­registries) are increasingly being used to link mother and baby records
to investigate the outcomes of medicines taken in pregnancy. However,
some effects of drugs on the unborn baby (e.g. developmental
­problems) may not be detectable through databases, and may require
bespoke longer term studies.

Monitoring the Safety of Biological Medicines

Scientific developments in molecular biology and genetics have been
exponential since the late 1980s/early 1990s and many new active sub-
stances now reaching the market are ‘biological’ products which have
been developed using these new technologies. Key examples include
inhibitors of specific growth factors (e.g. vascular endothelial growth
factor inhibitors for macular degeneration) and immunomodulators
for autoimmune diseases or cancer therapy. Biological products
such as erythropoietins and interferons, can (like vaccines) be prone
to batch problems and minor changes in manufacturing can lead to
­significant clinical adverse effects. In recent years, many ‘biosimilar’
drugs have been developed and authorised, but these are not a­ nalogous
Future Directions139

to generic medicines and post‐authorisation safety studies will be
needed as part of the risk management plan.
These developments have resulted in clinical advances for many
patients, but also provide new challenges for monitoring safety. Use of
registries to collect information on the exposed population (see
Chapter 3) may be a useful pharmacovigilance tool to study these spe-
cialised products, but better ways of accessing data and performing
comparative studies are still required.

Pharmacogenetics and ‘Personalised Medicine’

The discipline of pharmacogenetics is based on the premise that
genetic markers can predict the safety of many drugs, with potential
implications for their practical use. To date, pharmacogenetics
research has mostly been focused on genetic variations in hepatic
drug metabolism and on identifying hypersensitivity phenotypes.
An example is the investigation of abacavir hypersensitivity, which
was found to be associated with HLA‐B5701. Testing was intro-
duced in HIV clinics in London which resulted in decrease in
abacavir hypersensivity from 8% to 2%. Another example is carba-
mazepine‐induced cutaneous reactions which were found to be
associated with HLA‐B1502, which is more common in Asian
patients. In Hong Kong, testing was recommended before prescrip-
tion of carbamazepine, but some physicians saw this as an obstacle
to prescribing this medicine and starting prescribing other drugs.
This demonstrates how pharmacogenetics research has shown
potential to identify specific patients at risk of ADRs, but also how in
clinical practice there have been issues with the uptake of genetic
testing. There may be several reasons for this, including costs, access
to such tests and practicalities around performing such tests before
prescribing a particular medicine.
The ultimate goal of pharmacogenetics research is that, in the
future, ADRs could be preventable through recording of personal
pharmacogenetic profiles, individual recommendations for use or
avoidance of drugs, or tailored dosage regimens, for patients with
­specific genotypes This concept of ‘personalised medicine’ is both
exciting and challenging for the future. It has been argued that
­progress has been slower than expected but, in 2015, an editorial in
the British Medical Journal suggested that pharmacogenetics was
beginning to deliver some of its potential.
1

Development of Scientific Methods for Pharmacovigilance
Practice

Throughout this book we have touched on how scientific methods are
being applied to study the safety of medicines. There have been key
developments in the methods used for signal detection, prescription
event monitoring and in other pharmacoepidemiology studies (see
Chapter 3). Robust scientific method should be at the heart of pharma-
covigilance and pharmacoepidemiology research – this is possible in
many different settings around the world, but requires constant atten-
tion and review. In future clinical studies there should be more focus on
patient safety as a primary end‐point. This will generate valuable data on
which to make benefit–risk assessments. For publication of research
papers in scientific journals, peer review is now an essential part of the
process and there is an almost universal requirement to report any con-
flicts of interest and state if ethical approval was obtained (see Chapter 8).
There remains much potential for international collaborative
research, including using large datasets; global tissue banks (especially
for genetic research on rare diseases or ADRs) and sharing and pool-
ing data and expertise. Finally, there should continue to be scientific
analysis, discussion and communication of results in appropriate
environments, such as conferences and international meetings.

A Scientific Model for the Process of Pharmacovigilance
In terms of the overall process of pharmacovigilance, in 2003 a scien-
tific model to support excellence in the discipline was proposed by
Waller and Evans (Figure 9.1). The model represented a long‐term
vision of how pharmacovigilance could be conducted in the future
and was underpinned by the following key concepts:
●●Pharmacovigilance should be less focused on finding harm and
more on extending knowledge of safety.
●●There should be a clear starting point or ‘specification’ of what is
already known at the time of licensing a medicine and what is
required to extend safety knowledge post‐authorisation.
●●Complex risk–benefit decisions are amenable to, and likely to be
improved by, the use of formal decision analysis.
●●A new approach to provision of safety information which allows
greater flexibility in presenting key messages based on multiple
­levels of information with access determined by user requirements.
Future Directions141Best evidence Culture ofOutcome
Robust scientific
scientificmeasures
decision-making
developmentand audit

Tools for protecting
public healthMeasurable performance in terms of public health benefit

Figure 9.1 Model for excellence in pharmacovigilance.

●●Flexible decision support is the most likely means of changing the
behaviour of health professionals in order to promote safer use of
medicines.
●●There is a need to put in place outcome measures that indicate the
success or failure of the process.
●●Systematic audit of pharmacovigilance processes and outcomes
should be developed and implemented based on agreed standards.
●●Pharmacovigilance should operate in a culture of scientific
­development. This requires the right balance of inputs from various
disciplines, a strong academic base, adequate training and resource
which is dedicated to scientific strategy.
Some progress in these directions has since been made over the past
decade. This includes the development of risk management plans
which include a safety specification (see Chapter 5), and there has been
research into the use of decision analysis for risk–benefit ­purposes and
in measuring outcomes. As discussed next, there have also been sig-
nificant developments in education within the discipline.

­Education
A current and future challenge in any discipline is teaching the spe-
cialty to newcomers and the continuing development of those already
working in the field. While years ago, the general model for those
1

working in pharmacovigilance was an apprenticeship (i.e. ‘learning on
the job’), there have been several more recent developments, includ-
ing training courses run within national authorities/organisations,
and also internationally by professional organisations including the
WHO Uppsala Monitoring Centre (WHO‐UMC) and International
Society of Pharmacovigilance (ISoP) (see Chapters 6 and 10). In some
universities, pharmacovigilance is taught in the undergraduate cur-
riculum for health sciences and there are good reasons to increase
such opportunities in the future.
There are also postgraduate courses and diplomas in pharmacovigi-
lance and pharmacoepidemiology in some countries (see Chapter 10)
and online learning is now well‐established. As a further measure, a
collaboration between the WHO and ISoP has developed a proposed
Pharmacovigilance Curriculum as a way of standardising teaching.
It can be argued that the future of any specialty lies in the ability to
teach it to the next generation and thus education needs remain a
­priority for those working in pharmacovigilance.

­Public Health and Policy
It is recognised that pharmacovigilance is a key component of public
health and that ADRs cause a significant clinical burden on individu-
als and systems around the world (see Chapter 7). Within governmen-
tal public health systems, there are several areas relevant to drug
safety, the most important being the agencies or departments that
regulate the quality, efficacy and safety of medicines (see Chapters 5
and 6). Here, we briefly consider recent developments and possible
future directions in key public health areas.

Regulation

In the past, regulation of pharmaceuticals was much stronger before
authorisation than after it. This was understandable and to some
extent was appropriate, but the need for stronger regulation post‐
authorisation has now been recognised. In Europe, significant changes
were made to regulatory legislation in 2012, which resulted in many
measures to strengthen post‐marketing pharmacovigilance practice
(see Chapter 5). These included ways to strengthen regulation (e.g. by
pan‐European committees and GVP guidance documents) increase
Future Directions143

efficiency and collaboration with industry (e.g. by clarifying and
streamlining processes for ADR reporting, PSURs and RMPs) and
also by increasing transparency in regulatory systems. A particular
challenge regulators continue to face is ways to improve systems for
monitoring the safety of drugs that are authorised early on limited
data (e.g. novel treatments for cancer, orphan drugs).
While there is international variation in regulatory pharmacovigi-
lance practice around the world, many countries now use European
guidance, in addition to that originating from other international
organisations (see Chapter 6) and in their own country. At the time of
writing (mid‐2016) it appears that the UK is going to leave the EU, but
we expect that medicines regulation will continue to be a collaborative
process across many countries, both inside and outside the EU. It is
generally agreed that the future of regulation lies in global collabora-
tion and some ongoing international initiatives are discussed in
Chapter 6.

Other Areas of Public Health

Pharmacovigilance features in several areas of public health policy; for
example, in mental health policy, women’s health (including family
planning), hospital management and drug funding/health economics.
In the future, in part due to demographic change (i.e. an increasingly
older population), use of medicines is likely to increase and so the
importance of pharmacovigilance in all these areas is likely to grow.
Some years ago, the WHO stated that increasing access to medicines
must be accompanied by appropriate systems to monitor their safety.
This remains true and governmental public health policies must
respond to these needs. While situations can vary from country to
country, here are some suggestions for common future directions:
●●Drug safety should be placed higher on the public health agenda to
reflect the burden on individuals’ health and on health systems.
●●More government support is needed for pharmacovigilance moni-
toring and research, especially for prevention of ADRs.
●●There should be less separation of the different ‘silos’ in pharma-
covigilance practice (i.e. regulation, industry, science and research,
patient groups, clinical practitioners) and a more collaborative
and integrated means of working together alongside related sectors
(e.g. health technology assessment and health economics).
1

●●There should be ongoing public engagement of patients in ADR
reporting and involvement of lay members at key stages of the phar-
macovigilance process.
●●There remains a need for even greater transparency in every area of
pharmacovigilance practice.
●●Communication is a key component of public health policy and we
should continue to explore different methods to suit specific target
audiences for drug safety issues. In this regard, the increasing use
of social media over the past decade represents an opportunity for
the future.

­Conclusions
In this chapter, we have tried to give a high‐level glimpse of the
­possible future directions of pharmacovigilance. We have considered
several important areas, including improving the collection of safety
data; biological medicines and pharmacogenetics; and developing and
applying scientific methodology. We have also reviewed a suggested
model for excellence in the pharmacovigilance process, considered
education and teaching and made some suggestions for future public
health policy. The next and final chapter summarises how the new-
comer can deepen their knowledge, enabling them to contribute to
meeting the challenges outlined.
145
10

Learning More About Pharmacovigilance

In the previous chapters we have generally not included specific
­references so as to encourage the reader to continue to learn broadly
about pharmacovigilance rather than becoming too concerned about
details. We also assumed that, if there were specific topics to find out
more about, readers would easily be able to do so by searching the
internet and/or published scientific literature. In this chapter we aim
to help the newcomer who has read this far, and we hope now has
some breadth of knowledge about pharmacovigilance, to approach
how to deepen it.

­Books
This book was originally written because there were no small books
on the subject but several large ones. The large textbooks that we
would recommend are as follows.

Mann’s Pharmacovigilance, 3rd edition, 2014
(eds Andrews and Moore)

This is a large multi‐author text with 53 chapters in five sections
­covering signal detection and analysis, including the use of popula-
tion‐based databases and pharmacoepidemiological methodologies
to proactively monitor for and assess safety signals. It includes
­chapters on drug safety practice in specific organ classes, special
populations and special products, and new developments in
the field.

An Introduction to Pharmacovigilance, Second Edition. Patrick Waller
and Mira Harrison-Woolrych.
© 2017 John Wiley & Sons Ltd. Published 2017 by John Wiley & Sons Ltd.
1

Pharmacoepidemiology, 5th edition, 2012 (eds Strom,
Kimmel and Hennessy)

This has become the standard text on the subject. There is also an
abridged, paperback version called Textbook of Pharmacoepidemiology.

Stephens’ Detection and Evaluation of Adverse Drug Reactions,
6th edition, 2012 (eds Talbot and Aronson)

This book has broader scope than the title suggests and covers phar-
macovigilance from industry, academic and regulatory perspectives.

Cobert’s Manual of Drug Safety and Pharmacovigilance,
2nd edition, 2011

This is a very practical book with an American focus.
In terms of reference books about the adverse effects of specific drugs,
the following are generally the first places to go.

Meyler’s Side Effects of Drugs, 16th edition, 2015 (ed. Aronson)

Authoritative and well‐referenced, if this is not in the library you use,
then it should be.

Martindale: The Complete Drug Reference, 38th edition, 2014
(ed. Brayfield)

Broader in scope than Meyler’s, if you need to find out about any drug
and its adverse effects, this is a good place to start.
In terms of books on special populations, we would recommend the
following texts.

Prescribing for Elderly Patients, 2009 (eds Jackson and Jansen)

This is a large practical book covering the drugs used to treat the most
important clinical problems occurring the elderly.

Drugs in Pregnancy and Lactation: A Reference Guide to Fetal
and Neonatal Risk, 10th edition, 2015 (eds Briggs and Freeman)

This is comprehensive reference book, with each drug monograph
summarising potential side effects on the embryo and fetus and drug
passage to the nursing infant.
Learning More About Pharmacovigilance147

Medicines for Women, 2015 (ed. Harrison‐Woolrych)

This book is divided into three parts covering: (i) general principles
of prescribing medicines for women including in pregnancy and
­breastfeeding; (ii) benefits and risks of specific medicine groups for
women including contraceptive products, menopausal hormone
­therapy, bisphosphonates, human papilloma virus vaccines and herbal
products; and (iii) broader perspectives including issues in developing
countries and risk communication.

British National Formulary for Children

This is the essential reference guide for prescribing in children, an
update of which is published annually.­Journals
Quite a few important papers in the field, including the findings of
major studies, are published in the major weekly general medical
journals such as the New England Journal of Medicine, The Lancet,
British Medical Journal and JAMA. It is therefore a good idea to
screen the contents of these titles and also the major clinical phar-
macology journals. In terms of specialist journals in the field of
pharmacovigilance, the two major titles, both of which appear
monthly, are:
●●Drug Safety This is the official journal of International Society of
Pharmacovigilance (IsoP) (publishing all conference abstracts)
and also publishes themed editions, for example on risk
communication.
●●Pharmacoepidemiology and Drug Safety This journal regularly
includes a section called ‘current awareness’ which lists recent
­literature relevant to drug safety.
Another journal which is very useful in that respect is Reactions
Weekly which is primarily an alerting service based on case reports,
but also covers topical issues and news in the field.
All these journals are available in both paper and electronic formats
and access is essential for anyone working in the field.
1

­The Internet
We have mentioned and provided the addresses of some key websites
for pharmacovigilance in Boxes 5.1 and 6.1. In particular, the websites
of the WHO‐UMC and the major regulatory agencies are worth visit-
ing for information about specific issues/alerts, bulletins and to obtain
ADR data. While official websites generally provide reliable informa-
tion on pharmacovigilance, we would like to add a word of caution
about searching the internet for data on drug safety issues. It is worth
remembering that anyone can set up a website and – as there is no
regulation of information posted on the internet – some content may
therefore be misleading and/or promotional.

­Courses
Opportunities for training in the field are increasing all time and it is
impossible to be comprehensive here. We are aware of a variety of
options in many countries. In the UK, basic courses are run by the
Drug Safety Research Unit and there are also courses at certificate level
(e.g. at the London School of Hygiene), and diploma and masters level
(e.g. at the Universities of Hertfordshire and Portsmouth). In Europe,
there is a programme known as EU2P (European Programme in
Pharmacovigilance and Pharmacoepidemiology) which offers a variety
of courses at all levels, including the opportunity to undertake distance
learning online. Training courses are also run by the two international
societies mentioned below and by the WHO‐UMC. Training materials
and courses regarding the use of the Medical Dictionary for Regulatory
Activities (MedDRA) are available via their website.

­International Societies
Finally, there are two professional societies which exist to promote
development, training and international collaboration in their
disciplines:
●●International Society of Pharmacovigilance (ISoP)
●●International Society for Pharmacoepidemiology (ISPE).
See Chapter 6 for further information about these societies.
Learning More About Pharmacovigilance149

­Final Conclusions
The overarching messages we would like the newcomer to take away
from this book are that pharmacovigilance is:

1. A means of potentially preventing patients coming to harm as a
   result of the medicines they take in expectation of benefit through:
   ●● Science and research

●● Regulation and other public health policy

●● Clinical practice and post‐marketing monitoring

●● Effective communication about benefit–risk of medicines.

2. A vital stage of drug development. There is a need for a medicine
   to be shown to be acceptably safe in clinical practice.
3. A developing discipline with a global focus and plenty of scope for
   innovation. One of the attractions of the field that may not be
   immediately obvious is that, although pharmacovigilance is a spe-
   cialised subject, its application is very broad indeed. Every issue is
   different and there are no set recipes for dealing with the next
   safety concern to land on your desk.
   151
   Glossary

Absolute risk The probability of an adverse event occurring
expressed in absolute terms (e.g. as a rate per thousand
patients, or as a proportion). An absolute risk provides
information about how frequent an event is, but makes no
comparison with alternatives (see relative risk).
Additional monitoring A scheme for focusing attention on the
safety of specific medicines introduced by the European
Medicines Agency in 2013, which is primarily used for new
drugs and usually lasts for 5 years after first authorisation.
These products are identified by a black triangle symbol in the
product information.
Adverse drug reaction (ADR) An unintended and noxious effect
that is attributable to a medicine when it has been given within
the normal range of doses used in humans whether or not it has
been used within the terms of a marketing authorisation.
Adverse event (AE) An undesirable occurrence that occurs in the
context of drug treatment but which may or may not be causally
related to a medicine.
Bias Any process that leads to systematic distortion of results away
from the truth. Many types of bias have been described so when
designing a study steps usually need to be taken to eliminate or
minimise bias.
Black Triangle scheme A scheme introduced in the UK in the
1980s to promote intensive surveillance of new drugs. An inverted
black triangle is displayed on all product information as a
reminder to health professionals to report all suspected ADRs.

An Introduction to Pharmacovigilance, Second Edition. Patrick Waller
and Mira Harrison-Woolrych.
© 2017 John Wiley & Sons Ltd. Published 2017 by John Wiley & Sons Ltd.
152Glossary

The period of intensive surveillance is usually at least 2 years.
The EU introduced a similar scheme in 2013 (see additional
monitoring).
Case–control study A study that starts by identifying cases of the
disease of interest (in this context usually a potential ADR)
and makes comparisons of their past ‘exposures’ (e.g. to drugs)
with those of controls who did not develop the disease.
Clinical trial An interventional study (e.g. of a drug treatment)
conducted in patients with a specific disease or condition.
Such studies usually involve comparison with placebo or other
treatment and a randomisation process is used to determine
allocation of treatments. Ideally, trials also blind patients and
clinicians (i.e. they are double‐blind) to treatment allocations.
Conducting a clinical trial for research purposes requires informed
consent from each patient and ethical committee approval is
essential.
Cohort study A study that starts by identifying a particular
population with a common characteristic (e.g. a cohort based on
use of a specific drug) and follows them forward in time until
some individuals have developed the outcome of interest (e.g. ADR
or disease).
Confounding Distortion that occurs when measuring an
association between an exposure and an outcome because a
confounding factor (e.g. age) is present which influences both the
probability of being exposed and the risk of the outcome occurring
(see Figure 2.1).
Core (or reference) clinical safety information This is a minimum
standard of safety information which is considered essential for
safe use of a medicine and should be included in all product
information worldwide. The concept was originally proposed by
the CIOMS III working group and now constitutes an Annex to
the Periodic Safety Update Report.
Disproportionality A statistical indication of a signal in
spontaneous ADR data meaning that more reports of a specific
drug–ADR combination have been received than would have been
expected as ‘background noise’.
Drug interaction Interference of a medicine with another substance
(usually another drug) that affects the activity of either drug when
both are administered together.
Glossary153

Large simple trial A randomised trial which, in the context
of pharmacovigilance, may be useful for assessing safety. The key
elements are a large sample size meaning that relative rare
outcome(s) can be studied; one or very few easily measurable
outcomes (e.g. mortality); and that the trial should represent
the ‘real world’ as far as possible.
Medical Dictionary for Regulatory Activities (MedDRA) The
most widely used standardised international dictionary of medical
terminology for regulatory communication and evaluation of data
relating to human medicines. MedDRA was developed through
ICH and its use for coding is mandatory in the EU.
Medication error A failure in the treatment process that leads to, or
has the potential to lead to, harm to the patient – for example,
prescription of the wrong drug or giving an incorrect dose.
Meta‐analysis A meta‐analysis brings together data from several
different studies in a quantitative way, so as to provide a single overall
estimate of a specified effect. It is, in effect, a ‘study of studies’.
Observational study A study in which there is no intervention in
relation to the management of patients or participants.
Observational research is often based on data derived from
ordinary medical practice.
Orphan drug A drug used in the treatment of an ‘orphan’ (i.e. rare)
disease. Because development may be uneconomic, incentives to
companies may be provided. They are often authorised ‘early’
because of a lack of suitable alternative treatments and on the
basis of small clinical trial programmes.
Patient Information Leaflet A summary of the product
information for patients/carers, which in many countries is
included in the medicine’s packaging, or given to the patient as the
time of dispensing. Also known the package leaflet in the EU,
package insert in the USA and consumer information in some
other countries.
Periodic Safety Update Report (PSUR) A systematic review of the
global safety data which became available to the manufacturer of a
marketed drug during a specified time period in an internationally
agreed format. Submission of PSURs to regulatory authorities is a
legal obligation in many countries.
Pharmacoepidemiology The scientific discipline of studying drug
effects in populations.
154Glossary

Pharmacogenetics The investigation and use of genetic markers to
maximise the safety and/or efficacy of drugs.
Pharmacovigilance The science and activities relating to the
detection, assessment, understanding and prevention of adverse
effects or any other drug‐related problems (this is the current
definition of the World Health Organization.
Pharmacovigilance plan This is the second part of a risk
management plan for a medicine. The plan should indicate what
pharmacovigilance activities (both routine and any additional ones
that are specific to the product) will be undertaken in order to
further assess its safety.
Post‐authorisation safety study (PASS) A study of an authorised
and marketed medicine that aims to characterise or quantify a
safety hazard, assess its safety profile in real life use or measure the
effectiveness of risk minimisation measures.
Post‐marketing surveillance (PMS) Safety‐related activity after a
product is marketed. This process includes, but is not limited to,
spontaneous ADR reports and specific post‐marketing studies
(see post‐authorisation safety study) including prescription‐
event monitoring. After marketing, this term may be regarded as
synonymous with pharmacovigilance.
Pre‐clinical studies Studies conducted in laboratory animals; these
are normally performed before initiating a clinical trial programme.
Pregnancy prevention programme An additional risk
minimisation measure aimed at preventing fetal exposure to
teratogenic medicines.
Prescription‐event monitoring (PEM) (also known as cohort‐event
monitoring) A pharmacoepidemiological study in which a cohort
of users of a medicine is identified from prescriptions and
followed‐up for a defined period to identify all adverse events
occurring in the post‐treatment period.
Registry A registry is a collection of individual patient data which
can be used for epidemiological studies and can based on a
disease, treatment, specific exposure or outcome.
Relative risk The probability of an adverse event occurring
expressed in relative terms against a specified comparator.
A relative risk provides information about the strength of an
association, but it does not indicate how common or rare an event
is in absolute terms (see absolute risk).
Glossary155

Risk–benefit balance All medicines have both risks and benefits,
and for their use to be acceptable the balance of these must be
judged to favour benefit. Making the judgement requires
consideration of all the relevant data and this can be summarised
in a benefit–risk report.
Risk management plan (RMP) A document prepared by a
pharmaceutical company specifying what is and what is not
known about the safety of a product, what is planned to extend
safety knowledge and how known risks will be minimised.
Risk minimisation Measures designed to minimise the occurrence
of known ADRs. These are outlined in a risk minimisation plan
which is the final part of a risk management plan.
Safety Relative absence of harm. When we say that a drug is ‘safe’,
we mean that there is a low probability of harm that, in the context
of the disease being treated and the expected benefits of the drug,
can be considered acceptable.
Safety specification This is the first part of a risk management
plan which considers the evidence for and level of safety that has
been demonstrated so far. The specification should identify both
what is and what is not yet known about safety.
Seriousness An ADR or case report should be considered ‘serious’ if
it meets any of the following criteria:
●● Fatal outcome

●● Life‐threatening

●● Led to or prolonged hospitalisation

●● Led to long‐term disability

●● Congenital abnormality.

In addition, it is possible for a case to be medically judged as serious
even if none of the above criteria are met.
Severity The degree of impact of a particular ADR in an individual
patient (usually subjective and judged by the patient or doctor)
which is often categorised as mild, moderate or severe. This
concept is distinct from seriousness, and it is possible to have an
ADR that is severe (e.g. a very bad headache) but which does not
meet the criteria for seriousness.
Side effect An unintended effect of a medicine.
Signal An alert requiring further investigation from any available
data source that a drug may be associated with a previously
unrecognised hazard. The term is also used when there is new
156Glossary

evidence that a known hazard may be quantitatively (e.g. more
frequent) or qualitatively (e.g. more serious) different from what
was previously known.
Spontaneous ADR report A case report relating to an individual
patient describing a suspected adverse reaction.
Summary of Product Characteristics (SPC or SmPC) A
regulatory document in the EU which is attached to the marketing
authorisation which forms the basis of the product information (as
it is more widely known) and is primarily directed at prescribers.
Systematic review A systematic review evaluates all the relevant
research relating to a particular question. The Cochrane
Collaboration uses this method to appraise medical treatments
and publishes its findings in the Cochrane Library.
Yellow Card scheme The UK national spontaneous ADR reporting
scheme. In some other countries, spontaneous reporting schemes
also use yellow reporting cards, although electronic forms are now
becoming more common.
157
